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Summary
Background Up-to-date evidence on levels and trends for age-sex-speciﬁ c all-cause and cause-speciﬁ c mortality is 
essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 
2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess 
whether there is epidemiological convergence across countries.
Methods We estimated age-sex-speciﬁ c all-cause mortality using the GBD 2010 methods with some reﬁ nements to improve 
accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of 
death as in the GBD 2010. Key improvements included the addition of more recent vital registration data for 72 countries, 
an updated verbal autopsy literature review, two new and detailed data systems for China, and more detail for Mexico, UK, 
Turkey, and Russia. We improved statistical models for garbage code redistribution. We used six diﬀ erent modelling 
strategies across the 240 causes; cause of death ensemble modelling (CODEm) was the dominant strategy for causes with 
suﬃ  cient information. Trends for Alzheimer’s disease and other dementias were informed by meta-regression of 
prevalence studies. For pathogen-speciﬁ c causes of diarrhoea and lower respiratory infections we used a counterfactual 
approach. We computed two measures of convergence (inequality) across countries: the average relative diﬀ erence across 
all pairs of countries (Gini coeﬃ  cient) and the average absolute diﬀ erence across countries. To summarise broad ﬁ ndings, 
we used multiple decrement life-tables to decompose probabilities of death from birth to exact age 15 years, from exact age 
15 years to exact age 50 years, and from exact age 50 years to exact age 75 years, and life expectancy at birth into major 
causes. For all quantities reported, we computed 95% uncertainty intervals (UIs). We constrained cause-speciﬁ c fractions 
within each age-sex-country-year group to sum to all-cause mortality based on draws from the uncertainty distributions.
Findings Global life expectancy for both sexes increased from 65·3 years (UI 65·0–65·6) in 1990, to 71·5 years 
(UI 71·0–71·9) in 2013, while the number of deaths increased from 47·5 million (UI 46·8–48·2) to 54·9 million 
(UI 53·6–56·3) over the same interval. Global progress masked variation by age and sex: for children, average absolute 
diﬀ erences between countries decreased but relative diﬀ erences increased. For women aged 25–39 years and older than 
75 years and for men aged 20–49 years and 65 years and older, both absolute and relative diﬀ erences increased. 
Decomposition of global and regional life expectancy showed the prominent role of reductions in age-standardised death 
rates for cardiovascular diseases and cancers in high-income regions, and reductions in child deaths from diarrhoea, 
lower respiratory infections, and neonatal causes in low-income regions. HIV/AIDS reduced life expectancy in southern 
sub-Saharan Africa. For most communicable causes of death both numbers of deaths and age-standardised death rates fell 
whereas for most non-communicable causes, demographic shifts have increased numbers of deaths but decreased age-
standardised death rates. Global deaths from injury increased by 10·7%, from 4·3 million deaths in 1990 to 4·8 million in 
2013; but age-standardised rates declined over the same period by 21%. For some causes of more than 100 000 deaths per 
year in 2013, age-standardised death rates increased between 1990 and 2013, including HIV/AIDS, pancreatic cancer, atrial 
ﬁ brillation and ﬂ utter, drug use disorders, diabetes, chronic kidney disease, and sickle-cell anaemias. Diarrhoeal diseases, 
lower respiratory infections, neonatal causes, and malaria are still in the top ﬁ ve causes of death in children younger than 
5 years. The most important pathogens are rotavirus for diarrhoea and pneumococcus for lower respiratory infections. 
Country-speciﬁ c probabilities of death over three phases of life were substantially varied between and within regions.
Interpretation For most countries, the general pattern of reductions in age-sex speciﬁ c mortality has been associated 
with a progressive shift towards a larger share of the remaining deaths caused by non-communicable disease and 
injuries. Assessing epidemiological convergence across countries depends on whether an absolute or relative measure 
of inequality is used. Nevertheless, age-standardised death rates for seven substantial causes are increasing, suggesting 
the potential for reversals in some countries. Important gaps exist in the empirical data for cause of death estimates 
for some countries; for example, no national data for India are available for the past decade.
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Introduction
The Global Burden of Disease (GBD) study provides a 
unique comprehensive framework to systematically assess 
national trends in age-speciﬁ c and sex-speciﬁ c all-cause 
and cause-speciﬁ c mortality. Up-to-date and comprehensive 
evidence for levels and trends for each country is critical 
for informed priority setting. Trends quantify progress 
against explicit health targets, whether local, national, or 
global, and help to evaluate where programmes are 
working or not. Quantiﬁ cation across populations and 
over time using comparable deﬁ nitions and methods can 
also enable benchmarking. Regular comprehensive 
updates about causes of death will identify emerging 
public health challenges. The GBD 2013 study provides the 
ﬁ rst GBD study to use a continuously updated approach to 
global health surveillance.1
The GBD 2010 study, a collaboration of 488 investigators, 
showed important global and regional trends for all-cause 
and cause-speciﬁ c mortality.2–8 The GBD 2010 reported 
substantial decreases in child mortality driven by 
reductions in diarrhoea, lower respiratory infections, and 
more recently, malaria. The lowest income regions had 
progressed in combating maternal mortality, HIV/AIDS, 
tuberculosis, and malaria. Nevertheless, much work 
remains to be done for these Millennium Development 
Goal-related diseases. Outside sub-Saharan Africa, 
1990–2010 saw rapid shifts towards a larger share of death 
from non-communicable diseases and injuries and a 
rising mean age of death. Country analyses using the 
GBD 2010 database have been reported for China, Iran, 
Mexico, UK, and USA, taking advantage of the comparable 
methods and deﬁ nitions of the GBD to benchmark these 
countries against their peers.9–16
Much debate surrounds what should follow the 
Millennium Development Goals; objective, timely, and 
comprehensive evidence for the levels and trends in 
causes of death can be a useful input. Ambitious goals 
have been discussed,16 such as the elimination of 
preventable child and maternal mortality in a generation. 
Targets of zero disease have been formulated for HIV/
AIDS, tuberculosis, and malaria by various groups.17–23 
The Lancet Commission on Global health 2035: 
a world converging within a generation24 suggested that a 
grand convergence in health can be achieved between 
poor and rich countries by 2035. Advocates for 
non-communicable disease programmes argue25 that 
rapid epidemiological transitions in many regions of the 
world require broader health goals for the development 
community. Movements to focus on universal health 
coverage in the post-2015 health agenda emphasise the 
consequences of failure to meet basic health-care 
needs.24–27
Broad interest in the GBD 2010 has led to the 
expansion of the GBD collaboration to include more 
than 1000 investigators in 106 countries. The GBD 2013 
not only incorporates newly published or released 
datasets, particularly from the past 5 years, but also 
expands the analysis in other ways. We included 
subnational assessments for provinces of China, states 
of Mexico, and regions of the UK. These subnational 
assessments will help national decision makers to 
identify inequalities and local variation in leading 
diseases, injuries, and risk factors. The list of causes has 
been expanded and many new and more detailed data 
sources incorporated. We report the new ﬁ ndings for 
the ﬁ rst time at the country-level for 1990–2013.
Methods
Study design
The GBD approach to estimating all-cause mortality 
and cause-speciﬁ c mortality has been previously 
described.2,3 Here, we describe several reﬁ nements.28 
Figure 1 shows the general analysis of all-cause 
mortality and cause-speciﬁ c mortality and their 
interactions. GBD 2010 included 291 causes of death or 
disability, of which 235 were causes of death; we have 
expanded the list to include 306 causes of death or 
disability, of which 240 are causes of death. The extra 
causes were added on the basis of three considerations: 
(1) causes that were for epidemiological reasons already 
modelled separately but reported combined with other 
causes in GBD 2010—for example, silicosis, asbestosis, 
anorexia nervosa, and typhoid and paratyphoid fever; 
(2) the category of other unintentional injuries was 
large and heterogeneous so we broke it down further to 
include pulmonary aspiration and foreign body in 
trachea or lung, foreign body in other part of body, and 
unintentional suﬀ ocation; and (3) new datasets became 
available to enable estimation of mesothelioma, new 
maternal sub-causes, neonatal haemolytic anaemia, 
and chronic kidney disease caused by glom-
erulonephritis. Appendix pp 245–251 provides the 
International Classiﬁ cation of Diseases codes for the 
GBD 2013 cause list. After broad consultation, we have 
removed from the cause list the pathogen-speciﬁ c 
causes of diarrhoeal diseases and lower respiratory 
infections. Instead, we analysed these causes with a 
counterfactual approach.
We assessed 21 regions and seven super-regions as 
deﬁ ned in the GBD 2010. The GBD 2013 also included 
an assessment of subnational populations in 
three countries: provinces for China, states for Mexico, 
and the UK broken down into Scotland, Wales, 
Northern Ireland, and nine regions of England. We 
analysed these countries subnationally because of the 
interest from national collaborators and because 
suﬃ  cient data were made available by the teams in each 
country. In future iterations of the GBD, we hope to 
include further subnational breakdowns. In addition, 
we separately analysed data sources for rural and urban 
regions in India. This approach improved our 
estimation of mortality and causes of death and enabled 
us to analyse causes of death that were speciﬁ c to urban 
or rural regions alone.
See Online for appendix
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Covariates
We estimated national time series (1980–2013) for a range 
of covariates with data from surveys (household-level and 
individual-level data), censuses, oﬃ  cial reports, 
administrative data, and a systematic review. For lagged 
distributed income and education, we estimated national 
time series from 1950, to 2013. Details of how we imputed 
series for GDP, educational attainment, tobacco prevalence, 
and obesity prevalence have been published previously.29–32 
Appendix (pp 4961–4974) shows the sources and imputation 
methods used to generate time series for each covariate. 
Generally, we estimated uncertainty in covariate values 
when suﬃ  cient infor mation was available.
All-cause mortality
We analysed all-cause mortality for 188 countries from 1950 
to 2013; we present only results for 1990–2013 to coincide 
with the period of the overall GBD 2013 assessment. As a 
result of the split of Sudan, we re-extracted data and made 
new separately generated estimates for Sudan and South 
Sudan. We improved how we adjusted for data source bias 
for the analysis of child mortality in two ways. First, by 
using the improved functional forms between summary 
mortality indicators for child (age <5 years) and adult 
(age 15–59 years) age groups and other covariates, including 
crude rates of death caused by HIV/AIDS. And second, by 
modiﬁ cation of the model lifetable system to use a uniﬁ ed 
standard life-table selection process and improved re-
distribution of excess mortality rate from HIV/AIDS. We 
divided the analysis into eight steps. Input data and key 
indicators for all countries are available online.
First, to estimate under-5 mortality (5q0), we analysed all 
survey, census, sample registration, and vital registration 
sources. Wherever possible, we analysed microdata from 
surveys and censuses with updated methods for child 
mortality.33 We synthesised all measurements of under-5 
Figure 1: Components of GBD 2013 and their relations 
ICD=International Classiﬁ cation of Diseases. BTL=basic tabulation list. MI ratio=mortality:incidence ratio. CODEm=Cause of Death Ensemble model. YLLs=years of life lost. EPP=UNAIDS Estimates and 
Projects Package.
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mortality with spatiotemporal regression and Gaussian 
process regression.33 We corrected for bias in diﬀ erent 
sources in speciﬁ c countries.
Second, to estimate adult mortality (45q15), we 
systematically identiﬁ ed all available vital registration 
data, sibling history survey data, sample registration 
data, and household recall of deaths. We assessed vital 
registration data for completeness by optimised death 
distribution methods.2,34 We analysed sibling history 
data to account for survivor bias, zero-surviving 
sibships, and recall bias.2,35 We synthesised sources with 
a combination of spatiotemporal regression and 
Gaussian process regression. The mean function for the 
Gaussian process regression was based on the 
combination of a non-linear hierarchical model with 
income per person, mean years of education in age 
group 15–60 years, mortality caused by HIV/AIDS, 
and country random eﬀ ects2 as covariates, and a 
spatiotemporal regression in which we added to the ﬁ rst 
stage model without country random eﬀ ects, the 
smoothed residuals between the ﬁ rst stage model and 
observed data (appendix pp 66–79). We selected the 
hyper-parameters for Gaussian process regression 
through an out-of-sample predictive validity testing 
process.2 We ranked the estimated subnational adult 
mortality in China, India, Mexico, and the UK to ensure 
that the sum of subnational estimates for a given age-
sex group equalled the national estimates accounting 
for diﬀ erent population sizes.
Third, we assessed HIV-free under-5 mortality and 
adult mortality. HIV/AIDS causes more excess mortality 
in younger people and thus changes the age pattern of 
mortality that otherwise can be readily described by 
Gompertz law of mortality or the Kannisto-Thatcher 
model.36,37 Where HIV/AIDS is common, this pattern of 
mortality should be explicitly taken into account. We 
estimated the HIV-counterfactual under-5 mortality and 
adult mortality rates using the estimated coeﬃ  cients of 
crude death rate from HIV from the non-linear mixed 
eﬀ ects models for under-5 mortality and adult mortality 
respectively, and setting the crude death rates from 
HIV/AIDS in the respective age groups to zero (appendix 
pp 90–94).
Fourth, we constructed an HIV-free life-table. The GBD 
2010 introduced a model life-table system that used the 
under-5 death rate and adult mortality rate along with a 
selected standard mortality schedule to estimate the full 
age pattern of mortality for country-years of interest.33 
For GBD 2013, we modiﬁ ed how the standard mortality 
schedule was selected for each country-year so that the 
same approach was used for all countries. Speciﬁ cally, 
we empirically computed a set of space-time weights that 
relate the observed age pattern of the probability of death 
in a sex-country-year with other sex-country-year 
observations. These weights were derived by comparing 
every empirical life-table that is not aﬀ ected by the HIV/
AIDS epidemic in the GBD database (10 673 life-tables) 
with every other life-table for the same sex. We estimated 
space-time weights as a function of the time lag between 
the paired life-tables and location (ie, within the country, 
region, or super-region). We estimated these weights as 
the inverse of the average sum of age-speciﬁ c diﬀ erences 
in the logit of the probability of death (appendix pp 79–91). 
The key observation from this spatial-temporal analysis 
of age-speciﬁ c probabilities of death is that the mortality 
pattern in a country in a given year was more strongly 
related to the mortality pattern in the same country 
within 15 years than to mortality patterns in other 
countries; however, other countries in the same region or 
other regions generally are similarly related when the 
lag-in time was more than 20 years.
Fifth, we assessed the age pattern of HIV/AIDS 
mortality. Excess mortality from HIV/AIDS as quantiﬁ ed 
between the estimated 5q0 and 45q15 with their HIV 
counterfactual counterparts leads to increased mortality 
in speciﬁ c age groups. This excess HIV/AIDS mortality 
was assigned by age with the estimated relative risk of 
death caused by HIV/AIDS in an age group compared 
with the HIV/AIDS excess death rate in age group 
40–44 years. We estimated these relative risks with data 
from vital registration systems that have International 
Classiﬁ cation of Diseases 10 coded causes of death from 
HIV/AIDS, which includes South Africa.38 We used 
Seemingly Unrelated Regression model39 with only a 
constant and generated 95% uncertainty intervals (UIs) 
for the age pattern of relative risks by repeatedly sampling 
from the mean and covariance matrix of the estimated βs 
and the error term. Seemingly Unrelated Regression 
enables the error term of a series of linear regressions to 
be correlated. We used separate regressions by sex and 
for the pattern of mortality in concentrated epidemics 
and generalised epidemics as deﬁ ned by UNAIDS.38–40
Sixth, we minimised the diﬀ erence between demo-
graphic estimation of age-speciﬁ c mortality and HIV 
models. Murray and colleagues38 used a reﬁ ned version of 
the EPP-Spectrum framework to model HIV/AIDS 
mortality. This analysis yielded very large UIs for HIV/
AIDS in many countries. However, in some southern 
African countries, there remained a large discrepancy 
between data for all-cause mortality and estimates of HIV/
AIDS mortality with demographic sources suggesting 
smaller epidemics. To minimise the diﬀ erence between 
HIV/AIDS mortality and the demographic estimates, 
which are also uncertain, we computed a loss function that 
quantiﬁ es the extent to which the age-sex-country-year 
HIV/AIDS estimates exceed all-cause mortality:
For run (r) of a given country, excess mortality (e) is 
equal to the sum of all non-zero diﬀ erences between 
HIV/AIDS mortality (mHIV) and 0·8 times a randomly 
selected all-cause mortality draw (mall-cause) across all year 
er = ∑∑∑max(0,mr,t,a,s – 0·8 × mall-cause)
t a s
r,t,a,s
HIV
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(t), age (a), and sex (s) combinations. 0·8 was the highest 
observed cause fraction caused by HIV in any age group 
in any vital registration system. We selected from the 
uncertainty ranges for HIV and all-cause mortality 
those that minimised the diﬀ erence. If no draws had a 
positive loss function, we sampled randomly from all 
matched draws.
The CoDCorrect algorithm includes HIV/AIDS 
cause-speciﬁ c mortality and can alter the age and time 
distribution of deaths from HIV/AIDS. To incorporate 
the overall change in the number of HIV/AIDS deaths 
over the course of the epidemic in a country implied by 
the application of the CoDCorrect algorithm, but not to 
distort the Spectrum estimated time and age pattern, we 
adjusted the entire HIV/AIDS epidemic up or down on 
the basis of the cumulative eﬀ ects of CoDCorrect on 
HIV/AIDS for all estimated years in each country.
Seventh, we used the same method as Wang and 
colleagues2 to generate child mortality rate and adult 
mortality rate for natural disasters and armed conﬂ icts. 
We obtained data for conﬂ ict and war, including deaths 
from one-sided violence, non-state conﬂ ict, armed force 
battles, and other national or international conﬂ icts, from 
the Uppsala Conﬂ ict Data Program41 and the International 
Institute for Strategic Studies.42 Further data for war were 
obtained from countries’ vital registration systems and 
classiﬁ ed as caused by war.43 We included disaster data 
from the International Disaster Database from the Center 
for Research on the Epidemiology of Disasters (University 
of Louvain, Brussels, Belgium).44 From this database, we 
included deaths caused by complex disaster, drought, 
earthquake, ﬂ ood, and others. When these databases 
were not fully up-to-date or did not contain shocks known 
to exist, we supplemented with case-by-case sources. 
These with-shock mortality rates were then used as entry 
parameters to the GBD relational model life-table system 
to generate age-speciﬁ c mortality rates with the eﬀ ect of 
shocks added.
Eighth, we used age-speciﬁ c and sex-speciﬁ c death 
rates from the life-table to generate numbers of death by 
multiplying by population estimates from the World 
Population Prospects 2012 revision45 and the Human 
Mortality Database for people older than age 5 years. For 
the under-5 age groups, we applied the method of Wang 
and colleagues.33 In some cases, assumptions in the UN 
estimation process led to implausible population 
numbers for some countries and age groups—for 
example, low population estimates for older age groups 
in South Africa, especially for the most recent years. 
For GBD 2013, we applied a Bayesian population 
reconstruction model46 to re-estimate population for 
South Africa for 1970–2013.
Cause of death database
Lozano and colleagues3 described the key steps in the 
development of the GBD cause of death database. The 
database has been expanded to capture 2233 additional 
site-years of vital registration data and 52 additional verbal 
autopsy site-years (table 1); a site-year is deﬁ ned as data for 
a speciﬁ c geographical location (eg, a province of China) in 
a given year. We included data up to April 15, 2014. 
A major new addition was the incorporation of two 
data systems in China. First, the China National Oﬃ  ce 
for Maternal and Child Health Surveillance provided 
detailed information for child and maternal mortality by 
cause from 363 surveillance sites in China for 1996–2013. 
Second, the Disease Surveillance Points system was the 
main source of mortality data for 1991–2007, with 
145 disease surveillance points used from 1991 to 2003, 
and 161 points used from 2004 to 2007. From 2008 to 
2012, all of the deaths and cause of death information 
from the Disease Surveillance Points system and other 
system points throughout China were collected and 
reported via the Mortality Registration and Reporting 
System, an online reporting system of the Chinese 
Center for Disease Control and Prevention, which 
included 4·0 million deaths in 2012.47,48 Because of the 
discrepancy in proportions of deaths in hospital and out 
of hospital in the Mortality Registration and Reporting 
System, we divided each province in China into two 
strata based on the degree of urbanisation from the 2010 
China Census. We then applied the proportion of deaths 
in hospital and out of hospital and degree of urbanisation 
from the Disease Surveillance Points system to the 
Mortality Registration and Reporting System to account 
for biases in the latter. We disaggregated data for both 
systems by province and urban and rural regions within 
each province. We obtained new datasets for Russia that 
provided more detailed causes (appendix pp 180–244). 
Turkey expanded its vital registration system to cover 
nearly all the population after 2009 and we incorporated 
these new data into the analysis.
In total, we identiﬁ ed 538 verbal autopsy site-years, 
52 more than in GBD 2010. India, Bangladesh, and 
Tanzania had the most verbal autopsy site-years 
All geographies GBD 2013
GBD 2010 GBD 2013 Diﬀ erence National State, province, 
or region*
Local
Vital registration 2798 5039 2241† 2765 2112 162
Cancer registry 2715 3860 1145 1216 979 1665
Sibling history 1557 1798 241 1788 0 10
Police records 1129 1433 304 1429 1 3
Surveillance 128 1430 1302 73 1074 283
Verbal autopsy 486 538 52 110 0 428
Survey or census; hospital; 
burial or mortuary
154 146 –8‡ 94 0 52
Total 8967 14 244 5277 7475 4166 2603
GBD=Global Burden of Disease Study. *Data were analysed at the state level for Mexico, the province level for China, 
and the region level for the UK. †Signiﬁ cant increase because of incorporation of subnational sites in China, Mexico, 
and the UK. ‡Decrease caused by omission of World Health Survey data where adequate vital registration data was 
available for GBD 2013.
 Table 1: Number of site-years in database by source type
For the Human Mortality 
Database see http://mortality.
org/
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available. We re-extracted and re-mapped data from all 
verbal autopsy studies to ensure consistency with the 
GBD 2013 cause list. We excluded from the database 
verbal autopsy studies reporting cause assignment using 
InterVA because it has very low published validity.47 We 
incorporated 1145 registry-years of new cancer data, 
including 128 from Cancer Incidence in Five Continents 
Volume X48 and 1017 from supplemental sources. Our 
analysis of cancer incidence and models of the 
death:incidence ratio remains unchanged from GBD 
2010. Figure 2 shows site-years of data by country for any 
cause. Of note, Somalia and Equatorial Guinea had no 
cause of death data for any speciﬁ c cause.
Assessment and enhancement of quality and 
comparability of cause of death data
Using the general approach of the GBD 2010, we 
followed six steps to assess the quality of data and 
enhance comparability. First, we adjusted cause of 
death data from vital registration systems for 
incompleteness. The analysis of all-cause mortality 
yields a separate estimate of completeness for deaths of 
children younger than 5 years and deaths of people 
older than 5 years, which we used to correct the data for 
cause of death. When correcting for incomplete 
registration, we assumed that for each age-sex-country 
group, the cause of death composition of registered 
deaths and non-registered deaths were the same. 
77% of datapoints were from registration or sample 
registration that were more than 85% complete, 17% 
from systems that were 70–84% complete, and 6% were 
from systems less than 70% complete. Of the 6% of 
observations less than 70% complete, most (62%) were 
for children younger than 5 years. In sensitivity tests in 
the GBD 2010, exclusion of data below a ﬁ xed threshold 
of completeness for child causes of death did not 
substantially change the results; thus, we have used all 
the data in our analysis for GBD 2013.3
Second, we developed 103 maps (excluding verbal 
autopsy studies) to translate causes found in the data to 
the GBD 2013 cause list. The expanded cause list of this 
study required us to adjust the maps used for data 
included in GBD 2010. Appendix pp 245–251 show GBD 
2013 cause maps for International Classiﬁ cation of 
Diseases 9 and 10. The appendix (pp 252–253) includes 
more detail about changes made to the handling of 
various shorter tabulation lists used by some countries 
for reporting, such as the International Classiﬁ cation of 
Diseases 9 Basic Tabulation List.
Third, a crucial aspect of enhancing the comparability 
of data for cause of death is to deal with uninformative, 
so-called garbage codes. Garbage codes are codes for 
which deaths are assigned that cannot or should not be 
considered as the underlying cause of death—for 
Figure 2: Site-years for all causes of death data by country, 1980–2013
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
No data
1–4 site-years
5–14 site-years
15–24 site-years
25–34 site-years
≥35 site-years
Articles
www.thelancet.com   Vol 385   January 10, 2015 123
example, heart failure, ill-deﬁ ned cancer site, senility, 
ill-deﬁ ned external causes of injuries, and septicaemia. 
Figure 3 shows the number of deaths in the database for 
each calendar year with the number assigned to garbage 
codes. Because of lags in national reporting of cause of 
death data, the number of deaths available after 2010 fell. 
Important changes for the GBD 2013 in our approach to 
redistributing garbage codes included the statistical 
estimation of the fraction of deaths following the methods 
outlined by Ahern and colleagues49 for deaths assigned to 
ill-deﬁ ned cancer site, ill-deﬁ ned external causes of injury, 
heart failure, unspeciﬁ ed stroke, hypertension, and 
atherosclerosis by region, age, and sex. Because of 
variation in the coding of International Classiﬁ cation of 
Diseases 10 code X59 (exposure to unspeciﬁ ed factor)50 
and its subcauses in high-income countries, we 
redistributed these garbage codes with country-speciﬁ c 
estimates for high-income countries derived from our 
statistical analysis. Additionally, we did not use malaria as 
a target for any garbage code redistribution in adults.51 We 
also implemented geographical restrictions on garbage 
code redistribution for Chagas disease based on 
endemicity so that Chagas disease was not assigned 
deaths in countries outside Latin America.
Fourth, for some datasets, particularly some verbal 
autopsy studies, deaths were reported for broad age groups 
or with both sexes combined. With the addition of new 
data for GBD 2013, we identiﬁ ed 30 new age formats, 
totalling 112 unique age tabulations in the database. We 
used the algorithms described in the GBD 2010 to split 
these aggregated categories into estimates for speciﬁ c 
age-sex groups.
Fifth, because few overall deaths were included in verbal 
autopsy studies or reported in small countries, the number 
of deaths by cause can ﬂ uctuate substantially from year to 
year. For example, in Iceland, no maternal deaths were 
recorded from 1991 to 2000, then one maternal death in 
2001. We modiﬁ ed our approach to smoothing these 
stochastic ﬂ uctuations used in the GBD 2010 by use of a 
simple Bayesian algorithm. We assume a normally 
distributed prior and a normal data likelihood, such that:
Where X is the mean of the data and μ is the mean of 
the prior. We estimated the prior for vital registration 
series with a negative binomial regression with ﬁ xed 
eﬀ ects for year and age estimated separately for each 
country. When the data are based on a large sample size 
the variance is small and the prior has little eﬀ ect on the 
posterior. When the data have a large variance because of 
a small sample size, the prior has more eﬀ ect, eﬀ ectively 
borrowing strength on the age pattern from data within 
the same country but allowing for diﬀ erent levels in each 
year. For verbal autopsy studies, we modiﬁ ed this 
approach because many published reports are for a single 
site in a single year. The prior for each cause was based on 
a negative binomial with ﬁ xed eﬀ ects for age groups and 
random eﬀ ects for study-year; the regression was 
estimated independently for each region. For malaria, we 
did not group studies by region but by super-region and 
level of endemicity. To avoid very large negative values for 
log death rates or logit cause fractions, we limited the 
minimum non-zero posterior values to 1 per 10 000 000.
Sixth, we excluded outliers based on four criteria. (1) 
Studies with biologically implausible values, such as 
100% of mortality from a single rare cause. (2) Studies 
with results that were greatly inconsistent with other 
studies for the same country. (3) Studies that were greatly 
inconsistent with studies from other countries with 
similar sociodemographic proﬁ les within the same 
region. (4) Studies that, if included, led to abrupt changes 
in model-estimated time trends that could not be 
explained by contextual changes or policy initiatives. 
Outliers (0·89% of database entries) are shown in the 
online data visualisation of the cause of death database.
Modelling individual causes of death
As in the GBD 2010, we used six modelling strategies for 
causes of death depending on the strength of the available 
data. Where extensive data were available, we used cause 
of death ensemble modelling (CODEm), where fewer 
data were available we used simpler statistical models, 
and where available cause of death data might be 
substantially biased or not available we used natural 
history models (appendix pp 278–282). We generated 
95% UIs from all the modelling strategies. Uncertainty 
in the number of deaths for an age-sex-country-year was 
propagated into the computation of years of life lost 
(YLLs) for the same category.
For online data visualisation of 
the cause of death database see 
http://vizhub.healthdata.org/cod 
Figure 3: Total garbage and non-garbage coded deaths from vital 
registration and verbal autopsy sources, 1990–2013
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We used CODEm for 155 causes of death. CODEm has 
been extensively used for global health estimation 
including the GBD 2010.3,52,53 An advantage is that a wide 
range of diﬀ erent models are tested; only models meeting 
predetermined criteria for statistical signiﬁ cance and 
direction of regression coeﬃ  cients are retained. We 
excluded 30% of the data from the initial analysis so that 
the performance of diﬀ erent models could be assessed in 
terms of how well they predict the omitted data. Through 
multiple iterations of this process (cross-validation), we 
obtained stable objective information about the model’s 
performance. The best performing models in terms of 
root-mean squared error for level and trend were 
combined into a model ensemble. For some causes, we 
developed separate ensemble models for GBD developed 
and GBD developing regions;54 the main advantage of 
this approach is that uncertainty in model estimation 
from heterogeneous data in low-income regions does not 
inﬂ ate the UI for high-income countries. We used this 
approach for all cancers and transport injuries.
For 13 causes, the number of deaths in the cause of 
death database was too low to generate stable estimates. 
For these causes, we developed negative binomial 
regressions with either a constant or constant multiplied 
by the mean assumption for the dispersion parameter, 
using reverse step-wise model building. We selected 
between the two model dispersion assumptions on the 
basis of best ﬁ t to the data. Compared with the GBD 
2010, we modiﬁ ed how we generated uncertainty from 
these regressions by including in the uncertainty 
sampling draws from the γ distribution with shape equal 
to the expected rate (μ) divided by expected dispersion, 
and scale equal to the expected dispersion if the 
dispersion was assumed to be constant. For models in 
which dispersion was assumed to equal a constant 
multiplied by the mean, the scale parameter included μ 
as a multiplicative term (instead of the shape parameter).
As in the GBD 2010, for 14 causes for which death is 
rare, we ﬁ rst modelled the parent cause in the GBD 
hierarchy with CODEm and then allocated deaths to 
speciﬁ c causes using proportions of the parent cause for 
each sub-cause. For these causes, we identiﬁ ed no 
signiﬁ cant predictors in negative binomial regressions. 
We estimated proportions by simple averaging based on 
available vital registration data. Depending on the 
availability of data, we averaged the data across age, sex, 
region, and year.
We used DisMod-MR55 to estimate detailed cause 
fractions for several causes of death that had suﬃ  cient 
data to estimate proportions of a parent cause resulting 
from subcauses that vary across regions and countries 
but insuﬃ  cient data to run CODEm. The source code for 
estimation is available online. DisMod-MR uses data for 
subcause fractions gathered from systematic review and 
from International Classiﬁ cation of Diseases-coded vital 
registration and sample registration systems. It uses 
two types of ﬁ xed eﬀ ects (study characteristics and 
country covariates) with hierarchical random eﬀ ects for 
super-region, region, and country to generate estimates 
for each country, age group, both sexes, and six discrete 
time points: 1990, 1995, 2000, 2005, 2010, and 2013. We 
calculated predictions for intervening years—and back to 
1980—assuming an exponential rate of change. We used 
this approach for eight causes of maternal death, 
four causes of meningitis, one cause of chronic kidney 
disease, four causes of cirrhosis, four causes of liver 
cancer, and three causes of haemoglobinopathies.
For 14 causes in the GBD 2010, we used natural history 
models because data systems for cause of death did not 
capture suﬃ  cient information. The natural history 
model for African trypanosomiasis was updated to 
include the most recent case notiﬁ cation data from 
WHO (up to 2012). We made substantial changes to the 
HIV natural history model.25 Our natural history model 
for congenital syphilis was estimated as in the GBD 
2010, with updated data for antenatal care coverage to 
inform the number of births at risk and additional vital 
registration data sources to inform age and sex 
distribution of deaths. We also used simple natural 
history models for typhoid and paratyphoid fever, 
whooping cough, measles, visceral leishmaniasis, and 
yellow fever. Additionally, because vital registration data 
recording the speciﬁ c type of hepatitis were very sparse, 
we used natural history models for all the detailed 
causes of hepatitis. The natural history model takes into 
account the extensive serological data for the prevalence 
of antibodies or antigens for hepatitis A, B, and C, and 
more limited data for case-fatality rates.
Alzheimer’s disease and other dementias were 
analysed with CODEm in GBD 2010. Because of the 
large inconsistency between the data for prevalence and 
mortality, we used a natural history model in the GBD 
2013. Prevalences have not changed substantially over 
time, whereas age-standardised mortality rates in 
high-income countries have increased, ranging from 
about 25% (Denmark, Switzerland, Norway) to 46% 
(Germany). The prevalence of dementia varies between 
countries by a factor of three, whereas dementia 
mortality recorded in vital registration data and verbal 
autopsy studies varies by more than 20-fold. On the 
basis of these ﬁ ndings, we believe that the variation in 
dementia mortality rates between countries and over 
time was probably aﬀ ected by changes in coding 
practices with increased propensity to assign dementia 
as an underlying cause of death. To correct for this, we 
assessed data from 23 high-income countries with 
high-quality vital registration systems to estimate the 
ratio of registered dementia deaths:prevalent cases. In 
DisMod-MR, we used the mean of these ratios as an 
estimate of excess mortality to estimate age-speciﬁ c and 
sex-speciﬁ c mortality from dementia consistent with the 
meta-regression of prevalence.
In GBD 2010, because single-cause models were 
developed for each cause, the ﬁ nal step was to combine 
For the source code for 
estimation see http://ghdx.
healthdata.org/node/156633
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these models into estimates that are consistent with all-
cause mortality for each age-sex-country-year group. For 
each cause-speciﬁ c model and for all-cause mortality, we 
had 1000 draws from the posterior distribution for each 
age-sex-country-year group. We combined causes by 
taking a random draw without replacement from the 
posterior distribution of each cause and all-cause 
mortality. Each cause was rescaled by a scalar equal to the 
draw of all-cause mortality divided by the sum of the 
draws of individual causes. The GBD 2010 induced a 
correlation of 1·0 between the sum of cause-speciﬁ c and 
all-cause mortality. CoDCorrect was applied in a 
hierarchical fashion: ﬁ rst to level 1 causes and then to 
level 2 and level 3 causes. Level 2 causes were constrained 
to sum to the level 1 parent cause. Levels of this cascade 
were largely the same as those used in the GBD 2010 and 
were chosen on the basis of the amount and quality of 
available data for cause of death.
For GBD 2013, we made slight modiﬁ cations to this 
approach. Because tests showed no substantial eﬀ ect of the 
1·0 correlation between draws of all-cause mortality and 
the sum of individual causes and because each cause is 
modelled independently such that the ordering of draws 
across causes were unrelated, we have removed this 
assumption. Furthermore, because the modelling of HIV 
through the GBD version of Spectrum uses relationships 
between incidence, CD4 progression, and death that are 
age-dependent and antiretroviral therapy scale-up over 
time has had major eﬀ ects, we modiﬁ ed the way in which 
HIV deaths are handled in CoDCorrect. We ran 
CoDCorrect for all causes and then computed the 
pre-CoDCorrect cumulative deaths over time and age and 
compared with the cumulative deaths post-CoDCorrect. 
This provided an overall scalar, which we used to adjust the 
entire HIV epidemic. To avoid in any age-sex-country-year 
the sum of individual deaths exceeding all-cause mortality, 
we computed the diﬀ erence between the cumulatively 
scaled HIV deaths and the CoDCorrect HIV deaths and 
added this diﬀ erence to the estimate of all-cause mortality 
at the draw level.
In GBD 2010, diarrhoea deaths and lower respiratory 
infection deaths were reported for pathogen-speciﬁ c 
causes in tabulations that summed to 100% of each parent 
cause. Since the GBD 2010, the GEMS study56 has been 
published, which provided data for the relative risk of 
diarrhoea being related to diﬀ erent pathogens. This 
relative risk approach used a diﬀ erent conceptual 
framework than did the International Classiﬁ cation of 
Diseases approach for underlying cause. Underlying 
cause follows the more than 200-year history of health 
statistics of assigning each death uniquely to a single 
underlying cause. The relative risk approach follows the 
approach used more generally for risk factors, where 
cause is assigned based on comparison to a counterfactual. 
Counterfactual attribution to speciﬁ c risks or in this case 
pathogens, can sum to more or less than 100%. On the 
basis of the GEMS study and consultations among 
experts in both diarrhoea and lower respiratory infection, 
we report results for counterfactual causes in GBD 2013. 
To estimate diarrhoea mortality attributable to diﬀ erent 
pathogens, we calculated the population attributable 
fraction for pathogens including rotavirus, Shigella, 
enteropathogenic Escherichia coli, enterotoxigenic E coli, 
adenovirus (enteric adenovirus), norovirus, Aeromonas, 
other Salmonella (non-typhoidal Salmonella), 
Cryptosporidium, Campylobacter, and Entamoeba. We used 
the Miettinen formula, which uses the distribution of 
pathogens in patients and relative risks of pathogens for 
diarrhoea, to provide a population attributable fraction for 
each pathogen:57,58
Where PAFi is the population attributable fraction of 
diarrhoea caused by pathogen i, pi is the prevalence of 
pathogen i in patients with diarrhoea, and odds ratioi is 
the odds ratio of diarrhoea in people with the pathogen. 
We used DisMod-MR to estimate the proportion of 
patients in each age-sex-country-year with each 
pathogen with data from studies of inpatients and 
community samples. By use of study-level covariates in 
the meta-regression, we obtained diﬀ erent estimates 
for inpatients and community samples. We assumed 
inpatients to be a proxy for severe diarrhoea and death. 
We reanalysed GEMS59 to estimate the odds ratio for 
each pathogen in a multipathogen model by conditional 
logistic regression. Regression models included ﬁ xed 
eﬀ ects for a speciﬁ c pathogen with interaction terms 
for three age groups (0–1 years, 1–2 years, and 
2–6 years) to allow diﬀ erent odds ratios by age and 
interaction terms for diﬀ erent GEMS ﬁ eld sites 
(Bangladesh, India, Kenya, Mali, Mozambique, 
Pakistan, and The Gambia) to estimate site-speciﬁ c 
odds ratios. For other countries in the region, the odds 
ratio we used was the average of the odds ratios (in 
logarithm scale) of the countries with GEMS sites in 
that region. For countries in central and southern sub-
Saharan Africa, we used the average of GEMS sites 
located in eastern and western sub-Saharan Africa. For 
all other countries in regions without GEMS sites, we 
used the average of all odds ratio. To produce odds 
ratio uncertainty while averaging odds ratio, we 
generated 1000 draws of joint normal distribution 
using a covariance matrix from the conditional logistic 
regression for each of the GEMS countries in a region. 
To produce the draws for non-GEMS countries, we 
selected draws from each of the GEMS countries until 
we had a full set of 1000 draws. For example, to 
generate 1000 draws for countries in eastern 
sub-Saharan Africa, we used draws from Kenya and 
Mozambique—the two GEMS countries within that 
region. We pulled 500 of the Kenya draws and 500 of 
the Mozambique draws to produce our full set of 
PAFi = pi(pathogen in patients)(1 – )
1
odds ratioi
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1000 draws, which were used for all the other countries 
in this region. Because GEMS included only diarrhoea 
in children younger than 5 years, we applied the odds 
ratio of pathogens calculated for children aged 
2–5 years when calculating for adults. We did not 
assign diarrhoea cases or deaths to a pathogen for an 
age-country-year if more than 95% of draws were 
greater than 1.
For cholera, we used data from previous studies 
(appendix p 310) and compared them with WHO case 
notiﬁ cation data to estimate under-reporting for cholera 
and then the number of cases (appendix p 310). To 
estimate cholera deaths, we modelled cholera case fatality 
in DisMod-MR with data from previous studies.
Clostridium diﬃ  cile as a cause of diarrhoea in children is 
rarely studied; we could not estimate the epidemiological 
population attributable fraction as we did for other 
pathogens because C diﬃ  cile was not included in GEMS. 
Because C diﬃ  cile is related to hospital and health-care 
use, we used hospital data as the primary source for 
estimation. We modelled the incidence and case fatality of 
C diﬃ  cile and assumed a 1-month risk of death60 in 
DisMod-MR to estimate the number of deaths.
For GBD 2013, we split lower respiratory infection 
mortality into four categories: Streptococcus pneumoniae, 
Haemophilus inﬂ uenzae type B pneumonia, respiratory 
syncytial virus pneumonia, and inﬂ uenza. The counter-
factual approach captures the complex interactions 
between the these causes61 and also excludes the “other 
lower respiratory infection” category included in GBD 
2010. Moreover, we did not attribute lower respiratory 
infection to any cause for children younger than age 
1 month. We adopted a diﬀ erent approach to estimate 
bacterial and viral causes on the basis of available data. 
For pneumococcal and H inﬂ uenzae type B pneumonia, 
we estimated the causal fraction from vaccine eﬃ  cacy 
studies.62–64 For pneumococcal pneumonia, we included 
data from controlled trials and observational studies, 
such as before-after population analyses of the 
introduction of pneumococcal vaccine.65–76 For 
H inﬂ uenzae type B, we excluded case-control studies 
because of implausibly large estimates of vaccine eﬃ  cacy. 
Furthermore, unlike for pneumococcal vaccine, little data 
were available from vaccine eﬃ  cacy studies on the eﬀ ect 
outside of child ages. As a result, we did not estimate the 
causal fraction of H inﬂ uenzae type B for lower respiratory 
infection in people aged 5 years or older. We adjusted data 
for eﬃ  cacy, using invasive disease as a marker as well as 
serotype coverage for pneumococcal vaccine.64 We 
calculated pooled estimates of causal fractions by age 
with DisMod-MR for pneumococcal vaccine and 
random-eﬀ ects meta-analysis for H inﬂ uenzae type B, 
adjusted post-hoc for national-level coverage of 
pneumococcal vaccine and H inﬂ uenzae type B vaccine. 
For respiratory syncytial virus and inﬂ uenza, we relied on 
observational studies that measured causal fractions 
among hospital admissions for lower respiratory 
infection. We estimated the causal fractions among cases 
by country, age, and sex with DisMod-MR and the odds 
ratio of exposure from case-control studies. To account 
for the higher case-fatality of bacterial versus viral lower 
respiratory infections, we applied a relative case-fatality 
diﬀ erential based on in-hospital case-fatality using 
hospital admissions that included cases coded to the 
speciﬁ c pneumonia causes.
Convergence measures
To test whether all-cause and cause-speciﬁ c mortality 
converged in the 188 countries since 1990, we computed 
two measures: the average relative diﬀ erence and the 
average absolute diﬀ erence between any pair of countries 
included in the GBD 2013 study. The average relative 
diﬀ erence is known as the Gini coeﬃ  cient and is the most 
commonly used measure of inequality. For international 
comparisons, we used the population-weighted version of 
the Gini coeﬃ  cient in age-speciﬁ c mortality rates so that 
small populations do not have an undue inﬂ uence on the 
assessment of global mortality convergence (appendix 
pp 556–557).77 For the Gini coeﬃ  cient to fall, the percent 
decrease in mortality for countries with higher mortality 
must in general be faster than that for countries with 
lower mortality.
We also computed the mean absolute diﬀ erence for 
all-cause mortality for each age group for 1990–2013 and 
for age-standardised rates for each cause (appendix 
pp 556–557). Average absolute diﬀ erence can fall while 
average relative diﬀ erence (the Gini coeﬃ  cient) rises. 
The two measures provide diﬀ erent perspectives on 
convergence.
Multiple decrement lifetables
We used age-speciﬁ c cause of death and all-cause 
mortality life-tables to compute the conditional 
probability of death for three summary intervals: 
childhood and adolescence (0 to exact age 15 years), 
reproductive-age adults (15 years to exact age 50 years), 
middle-aged adults (50 years to exact age 75 years), and 
the cause-speciﬁ c contributions to each of these 
summary indicators. For each conditional probability of 
death, we used the multiple decrement life-table 
method78 to compute the probability of death from each 
cause and the overall contribution of each cause of 
death to the summary probability of death indicators 
for the three broad age groups (appendix pp 556–557). 
We calculated the decomposition of changes in life 
expectancy by age and cause of death as detailed by 
Beltran-Sanchez, Preston, and Canudas-Romo.79
Age-standardised rates and YLLs
For GBD 2010, we computed age-standardised mortality 
rates and YLL rates from the world population age 
standard issued by WHO in 2001.80 To account for the 
substantial change in global demographics since 2001, 
we updated this standard. We used the same method as 
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WHO and computed a standard population structure 
with population estimates for 2010–35 from the most 
recent World Population Prospects by the United 
Nations Population Division. Appendix pp 95–96 
provides details of the GBD world population age-
standard. We computed YLLs by multiplying numbers 
of deaths from each cause in each age group by the 
reference life expectancy at the average age of death for 
those who die in the age group following the standard 
GBD 2010 methods.3 The appendix (pp 121–40) shows 
key indicators from the new GBD standard life-table.
Ranking lists and decomposition analysis
We used the GBD 2010 approach to create ranked lists 
of speciﬁ c diseases and injuries. We modiﬁ ed GBD 
2010 ranking list to incorporate newly estimated causes 
with the same overall assignment of rank causes as 
GBD 2010: typhoid and paratyphoid separately, 
haemolytic disease in fetus and newborn and other 
neonatal jaundice, mesothelioma, unintentional 
suﬀ ocation, pulmonary aspiration and foreign body in 
trachea or lung, and foreign body in other part of body. 
Following the methods developed by Lozano and 
colleagues,3 we decomposed changes in the number of 
global deaths and global YLLs into the contributions 
from population growth, population aging, and age-
speciﬁ c death rates.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The authors had access to the 
data in the study and the ﬁ nal responsibility to submit 
the paper.
Results
Global all-cause mortality
Global life expectancy at birth for both sexes increased 
from 65·3 years in 1990, to 71·5 years in 2013, an 
average increase of 0·27 years per calendar year. Life 
expectancy increased over this period by 6·6 years for 
females and 5·8 years for males. Figure 4 shows the 
yearly change in global life expectancy at birth, with a 
large drop in the 1990s as a result of the Rwanda 
genocide and famine in North Korea and the return to 
increases of about 0·3 years or more per year since 
2003. If the median rate of change of the last 23 years 
continues, by 2030 global female life expectancy will be 
85·3 years and male life expectancy will be 78·1 years. 
Reduced fertility and the consequent demographic 
shift of the world’s population to older ages has led to 
the mean age of death increasing from 46·7 years in 
1990, to 59·3 years in 2013.81
The number of deaths globally for both sexes all ages 
increased from 47·47 (UI 46·77–48·22) million in 1990, 
to 54·86 (53·57–56·33) million in 2013, partly because of 
consistent increases in global population over the past 
decades. Rapid falls in child death rates compared with 
other age-speciﬁ c death rates have led to a shift in the age 
structure of global deaths with substantial decreases in 
children and large increases in the proportion of deaths 
of people older than age 80 years (ﬁ gure 5). The number 
of child deaths fell between 1990 and 2013 in southeast 
Asia, east Asia, and Oceania with very substantial falls in 
north Africa and the Middle East, and Latin America and 
the Caribbean (ﬁ gure 5). However, the number of child 
deaths in sub-Saharan Africa only changed from 3·68 
(3·63–3·73) million in 1990, to 3·20 (3·00–3·42) million 
in 2013. Substantial increases in the number of deaths of 
people older than age 80 years have occurred in 
high-income regions as well as in southeast Asia, east 
Asia, and Oceania.
Rising global life expectancy at birth has not come from 
uniform progress across age-groups or countries. In all 
age-groups except the 80 years and older age group, mean 
mortality rate has decreased more for females than for 
males (ﬁ gure 6). Larger decreases in males older than age 
80 years might be a result of the diﬀ erences in the age 
composition between males and females in this open-
ended age group. The mortality rate in the under-5 age 
group has fallen much more between 1990 and 2013 than 
has that for older age groups. The smallest decreases 
occurred in men in age groups 30–34 years, 35–39 years, 
and 80 years or older, and in women aged 80 years or 
older.
For all age groups, population-weighted average relative 
diﬀ erence for age-speciﬁ c mortality rates diﬀ erences 
across countries (ie, inequality) increased except in 
age group 10–14 years and 15–19 years for females. The 
divergence in age-speciﬁ c mortality rates was greatest in 
young adult age groups between ages 20 years and 44 years 
for both males and females; dominant causes in these age 
groups include HIV/AIDS, interpersonal violence, 
maternal mortality, and road injury (data not shown). For 
many age groups, in both sexes, the absolute diﬀ erences 
have fallen while relative inequalities have increased 
(ﬁ gure 6). For women aged 25–39 years and 75 years and 
older, and for men aged 20–49 years and 65 years and 
Figure 4: Change in global life expectancy at birth for males and females
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older, both relative and absolute diﬀ erences in mean age-
speciﬁ c mortality rates have increased since 1990.
Global causes of death
We decomposed change in global and regional life 
expectancy by cause (level 2 of the GBD cause hierarchy; 
ﬁ gure 7). Increased life expectancy since 1990 was mainly 
caused by a fall in mortality from lower respiratory 
infections and diarrhoeal diseases (contributing 
2·2 years), cardiovascular and circulatory diseases 
(contributing 1·1 years), neonatal conditions (contributing 
0·7 years), cancers (contributing 0·4 years), and chronic 
respiratory diseases (contributing 0·5 years). Decreases 
in mortality from unintentional injuries added another 
0·3 years to life expectancy, while female life expectancy 
increased by about 0·2 years because of reductions in 
maternal mortality. These gains were oﬀ set by increased 
mortality from diabetes, chronic kidney diseases, and 
related conditions, as well as musculoskeletal disorders, 
although the net eﬀ ect of these increases was small, 
reducing life expectancy, on average, by about 0·1 years. 
Five main causes reduced life expectancy: HIV/AIDS was 
a major cause of death in southern sub-Saharan Africa 
and to a smaller extent in western and eastern sub-
Saharan Africa; diabetes, chronic kidney disease, and 
other endocrine disorders decreased life expectancy 
across many regions, most notably in Oceania and central 
Latin America; mental disorders made a negative 
contribution in multiple regions, especially high-income 
north America; intentional injuries reduced life 
expectancy in south Asia, high-income Asia Paciﬁ c, and 
southern sub-Saharan Africa; and cirrhosis made a 
negative impact in eastern Europe and central Asia 
(ﬁ gure 7). Large gains in life expectancy in sub-Saharan 
Africa were mainly driven by reductions of diarrhoea and 
lower respiratory infections and of neonatal disorders. 
Gains in high-income regions were driven by reductions 
in cardiovascular disease, some cancers, transport 
injuries, and chronic respiratory conditions (ﬁ gure 7).
Between 1990 and 2013, numbers of deaths from 
non-communicable diseases and injuries steadily 
increased while deaths from communicable, maternal, 
neonatal, and nutritional causes decreased (table 2). 
However, age-standardised rates decreased in these 
three broad categories. The shift to non-communicable 
diseases, at least at globally, was driven by faster rates of 
decline for communicable, maternal, neonatal and 
nutritional causes and an ageing world population.
In 2013, 11·8 million (11·3–12·3) deaths were caused by 
communicable, maternal, neonatal, and nutritional 
disorders: 2·7 million (2·4–2·8) by lower respiratory 
infections, 1·3 million (1·3–1·5) by HIV/AIDS, 1·3 million 
(1·2–1·4) by tuberculosis, and 1·3 million (1·2–1·4) by 
diarrhoeal diseases, 2·0 million (1·9–2·2) by neonatal 
conditions, 854 600 (702 924–1 032 497) by malaria, and 
293 336 (261 322–328 200) by maternal causes (about 20% 
Figure 5: Global deaths by age and  super region in 1990 and 2013
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less than in 2000). Between 2000 and 2013, deaths from 
diarrhoeal diseases fell by 31·1% (from 1·8 million 
[1·7–2·0] to 1·3 million [1·2–1·4]), tuberculosis and 
meningitis each by about 20% (1·6 million [1·4–1·7] to 1·3 
million [1·2–1·4] for tuberculosis, 377 300 [331 400–438 000] 
to 303 500 [261 400–346 300] for meningitis), while 
mortality from tetanus fell by about 60% (142 400 
[108 800–163 100] to 58 900 [39 800–77 300]), from measles 
by about 80% (494 500 [279·4–763·8] to 95 600 
[48 500–172 900]), from diphtheria by about 40% (5400 
[2800–10 700] to 3300 [1700–6600]), and from whooping 
cough by about 40% (111 800 [42 300–242 400] to 60 600 
[22 300–136 800]). Deaths from neonatal causes fell by a 
quarter since 2000 (2·8 million to 2·0 million), and by 
about one-ﬁ fth for maternal causes (364 900 to 293 300). 
Comparing 2013 to 1990, malaria deaths decreased by 
4·4% and HIV/AIDS increased by 368% (table 2). HIV/
AIDS mortality and malaria mortality both peaked in 2005 
(1·7 million [1·6–1·9] for HIV/AIDS, 1·2 million [1·1–1·4] 
for malaria); HIV/AIDS mortality fell by 21% (20·4–21·5) 
from 2005 to 2013, and malaria mortality fell by 30% 
(24·8–35·4).38 The risk of death from various leading 
causes of communicable, maternal, neonatal, and 
nutritional disorders as measured by the age-standardised 
death rate (table 2), has generally declined by an even 
greater amount than the risk for HIV/AIDS and malaria. 
Age-standardised death rates decreased by about 40% 
since 1990 for the category as a whole, as well as most 
notably, for lower respiratory infections, maternal 
disorders, neonatal disorders, and asthma, and by 50–60% 
for tuberculosis, diarrhoeal diseases, pneumoconiosis and 
several neglected tropical diseases (table 2). Despite a 
small decrease in numbers of deaths, age-standardised 
malaria mortality have fallen by 19% since 1990, with 
much of that decline occurring in the past 5 years or so 
(data not shown).33
For most of the leading non-communicable diseases, 
the number of deaths has increased, by 42% between 
1990 and 2013 (from 27·0 million [UI 26·3–27·6] in 1990, 
to 38·3 million [37·2–39·4] in 2013), but age-standardised 
mortality rates have fallen. Allowing for changes in 
the age structure of the world’s population between 
1990 and 2013, age-standardised death rates from 
non-communicable diseases fell by 18·6%; by 22% for 
cardiovascular and circulatory diseases, 13·7–14·7% for 
cirrhosis of the liver and cancer, and 21·9–30·4% for 
other digestive diseases and chronic respiratory diseases 
(table 2). For many disorders, including stomach cancer, 
Hodgkin lymphoma, rheumatic heart disease, peptic 
ulcer disease, appendicitis, and schizophrenia, age-
standardised death rates have fallen by more than one-
third since 1990 (table 2). Age-standardised death rates 
Figure 6: Change in age-speciﬁ c population-weighted Gini coeﬃ  cient versus relative change in mortality rate from 1990 to 2013
Solid points show age groups for which the mean absolute diﬀ erence between countries has increased and hollow points show those for which mean absolute 
diﬀ erence has decreased.
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for some cancers have fallen (lung by 9%, breast by 18%, 
and leukaemia by 20%), but have remained unchanged 
for others (table 2). Global age-standardised death rates 
have fallen by more than one-ﬁ fth for ischaemic heart 
disease and stroke (table 2).
Global age-standardised mortality rates increased 
signiﬁ cantly for very few disease between 1990 and 2013. 
The largest increase was for HIV/AIDS, which peaked in 
2005 and then fell by 31·0% (UI 25·7% to 35·9%) from 
2005 to 2013 (from 26·9 to 18·5 per 100 000). Among the 
Figure 7: Change in life expectancy at birth by GBD region and cause group from 1990 to 2013
An interactive ﬁ gure with these data is available at http://vizhub.healthdata.org/le. Changes in life expectancy as a result of speciﬁ c causes were decomposed from 
the diﬀ erence between all-cause lifetables and cause-deleted lifetables (mortality set to zero for a speciﬁ c cause). Because all changes in life expectancy are based on 
cross-sectional lifetables, the cause-speciﬁ c changes add up to the total change in life-expectancy. NTDs=neglected tropical diseases.
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cancers, only liver cancer caused by hepatitis C increased 
substantially (table 2). Although age-standardised 
mortality for cardiovascular and circulatory diseases 
decreased by 22%, signiﬁ cant increases occurred for 
atrial ﬁ brillation and ﬂ utter and peripheral vascular 
disease (table 2). Mortality rates for Alzheimer’s disease 
and other dementias increased by only 3·2% (UI –3·01 
to 11·61) and Parkinson’s disease by 28·2% (–6·42 to 
37·83; table 2). Important worldwide increases occurred 
for diabetes (9·0%) and an even larger increase for 
chronic kidney disease (36·9%; table 2). The age-
standardised death rate for sickle-cell disease increased 
All ages deaths (thousands) Age-standardised death rate (per 100 000)
1990 2013 Median % change 1990 2013 Median % change
All causes 47 468·7
(46 771·7 to 48 223·3)
54 863·8
(53 576·1 to 56 333·6)
15·6
(12·54 to 19·11)
1160·5
(1143·2 to 1179·0)
879·7
(859·9 to 902·2)
–24·2
(–26·20 to –21·96)
Communicable, maternal, neonatal, 
and nutritional diseases
16 149·4
(15 674·5 to 16 597·6)
11 809·6
(11 335·5 to 12 283·0)
–26·8
(–29·99 to –24·10)
289·5
(281·2 to 298·4)
172·2
(165·2 to 178·8)
–40·5
(–42·98 to –38·35)
HIV/AIDS and tuberculosis 2072·5
(1938·2 to 2246·1)
2631·2
(2497·3 to 2863·2)
26·8
(17·08 to 37·92)
49·3
(46·2 to 53·3)
38·0
(36·0 to 41·6)
–23·1
(–29·02 to –16·39)
Tuberculosis 1786·1
(1666·4 to 1945·4)
1290·3
(1167·3 to 1406·2)
–27·7
(–34·99 to –20·56)
43·5
(40·4 to 47·2)
19·4
(17·6 to 21·2)
–55·3
(–59·67 to –51·01)
HIV/AIDS 286·4
(227·4 to 370·3)
1341·0
(1257·8 to 1482·6)
374·2
(262·47 to 490·73)
5·8
(4·6 to 7·6)
18·5
(17·4 to 20·5)
222·0
(145·14 to 303·34)
HIV/AIDS resulting in mycobacterial 
infection
27·8
(20·5 to 37·4)
84·0
(67·4 to 104·9)
205·1
(130·68 to 291·83)
0·6
(0·4 to 0·8)
1·2
(0·9 to 1·4)
105·5
(55·00 to 166·22)
HIV/AIDS resulting in other 
diseases
258·6
(206·1 to 334·4)
1257·0
(1178·1 to 1391·1)
393·2
(276·86–511·66)
5·3
(4·2 to 6·8)
17·4
(16·3 to 19·2)
235·0
(154·55 to 319·43)
Diarrhoea, lower respiratory infections, 
and other common infectious diseases
7880·5
(7468·3 to 8337·2)
4750·5
(4388·8 to 5029·9)
–39·4
(–45·17 to –35·89)
143·7
(137·3 to 151·9)
72·4
(66·7 to 76·5)
–49·4
(–53·54 to –46·75)
Diarrhoeal diseases 2578·7
(2412·2 to 2748·9)
1264·1
(1151·2 to 1383·2)
–51·0
(–55·55 to –46·25)
47·4
(44·4 to 50·1)
19·0
(17·4 to 20·8)
–59·8
(–63·54 to –55·96)
Intestinal infectious diseases 259·1
(145·6 to 424·6)
221·3
(122·6 to 362·6)
–14·3
(–26·08 to –2·75)
4·3
(2·4 to 7·0)
3·1
(1·7 to 5·0)
–28·7
(–38·19 to –18·98)
Typhoid fever 180·5
(96·4 to 302·3)
160·7
(85·9 to 268·0)
–10·8
(–23·70 to 4·24)
3·0
(1·6 to 5·0)
2·2
(1·2 to 3·7)
–25·9
(–36·31 to –13·57)
Paratyphoid fever 63·4
(33·6 to 106·7)
54·3
(29·3 to 92·0)
–14·9
(–30·51 to 9·48)
1·0
(0·6 to 1·7)
0·7
(0·4 to 1·3)
–28·0
(–40·99 to –7·97)
Other intestinal infectious diseases 15·3
(13·5 to 17·3)
6·3
(5·5 to 7·0)
–59·1
(–63·26 to –54·09)
0·3
(0·2 to 0·3)
0·1
(0·1 to 0·1)
–66·7
(–70·02 to –62·84)
Lower respiratory infections 3420·7
(3211·6 to 3638·4)
2652·6
(2368·0 to 2808·1)
–22·2
(–29·71 to –16·32)
66·8
(63·1 to 71·6)
41·7
(37·1 to 44·1)
–37·4
(–42·54 to –33·45)
Upper respiratory infections 4·7
(4·0 to 5·6)
3·9
(3·3 to 4·7)
–16·4
(–33·55 to 4·22)
0·1
(0·1 to 0·1)
0·1
(0·1 to 0·1)
–40·8
(–52·40 to –26·16)
Otitis media 4·9
(4·5 to 5·3)
2·4
(2·3 to 2·6)
–50·8
(–54·22 to –46·41)
0·1
(0·1 to 0·1)
0·0
(0·0 to 0·0)
–60·8
(–63·34 to –57·76)
Meningitis 464·4
(405·0 to 559·0)
303·5
(261·4 to 346·3)
–34·3
(–45·34 to –24·08)
7·7
(6·8 to 9·0)
4·3
(3·7 to 4·9)
–43·9
(–52·65 to –36·07)
Pneumococcal meningitis 112·1
(97·7 to 132·6)
79·1
(67·8 to 91·1)
–29·4
(–39·84 to –16·86)
1·9
(1·7 to 2·2)
1·1
(1·0 to 1·3)
–41·7
(–49·60 to –31·37)
Haemophilus inﬂ uenzae type B 
meningitis
118·0
(98·2 to 147·0)
64·4
(53·0 to 76·4)
–45·4
(–54·79 to –33·50)
1·8
(1·5 to 2·2)
0·9
(0·7 to 1·1)
–49·7
(–58·21 to –39·32)
Meningococcal meningitis 88·1
(76·1 to 108·0)
65·7
(55·9 to 75·8)
–24·9
(–38·82 to –12·62)
1·5
(1·3 to 1·8)
0·9
(0·8 to 1·1)
–37·3
(–47·55 to –27·80)
Other meningitis 146·1
(128·0 to 174·9)
94·2
(82·2 to 106·4)
–35·1
(–47·16 to –24·71)
2·5
(2·2 to 2·9)
1·3
(1·2 to 1·5)
–45·9
(–54·98 to –37·48)
Encephalitis 92·2
(65·2 to 116·2)
77·3
(65·4 to 97·0)
–15·2
(–40·15 to 16·01)
1·6
(1·1 to 1·9)
1·1
(0·9 to 1·4)
–28·7
(–48·10 to –4·52)
Diphtheria 8·0
(3·9 to 18·8)
3·3
(1·7 to 6·6)
–57·7
(–85·61 to 12·54)
0·1
(0·1 to 0·3)
0·0
(0·0 to 0·1)
–60·8
(–86·70 to 2·82)
Whooping cough 138·2
(52·9 to 300·2)
60·6
(22·3 to 136·8)
–56·7
(–83·76 to 14·31)
1·9
(0·7 to 4·2)
0·8
(0·3 to 1·9)
–58·2
(–84·31 to 10·44)
Tetanus 356·2
(292·9 to 578·6)
58·9
(39·8 to 77·3)
–82·1
(–92·00 to –76·10)
5·7
(4·7 to 9·1)
0·8
(0·6 to 1·1)
–83·9
(–92·72 to –77·84)
(Table 2 continues on next page)
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All ages deaths (thousands) Age-standardised death rate (per 100 000)
1990 2013 Median % change 1990 2013 Median % change
(Continued from previous page)
Measles 544·5
(304·0 to 867·8)
95·6
(48·5 to 172·9)
–83·0
(–90·23 to –67·93)
7·8
(4·3 to 12·4)
1·3
(0·7 to 2·4)
–83·7
(–90·66 to –69·19)
Varicella 8·9
(7·2 to 11·7)
7·0
(5·7 to 8·7)
–21·4
(–43·72 to 4·63)
0·2
(0·2 to 0·3)
0·1
(0·1 to 0·1)
–45·6
(–61·28 to –27·33)
Neglected tropical diseases and malaria 1 092·4
(994·1 to 1 196·7)
997·0
(840·5 to 1 185·2)
–9·2
(–25·09 to 10·78)
18·5
(17·0 to 20·2)
13·9
(11·8 to 16·5)
–24·9
(–37·19 to –9·70)
Malaria 888·1
(793·4 to 992·7)
854·6
(702·9 to 1 032·5)
–4·4
(–23·61 to 19·83)
14·6
(13·2 to 16·2)
11·9
(9·8 to 14·4)
–18·9
(–34·32 to 0·18)
Chagas disease 12·7
(5·2 to 39·4)
10·6
(4·2 to 33·0)
–19·3
(–41·12 to 25·58)
0·3
(0·1 to 1·1)
0·2
(0·1 to 0·5)
–51·7
(–66·06 to –24·52)
Leishmaniasis 52·2
(44·6 to 60·6)
62·5
(52·3 to 73·3)
19·8
(3·56 to 37·74)
0·9
(0·7 to 1·0)
0·9
(0·7 to 1·0)
–0·3
(–14·18 to 14·25)
Visceral leishmaniasis 52·2
(44·6 to 60·6)
62·5
(52·3 to 73·3)
19·8
(3·56 to 37·74)
0·9
(0·7 to 1·0)
0·9
(0·7 to 1·0)
–0·3
(–14·18 to 14·25)
African trypanosomiasis 23·0
(11·4 to 37·7)
6·9
(3·7 to 10·9)
–69·7
(–73·88 to –64·94)
0·5
(0·2 to 0·7)
0·1
(0·1 to 0·1)
–78·9
(–81·76 to –75·54)
Schistosomiasis 17·4
(14·8 to 20·6)
5·5
(4·9 to 6·2)
–68·2
(–73·56 to –61·68)
0·4
(0·4 to 0·5)
0·1
(0·1 to 0·1)
–80·7
(–84·06 to –76·71)
Cysticercosis 0·9
(0·8 to 1·1)
0·7
(0·5 to 1·0)
–28·6
(–35·23 to –15·09)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–53·0
(–57·59 to –43·63)
Cystic echinococcosis 4·0
(3·8 to 4·3)
2·2
(2·1 to 2·4)
–45·0
(–48·34 to –41·22)
0·1
(0·1 to 0·1)
0·0
(0·0 to 0·0)
–60·8
(–62·99 to –58·26)
Dengue 8·8
(5·2 to 11·3)
9·1
(5·6 to 10·8)
–1·3
(–21·69 to 74·08)
0·1
(0·1 to 0·2)
0·1
(0·1 to 0·2)
–13·6
(–31·42 to 42·41)
Yellow fever 2·2
(1·9 to 2·5)
0·5
(0·4 to 0·6)
–77·2
(–80·99 to –72·34)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–83·3
(–86·08 to –79·71)
Rabies 38·4
(26·7 to 48·7)
23·5
(17·3 to 28·6)
–38·3
(–53·14 to –24·37)
0·7
(0·5 to 0·9)
0·3
(0·2 to 0·4)
–54·0
(–64·09 to –44·23)
Intestinal nematode infections 9·1
(8·1 to 10·2)
4·5
(4·0 to 5·1)
–50·7
(–56·28 to –43·47)
0·1
(0·1 to 0·2)
0·1
(0·1 to 0·1)
–54·7
(–59·66 to –48·46)
Ascariasis 9·1
(8·1 to 10·2)
4·5
(4·0 to 5·1)
–50·7
(–56·28 to –43·47)
0·1
(0·1 to 0·2)
0·1
(0·1 to 0·1)
–54·7
(–59·66 to –48·46)
Other neglected tropical diseases 35·6
(26·4 to 44·2)
16·3
(13·9 to 19·6)
–54·4
(–64·57 to –36·37)
0·6
(0·5 to 0·8)
0·2
(0·2 to 0·3)
–62·3
(–69·58 to –49·75)
Maternal disorders 376·6
(344·0 to 408·2)
293·3
(261·3 to 328·2)
–22·3
(–31·63 to –11·38)
6·9
(6·3 to 7·5)
3·9
(3·5 to 4·4)
–43·6
(–50·45 to –35·70)
Maternal haemorrhage 71·4
(64·6 to 78·5)
44·2
(38·3 to 51·0)
–38·1
(–47·24 to –27·03)
1·3
(1·2 to 1·4)
0·6
(0·5 to 0·7)
–55·0
(–61·51 to –46·97)
Maternal sepsis and other maternal 
infections
34·1
(30·5 to 38·0)
23·8
(20·1 to 28·0)
–30·4
(–42·43 to –15·10)
0·6
(0·6 to 0·7)
0·3
(0·3 to 0·4)
–50·0
(–58·40 to –39·00)
Maternal hypertensive disorders 36·6
(33·3 to 39·9)
29·3
(25·7 to 33·5)
–20·0
(–30·89 to –7·22)
0·7
(0·6 to 0·7)
0·4
(0·3 to 0·4)
–41·3
(–49·14 to –32·20)
Obstructed labour 29·3
(26·3 to 32·7)
18·8
(16·3 to 21·8)
–35·9
(–45·56 to –23·86)
0·5
(0·5 to 0·6)
0·2
(0·2 to 0·3)
–53·4
(–60·20 to –44·45)
Complications of abortion 50·0
(45·8 to 54·8)
43·7
(38·3 to 49·9)
–12·6
(–24·72 to 2·00)
0·9
(0·9 to 1·0)
0·6
(0·5 to 0·7)
–37·5
(–46·15 to –26·71)
Indirect maternal deaths 40·1
(35·5 to 44·4)
31·1
(26·8 to 35·8)
–22·7
(–34·25 to –7·62)
0·7
(0·6 to 0·8)
0·4
(0·4 to 0·5)
–43·4
(–51·81 to –32·38)
Late maternal deaths 44·9
(36·4 to 53·2)
43·5
(35·7 to 52·4)
–1·8
(–26·81 to 21·95)
0·8
(0·7 to 1·0)
0·6
(0·5 to 0·7)
–28·4
(–46·61 to –11·67)
Maternal deaths aggravated by HIV/
AIDS
0·8
(0·5 to 1·1)
2·1
(1·3 to 2·9)
161·7
(128·02 to 202·66)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
94·1
(69·26 to 124·47)
Other maternal disorders 68·6
(58·4 to 80·4)
56·2
(48·7 to 64·4)
–18·2
(–31·79 to –0·04)
1·3
(1·1 to 1·5)
0·7
(0·6 to 0·9)
–40·8
(–50·36 to –27·88)
(Table 2 continues on next page)
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All ages deaths (thousands) Age-standardised death rate (per 100 000)
1990 2013 Median % change 1990 2013 Median % change
(Continued from previous page)
Neonatal disorders 3 433·3
(3 225·7 to 3 586·1)
2 048·0
(1 934·7 to 2 160·3)
–40·3
(–43·96 to –36·30)
46·9
(44·1 to 49·0)
27·6
(26·1 to 29·1)
–41·1
(–44·71 to –37·13)
Preterm birth complications 1 570·5
(1 285·0 to 1 803·5)
742·4
(591·3 to 910·8)
–52·9
(–58·70 to –45·50)
21·4
(17·5 to 24·6)
10·0
(8·0 to 12·3)
–53·5
(–59·23 to –46·20)
Neonatal encephalopathy (birth 
asphyxia/trauma)
874·1
(688·5 to 1 055·4)
643·8
(515·0 to 760·5)
–26·1
(–38·29 to –11·35)
11·9
(9·4 to 14·4)
8·7
(6·9 to 10·3)
–27·1
(–39·06 to –12·49)
Neonatal sepsis and other neonatal 
infections
346·4
(195·7 to 484·0)
366·0
(233·2 to 510·8)
6·1
(–15·94 to 38·04)
4·7
(2·7 to 6·6)
4·9
(3·1 to 6·9)
4·6
(–17·13 to 35·99)
Haemolytic disease and other neonatal 
jaundice
64·8
(39·5 to 96·3)
19·6
(13·0 to 29·7)
–70·0
(–79·78 to –50·43)
0·9
(0·5 to 1·3)
0·3
(0·2 to 0·4)
–70·6
(–80·17 to –51·17)
Other neonatal disorders 577·6
(457·5 to 756·0)
276·2
(219·6 to 350·7)
–52·3
(–62·41 to –36·77)
7·9
(6·3 to 10·3)
3·7
(3·0 to 4·7)
–53·0
(–63·01 to –37·68)
Nutritional deﬁ ciencies 757·7
(641·5 to 934·4)
681·1
(533·5 to 795·5)
–9·7
(–22·87 to 1·86)
14·7
(12·4 to 18·2)
10·4
(8·2 to 12·2)
–28·6
(–38·77 to –20·45)
Protein-energy malnutrition 507·9
(394·3 to 648·5)
468·8
(350·0 to 560·9)
–7·3
(–22·92 to 7·51)
9·2
(7·1 to 11·8)
7·1
(5·3 to 8·5)
–22·5
(–34·54 to –11·34)
Iodine deﬁ ciency 2·1
(1·4 to 3·4)
2·7
(1·5 to 4·7)
24·5
(–29·82 to 137·21)
0·0
(0·0 to 0·1)
0·0
(0·0 to 0·1)
–7·9
(–47·13 to 80·62)
Iron-deﬁ ciency anemia 213·4
(143·5 to 309·3)
183·4
(122·0 to 259·2)
–13·8
(–32·36 to 5·33)
4·6
(3·3 to 6·6)
2·8
(1·9 to 4·0)
–38·8
(–50·36 to –26·57)
Other nutritional deﬁ ciencies 34·3
(23·8 to 56·1)
26·2
(17·0 to 41·2)
–22·5
(–42·66 to –4·64)
0·8
(0·5 to 1·3)
0·4
(0·3 to 0·7)
–45·4
(–56·40 to –33·85)
Other communicable, maternal, 
neonatal, and nutritional diseases
536·5
(433·0 to 674·9)
408·4
(342·1 to 488·3)
–23·8
(–33·94 to –11·53)
9·4
(7·9 to 11·4)
5·9
(5·0 to 7·0)
–37·4
(–44·55 to –28·28)
Sexually transmitted diseases 
excluding HIV
257·6
(154·7 to 396·4)
142·0
(87·6 to 213·9)
–44·5
(–55·96 to –32·77)
3·8
(2·4 to 5·7)
1·9
(1·2 to 2·9)
–48·4
(–58·54 to –37·36)
Syphilis 250·6
(147·4 to 389·1)
136·8
(82·4 to 208·9)
–45·1
(–56·56 to –33·02)
3·6
(2·2 to 5·5)
1·9
(1·1 to 2·9)
–48·0
(–58·61 to –36·83)
Chlamydial infection 1·5
(1·1 to 1·9)
1·1
(0·9 to 1·4)
–23·0
(–42·59 to 0·03)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–51·1
(–64·66 to –34·62)
Gonococcal infection 3·2
(2·5 to 3·8)
2·3
(2·0 to 2·9)
–26·6
(–41·91 to –6·75)
0·1
(0·1 to 0·1)
0·0
(0·0 to 0·0)
–54·0
(–64·57 to –39·74)
Other sexually transmitted diseases 2·4
(1·9 to 2·8)
1·7
(1·5 to 2·1)
–27·3
(–42·08 to –10·71)
0·1
(0·0 to 0·1)
0·0
(0·0 to 0·0)
–53·2
(–63·49 to –40·60)
Hepatitis 162·0
(152·8 to 171·4)
136·7
(123·7 to 163·2)
–16·8
(–25·24 to 2·96)
3·3
(3·1 to 3·5)
2·0
(1·8 to 2·4)
–39·6
(–45·37 to –25·80)
Hepatitis A 22·6
(7·9 to 40·2)
14·9
(5·0 to 27·7)
–36·3
(–50·41 to –2·45)
0·3
(0·1 to 0·6)
0·2
(0·1 to 0·4)
–41·9
(–54·39 to –12·04)
Hepatitis B 85·0
(65·1 to 104·0)
68·6
(52·0 to 86·6)
–19·7
(–28·94 to –4·23)
1·9
(1·5 to 2·2)
1·1
(0·8 to 1·3)
–44·6
(–50·38 to –35·37)
Hepatitis C 2·3
(0·5 to 5·3)
3·5
(0·7 to 8·2)
51·0
(24·40 to 86·56)
0·1
(0·0 to 0·1)
0·1
(0·0 to 0·1)
–4·2
(–20·86 to 17·67)
Hepatitis E 52·1
(39·0 to 67·2)
49·7
(36·1 to 67·5)
–6·1
(–17·83 to 20·41)
1·0
(0·7 to 1·3)
0·7
(0·5 to 1·0)
–30·8
(–39·35 to –11·37)
Other infectious diseases 116·9
(94·0 to 144·3)
129·8
(89·6 to 164·9)
11·3
(–21·67 to 45·00)
2·4
(1·9 to 3·0)
2·0
(1·4 to 2·5)
–17·7
(–42·92 to 7·31)
Non-communicable diseases 26 993·5
(26 298·1 to 
27 639·1)
38 267·2
(37 202·2 to 39 417·6)
41·7
(36·86 to 47·00)
782·5
(765·5 to 798·2)
637·5
(620·4 to 655·7)
–18·6
(–21·08 to –15·78)
Neoplasms 5659·7
(5440·4 to 5826·6)
8235·7
(7941·4 to 8538·9)
45·6
(39·82 to 51·55)
157·0
(151·3 to 161·5)
133·8
(128·9 to 138·6)
–14·7
(–17·91 to –11·49)
Oesophageal cancer 313·1
(275·0 to 351·5)
440·2
(389·2 to 516·8)
39·9
(26·42 to 56·36)
8·8
(7·8 to 9·9)
7·2
(6·3 to 8·4)
–19·3
(–27·13 to –9·94)
Stomach cancer 763·4
(725·6 to 803·2)
841·0
(791·6 to 894·1)
10·1
(3·94 to 17·43)
21·7
(20·6 to 22·9)
13·8
(13·0 to 14·7)
–36·3
(–39·82 to –32·14)
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Liver cancer 510·1
(474·9 to 543·1)
818·0
(763·7 to 879·0)
60·3
(46·21 to 75·28)
13·7
(12·7 to 14·5)
13·0
(12·1 to 13·9)
–5·0
(–13·01 to 3·61)
Liver cancer secondary to hepatitis B 198·4
(181·7 to 215·4)
300·0
(272·0 to 329·2)
51·6
(33·51 to 72·02)
5·1
(4·7 to 5·5)
4·6
(4·2 to 5·1)
–9·1
(–19·63 to 2·69)
Liver cancer secondary to hepatitis C 87·4
(79·5 to 94·7)
342·5
(317·1 to 375·3)
290·8 (251·46 to 
342·52)
2·4
(2·2 to 2·6)
5·5
(5·1 to 6·0)
125·4
(103·82 to 154·85)
Liver cancer secondary to alcohol use 122·8
(113·8 to 132·5)
92·2
(84·8 to 100·3)
–25·2 (–31·20 to 
–17·09)
3·5
(3·2 to 3·7)
1·5
(1·4 to 1·6)
–56·4
(–59·87 to –51·82)
Other liver cancer 101·5
(92·8 to 110·0)
83·3
(75·1 to 92·2)
–17·5
(–28·57 to –7·02)
2·6
(2·4 to 2·9)
1·3
(1·2 to 1·4)
–50·5
(–56·97 to –44·23)
Larynx cancer 76·2
(62·7 to 88·1)
87·6
(74·3 to 106·2)
14·2
(7·25 to 27·55)
2·1
(1·7 to 2·4)
1·4
(1·2 to 1·7)
–33·4
(–37·26 to –26·29)
Tracheal, bronchus, and lung cancer 1050·0
(1010·6 to 1078·2)
1639·6
(1565·6 to 1706·0)
56·5
(47·83 to 62·84)
29·6
(28·5 to 30·4)
27·0
(25·7 to 28·1)
–8·7
(–13·62 to –5·16)
Breast cancer 327·3
(289·2 to 366·8)
471·0
(412·0 to 514·2)
44·2
(35·01 to 51·82)
9·0
(7·9 to 10·1)
7·4
(6·4 to 8·1)
–17·5
(–23·42 to –13·38)
Cervical cancer 196·3
(162·9 to 212·4)
235·7
(201·9 to 257·9)
20·1
(10·74 to 30·15)
5·2
(4·3 to 5·6)
3·6
(3·1 to 4·0)
–30·1
(–35·55 to –24·13)
Uterine cancer 45·6
(36·6 to 55·6)
67·7
(53·6 to 79·0)
48·6
(30·64 to 64·39)
1·3
(1·0 to 1·6)
1·1
(0·9 to 1·3)
–15·0
(–24·61 to –6·58)
Prostate cancer 157·1
(124·0 to 193·1)
292·7
(242·2 to 373·9)
82·8
(71·77 to 109·02)
5·1
(4·0 to 6·3)
5·2
(4·3 to 6·6)
–1·0
(–7·17 to 13·05)
Colon and rectum cancer 490·2
(476·1 to 504·5)
771·1
(741·5 to 799·2)
57·4
(51·89 to 62·64)
14·5
(14·1 to 14·9)
12·8
(12·4 to 13·3)
–11·1
(–14·40 to –8·17)
Lip and oral cavity cancer 83·9
(74·0 to 96·2)
135·0
(115·3 to 154·3)
59·7
(46·91 to 78·39)
2·3
(2·0 to 2·6)
2·1
(1·8 to 2·5)
–7·9
(–14·96 to 2·32)
Nasopharynx cancer 53·7
(47·7 to 63·5)
60·5
(54·0 to 69·5)
12·7
(1·19 to 24·74)
1·4
(1·2 to 1·6)
0·9
(0·8 to 1·1)
–32·5
(–39·31 to –25·55)
Other pharynx cancer 48·9
(43·7 to 53·5)
78·6
(67·0 to 86·3)
60·9
(43·26 to 76·41)
1·3
(1·2 to 1·4)
1·2
(1·0 to 1·3)
–7·1
(–16·97 to 2·04)
Gallbladder and biliary tract cancer 115·4
(100·6 to 130·4)
139·5
(120·0 to 155·0)
22·1
(6·85 to 32·36)
3·4
(3·0 to 3·9)
2·3
(2·0 to 2·6)
–31·2
(–39·96 to –25·22)
Pancreatic cancer 186·4
(181·3 to 191·8)
352·4
(339·4 to 364·8)
89·0
(82·43 to 95·46)
5·4
(5·3 to 5·6)
5·9
(5·6 to 6·1)
7·4
(3·63 to 11·04)
Malignant skin melanoma 38·7
(30·1 to 50·9)
56·9
(43·9 to 75·7)
47·6
(31·54 to 57·81)
1·1
(0·8 to 1·4)
0·9
(0·7 to 1·2)
–14·1
(–23·86 to –8·06)
Non-melanoma skin cancer 25·0
(20·2 to 30·0)
39·2
(32·8 to 48·7)
55·0
(43·30 to 76·59)
0·8
(0·6 to 0·9)
0·7
(0·6 to 0·8)
–12·9
(–20·00 to –0·93)
Ovarian cancer 98·9
(93·1 to 106·1)
157·8
(147·5 to 169·5)
59·6
(50·81 to 68·88)
2·7
(2·6 to 2·9)
2·5
(2·3 to 2·7)
–7·8
(–12·97 to –2·56)
Testicular cancer 7·0
(5·4 to 8·2)
8·3
(6·3 to 10·4)
18·4
(8·86 to 35·42)
0·2
(0·1 to 0·2)
0·1
(0·1 to 0·1)
–23·0
(–28·60 to –11·08)
Kidney cancer 77·9
(73·8 to 83·0)
133·8
(126·0 to 141·1)
71·8
(63·06 to 81·02)
2·1
(2·0 to 2·3)
2·2
(2·0 to 2·3)
1·6
(–3·95 to 8·11)
Bladder cancer 130·8
(116·6 to 140·9)
173·9
(156·8 to 192·5)
32·2
(27·35 to 43·06)
4·0
(3·5 to 4·3)
3·0
(2·7 to 3·3)
–25·6
(–28·36 to –20·14)
Brain and nervous system cancers 136·0
(116·6 to 155·2)
203·9
(169·5 to 234·8)
50·4
(34·04 to 60·33)
3·3
(2·8 to 3·8)
3·1
(2·6 to 3·6)
–4·6
(–13·99 to 0·96)
Thyroid cancer 23·8
(20·3 to 26·1)
33·7
(29·6 to 38·2)
41·1
(29·80 to 59·27)
0·7
(0·6 to 0·8)
0·6
(0·5 to 0·6)
–19·6
(–25·50 to –9·09)
Mesothelioma 17·0
(15·2 to 20·3)
33·7
(29·4 to 38·7)
100·5
(69·94 to 115·47)
0·5
(0·4 to 0·6)
0·5
(0·5 to 0·6)
16·2
(–2·42 to 24·92)
Hodgkin lymphoma 33·6
(24·1 to 38·0)
24·2
(22·0 to 31·6)
–33·0
(–40·41 to 15·35)
0·8
(0·5 to 0·8)
0·4
(0·3 to 0·5)
–54·9
(–58·93 to –24·34)
Non-Hodgkin lymphoma 133·6
(116·3 to 158·0)
225·5
(186·3 to 245·8)
72·0
(41·51 to 84·35)
3·5
(3·1 to 4·2)
3·6
(2·9 to 3·9)
6·1
(–14·56 to 13·42)
Multiple myeloma 45·3
(37·4 to 57·4)
79·4
(65·3 to 94·2)
77·1
(53·64 to 90·08)
1·3
(1·1 to 1·7)
1·3
(1·1 to 1·6)
0·4
(–13·32 to 8·27)
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Leukaemia 223·8
(215·1 to 234·2)
265·1
(253·9 to 275·8)
18·7
(11·69 to 24·19)
5·2
(5·0 to 5·4)
4·1
(3·9 to 4·3)
–20·0
(–24·12 to –16·68)
Other neoplasms 250·6
(231·8 to 305·2)
369·6
(328·0 to 400·1)
51·3
(15·57 to 62·10)
6·2
(5·8 to 7·3)
5·8
(5·2 to 6·3)
–4·2
(–23·44 to 3·32)
Cardiovascular diseases 12 279·6
(11 776·6 to 12 764·1)
17 297·5
(16 520·2 to 18 071·9)
40·8
(36·17 to 46·36)
375·5
(360·5 to 389·1)
293·2
(280·4 to 306·1)
–22·0
(–24·50 to –19·07)
Rheumatic heart disease 373·5
(302·5 to 464·6)
275·1
(222·6 to 353·9)
–26·5
(–33·64 to –17·20)
9·8
(7·9 to 12·2)
4·4
(3·5 to 5·6)
–55·4
(–59·47 to –50·11)
Ischaemic heart disease 5737·5
(5254·9 to 6148·6)
8139·9
(7322·9 to 8758·5)
41·7
(35·96 to 48·44)
177·3
(161·8 to 190·2)
137·8
(123·9 to 148·2)
–22·3
(–25·48 to –18·68)
Cerebrovascular disease 4584·8
(4162·1 to 4968·1)
6446·9
(5963·0 to 7155·2)
40·2
(34·43 to 49·56)
141·6
(128·5 to 153·9)
110·1
(101·8 to 122·2)
–22·5
(–25·56 to –17·30)
Ischaemic stroke 21 82·9
(1923·3 to 2430·9)
3272·9
(2812·7 to 3592·6)
50·2
(41·02 to 59·27)
71·3
(63·0 to 79·3)
57·3
(49·3 to 62·9)
–19·6
(–24·52 to –14·97)
Haemorrhagic stroke 2401·9
(2109·4 to 2669·1)
3174·0
(2885·7 to 3719·7)
30·7
(22·23 to 49·07)
70·3
(61·2 to 77·9)
52·8
(48·0 to 62·3)
–25·9
(–30·64 to –14·73)
Hypertensive heart disease 622·1
(525·7 to 783·9)
1068·6
(849·8 to 1 242·2)
74·1
(47·34 to 93·73)
19·3
(16·4 to 24·4)
18·2
(14·5 to 21·3)
–4·5
(–18·86 to 6·41)
Cardiomyopathy and myocarditis 293·9
(243·5 to 346·3)
443·3
(370·1 to 512·0)
51·4
(37·27 to 61·45)
8·2
(6·9 to 9·6)
7·1
(6·0 to 8·3)
–12·6
(–19·98 to –7·68)
Atrial ﬁ brillation and ﬂ utter 28·9
(26·0 to 32·4)
112·2
(97·7 to 126·7)
288·1
(246·32 to 335·03)
1·0
(0·9 to 1·1)
2·0
(1·8 to 2·3)
100·0
(77·55 to 124·90)
Aortic aneurysm 99·6
(82·4 to 118·5)
151·5
(124·2 to 180·0)
52·1
(43·75 to 60·91)
3·0
(2·5 to 3·6)
2·6
(2·1 to 3·1)
–15·3
(–20·06 to –10·50)
Peripheral vascular disease 15·9
(14·4 to 17·5)
40·5
(35·5 to 44·9)
155·3
(126·51 to 178·39)
0·5
(0·5 to 0·6)
0·7
(0·6 to 0·8)
34·1
(18·77 to 46·62)
Endocarditis 45·1
(35·6 to 58·6)
65·0
(48·6 to 79·4)
46·3
(23·88 to 65·52)
1·2
(1·0 to 1·6)
1·0
(0·8 to 1·3)
–12·7
(–25·81 to –2·80)
Other cardiovascular and circulatory 
diseases
478·3
(403·9 to 546·4)
554·6
(499·1 to 654·2)
15·2
(9·38 to 32·52)
13·6
(11·5 to 15·5)
9·3
(8·3 to 10·8)
–32·2
(–35·44 to –22·40)
Chronic respiratory diseases 3490·2
(3280·4 to 3795·3)
4267·5
(3996·3 to 4694·2)
21·9
(14·95 to 31·48)
104·5
(98·5 to 113·3)
73·0
(68·4 to 80·2)
–30·4
(–34·19 to –25·05)
Chronic obstructive pulmonary disease 2421·3
(2151·3 to 2632·4)
2931·2
(2626·3 to 3215·8)
21·0
(12·70 to 31·26)
74·8
(66·8 to 81·2)
50·7
(45·4 to 55·6)
–32·3
(–36·75 to –26·54)
Pneumoconiosis 251·2
(184·0 to 317·8)
259·7
(201·7 to 331·2)
1·9
(–15·21 to 40·27)
7·2
(5·3 to 9·0)
4·3
(3·3 to 5·5)
–40·5
(–50·81 to –19·84)
Silicosis 55·4
(36·7 to 77·1)
46·3
(32·1 to 64·8)
–16·0
(–32·85 to 6·14)
1·6
(1·0 to 2·2)
0·8
(0·5 to 1·1)
–50·7
(–61·18 to –38·06)
Asbestosis 21·0
(13·9 to 30·4)
24·1
(17·5 to 32·3)
14·2
(–10·20 to 54·87)
0·6
(0·4 to 0·9)
0·4
(0·3 to 0·5)
–32·6
(–47·35 to –9·61)
Coal workers pneumoconiosis 28·9
(18·2 to 43·9)
25·2
(19·0 to 35·6)
–13·7
(–30·65 to 23·06)
0·8
(0·5 to 1·2)
0·4
(0·3 to 0·6)
–50·2
(–60·26 to –29·13)
Other pneumoconiosis 145·9
(100·3 to 189·2)
164·1
(123·1 to 213·6)
10·9
(–13·48 to 61·23)
4·2
(2·9 to 5·5)
2·7
(2·0 to 3·6)
–35·3
(–50·19 to –6·77)
Asthma 504·3
(399·7 to 731·8)
489·0
(397·7 to 676·8)
–2·9
(–24·58 to 19·21)
13·7
(10·8 to 20·4)
8·0
(6·5 to 11·1)
–41·5
(–55·17 to –28·01)
Interstitial lung disease and pulmonary 
sarcoidosis
217·6
(128·7 to 299·4)
471·5
(372·3 to 606·8)
114·1
(53·25 to 214·86)
6·6
(3·9 to 8·9)
8·0
(6·3 to 10·3)
20·1
(–11·89 to 74·20)
Other chronic respiratory diseases 95·8
(78·3 to 113·8)
116·1
(99·2 to 136·9)
21·2
(7·78 to 40·66)
2·2
(1·8 to 2·7)
1·9
(1·6 to 2·3)
–15·1
(–24·22 to –3·39)
Cirrhosis of the liver 838·0
(807·0 to 866·7)
1 221·1
(1 170·3 to 1 284·3)
45·6
(38·47 to 54·52)
21·8
(20·9 to 22·5)
18·8
(18·0 to 19·7)
–13·7
(–17·75 to –8·49)
Cirrhosis of the liver secondary to 
hepatitis B
233·9
(220·8 to 250·0)
317·4
(292·3 to 344·6)
35·6
(22·66 to 49·58)
6·1
(5·7 to 6·5)
4·9
(4·5 to 5·3)
–19·3
(–26·86 to –11·11)
Cirrhosis of the liver secondary to 
hepatitis C
213·1
(200·4 to 226·7)
357·8
(334·3 to 386·1)
67·3
(54·60 to 83·86)
5·7
(5·4 to 6·0)
5·6
(5·2 to 6·0)
–2·4
(–9·58 to 7·48)
Cirrhosis of the liver secondary to 
alcohol use
292·2
(276·5 to 307·1)
383·8
(356·2 to 414·7)
31·2
(20·27 to 43·97)
7·8
(7·4 to 8·2)
5·9
(5·5 to 6·4)
–24·1
(–30·24 to –16·92)
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Other cirrhosis of the liver 98·8
(92·1 to 106·0)
162·1
(145·5 to 182·9)
63·5
(47·65 to 86·21)
2·2
(2·0 to 2·3)
2·4
(2·1 to 2·7)
9·3
(–1·52 to 24·19)
Digestive diseases 1053·2
(958·6 to 1 131·2)
1168·3
(1 064·4 to 1 275·5)
10·4
(2·11 to 22·38)
28·4
(25·8 to 30·5)
19·0
(17·4 to 20·7)
–33·5
(–38·30 to –26·51)
Peptic ulcer disease 326·9
(288·8 to 388·7)
301·4
(249·8 to 350·5)
–7·6
(–21·26 to 5·52)
9·1
(8·0 to 10·7)
4·9
(4·1 to 5·7)
–45·8
(–53·37 to –38·53)
Gastritis and duodenitis 54·2
(32·1 to 76·3)
59·5
(42·2 to 90·1)
5·8
(–13·46 to 50·38)
1·4
(0·8 to 2·0)
1·0
(0·7 to 1·5)
–35·1
(–46·54 to –6·86)
Appendicitis 87·5
(70·8 to 105·9)
71·9
(51·4 to 89·5)
–17·8
(–34·66 to 2·68)
2·0
(1·6 to 2·4)
1·1
(0·8 to 1·4)
–45·7
(–56·37 to –33·27)
Paralytic ileus and intestinal 
obstruction
178·0
(116·3 to 228·5)
235·7
(175·6 to 327·0)
29·4
(11·32 to 68·61)
4·7
(3·1 to 6·1)
3·8
(2·8 to 5·3)
–20·3
(–31·07 to 1·80)
Inguinal, femoral, and abdominal 
hernia
50·5
(33·2 to 61·2)
32·5
(25·6 to 48·8)
–41·8
(–49·26 to –4·88)
1·4
(0·9 to 1·7)
0·5
(0·4 to 0·8)
–64·8
(–69·29 to –44·12)
Inﬂ ammatory bowel disease 54·9
(40·4 to 67·2)
51·2
(42·4 to 69·7)
–8·7
(–17·41 to 13·01)
1·4
(1·0 to 1·6)
0·8
(0·7 to 1·1)
–41·8
(–47·30 to –25·30)
Vascular intestinal disorders 52·6
(34·7 to 78·4)
79·5
(51·9 to 113·3)
51·8
(36·03 to 67·16)
1·6
(1·1 to 2·4)
1·4
(0·9 to 1·9)
–16·3
(–24·49 to –8·10)
Gallbladder and biliary diseases 80·5
(68·9 to 94·1)
105·9
(89·1 to 122·3)
32·2
(18·76 to 43·46)
2·4
(2·0 to 2·8)
1·8
(1·5 to 2·1)
–24·5
(–31·76 to –18·21)
Pancreatitis 83·0
(59·2 to 111·3)
122·6
(85·9 to 152·3)
49·1
(16·02 to 76·94)
2·1
(1·5 to 2·9)
1·9
(1·3 to 2·4)
–10·2
(–29·33 to 5·74)
Other digestive diseases 85·2
(73·3 to 99·5)
108·0
(90·4 to 124·2)
27·1
(14·25 to 39·04)
2·3
(2·0 to 2·6)
1·8
(1·5 to 2·0)
–21·9
(–29·04 to –15·13)
Neurological disorders 1017·5
(965·0 to 1 072·3)
1976·8
(1875·0 to 2080·7)
94·0
(83·99 to 106·61)
34·2
(32·3 to 36·1)
35·0
(33·2 to 36·9)
2·3
(–3·27 to 9·08)
Alzheimer’s disease and other 
dementias
795·8
(747·9 to 844·3)
1655·1
(1563·5 to 1765·3)
107·2
(94·94 to 124·00)
28·9
(27·1 to 30·7)
29·9
(28·2 to 31·9)
3·2
(–3·01 to 11·61)
Parkinson’s disease 43·7
(38·3 to 55·1)
102·5
(79·3 to 112·6)
139·8
(77·36 to 156·99)
1·5
(1·3 to 1·9)
1·8
(1·4 to 2·0)
28·2
(–6·42 to 37·83)
Epilepsy 111·0
(95·5 to 129·9)
115·8
(93·7 to 132·0)
4·7
(–12·05 to 24·00)
2·2
(1·9 to 2·5)
1·7
(1·3 to 1·9)
–22·4
(–33·73 to –10·21)
Multiple sclerosis 12·4
(9·2 to 19·0)
19·8
(12·8 to 25·5)
64·8
(3·60 to 87·09)
0·3
(0·2 to 0·5)
0·3
(0·2 to 0·4)
–1·1
(–38·78 to 11·91)
Other neurological disorders 54·6
(47·1 to 60·8)
83·7
(71·8 to 90·8)
54·2
(37·88 to 60·72)
1·4
(1·2 to 1·5)
1·3
(1·1 to 1·4)
–3·6
(–10·27 to 0·43)
Mental and substance use disorders 188·3
(157·2 to 242·3)
282·4
(233·9 to 329·3)
51·5
(32·26 to 63·84)
4·3
(3·6 to 5·7)
4·0
(3·3 to 4·7)
–5·7
(–18·55 to 2·10)
Schizophrenia 22·8
(14·7 to 28·3)
16·0
(13·7 to 22·8)
–35·5
(–46·52 to 29·94)
0·6
(0·4 to 0·7)
0·2
(0·2 to 0·3)
–59·7
(–66·47 to –20·07)
Alcohol use disorders 111·9
(84·0 to 165·3)
139·2
(90·2 to 178·5)
28·2
(1·78 to 35·66)
2·7
(2·0 to 3·9)
2·0
(1·3 to 2·6)
–22·0
(–38·53 to –17·54)
Drug use disorders 53·2
(47·8 to 64·1)
126·6
(110·8 to 135·5)
140·4
(101·60 to 159·88)
1·1
(1·0 to 1·3)
1·8
(1·6 to 1·9)
63·0
(36·10 to 74·81)
Opioid use disorders 18·0
(16·5 to 22·2)
50·7
(43·4 to 54·4)
187·3
(134·80 to 210·24)
0·4
(0·3 to 0·5)
0·7
(0·6 to 0·8)
92·7
(56·69 to 107·16)
Cocaine use disorders 2·4
(2·2 to 2·9)
4·3
(3·9 to 4·7)
77·2
(49·11 to 102·26)
0·1
(0·0 to 0·1)
0·1
(0·1 to 0·1)
20·9
(1·97 to 36·34)
Amphetamine use disorders 2·1
(1·9 to 2·5)
3·8
(3·4 to 4·1)
80·4
(52·49 to 106·70)
0·0
(0·0 to 0·1)
0·1
(0·0 to 0·1)
23·2
(4·70 to 40·49)
Other drug use disorders 30·7
(26·1 to 37·3)
67·7
(59·5 to 72·8)
122·8
(86·51 to 146·32)
0·6
(0·6 to 0·8)
1·0
(0·8 to 1·0)
51·6
(26·34 to 65·39)
Eating disorders 0·4
(0·3 to 0·4)
0·6
(0·5 to 0·7)
60·4
(41·17 to 84·68)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
13·5
(–0·42 to 30·16)
Anorexia nervosa 0·4
(0·3 to 0·4)
0·6
(0·5 to 0·7)
60·4
(41·17 to 84·68)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
13·5
(–0·42 to 30·16)
(Table 2 continues on next page)
Articles
www.thelancet.com   Vol 385   January 10, 2015 137
All ages deaths (thousands) Age-standardised death rate (per 100 000)
1990 2013 Median % change 1990 2013 Median % change
(Continued from previous page)
Diabetes, urogenital, blood, and 
endocrine diseases
1569·4
(1456·7 to 1709·2)
2955·0
(2764·0 to 3171·1)
88·9
(76·44 to 99·49)
42·2
(39·5 to 44·7)
48·3
(45·1 to 51·4)
14·4
(9·53 to 20·14)
Diabetes mellitus 684·3
(653·2 to 711·5)
1299·4
(1234·5 to 1374·8)
89·7
(81·77 to 99·94)
19·8
(18·9 to 20·6)
21·6
(20·6 to 22·9)
9·0
(4·59 to 14·69)
Acute glomerulonephritis 23·6
(13·7 to 33·4)
18·8
(14·3 to 22·8)
–21·4
(–36·96 to 14·96)
0·5
(0·3 to 0·8)
0·3
(0·2 to 0·3)
–45·8
(–55·70 to –21·57)
Chronic kidney disease 408·6
(363·8 to 433·4)
956·2
(812·9 to 1 034·5)
134·6
(115·70 to 150·20)
11·6
(10·4 to 12·3)
15·8
(13·5 to 17·1)
36·9
(25·43 to 46·11)
Chronic kidney disease due to 
diabetes mellitus
46·3
(34·8 to 54·8)
173·1
(139·3 to 208·8)
274·1
(243·06 to 309·05)
1·4
(1·0 to 1·6)
2·9
(2·3 to 3·5)
106·5
(89·67 to 127·74)
Chronic kidney disease due to 
hypertension
120·0
(91·6 to 144·8)
275·7
(196·9 to 336·5)
130·6
(106·28 to 151·38)
3·6
(2·8 to 4·4)
4·6
(3·3 to 5·6)
29·4
(15·20 to 40·43)
Chronic kidney disease due to 
glomerulonephritis
99·0
(84·5 to 114·7)
116·3
(92·9 to 144·0)
16·9
(1·69 to 35·32)
2·5
(2·1 to 2·9)
1·8
(1·5 to 2·3)
–26·8
(–35·84 to –15·66)
Chronic kidney diseases due to other 
causes
143·3
(115·3 to 168·0)
391·2
(297·0 to 452·3)
175·3
(140·05 to 202·16)
4·1
(3·3 to 4·8)
6·5
(4·9 to 7·5)
58·8
(37·59 to 74·71)
Urinary diseases and male infertility 
due to other causes
151·4
(129·1 to 161·1)
245·8
(205·5 to 264·7)
62·8
(49·74 to 72·37)
4·3
(3·7 to 4·6)
4·1
(3·4 to 4·4)
–3·7
(–12·86 to 1·66)
Interstitial nephritis and urinary tract 
infections
109·9
(92·9 to 118·1)
175·5
(144·6 to 192·0)
58·9
(48·57 to 74·08)
3·1
(2·7 to 3·4)
2·9
(2·4 to 3·2)
–6·3
(–14·36 to 2·19)
Urolithiasis 15·1
(11·1 to 18·7)
14·7
(12·4 to 20·1)
–5·9
(–16·02 to 44·87)
0·4
(0·3 to 0·5)
0·2
(0·2 to 0·3)
–45·3
(–50·97 to –14·32)
Other urinary diseases 26·3
(21·9 to 35·0)
55·5
(40·4 to 66·5)
122·4
(69·54 to 151·57)
0·7
(0·6 to 1·0)
0·9
(0·7 to 1·1)
32·5
(2·75 to 50·04)
Gynaecological diseases 5·3
(3·9 to 7·0)
3·4
(2·9 to 4·8)
–36·7
(–47·76 to –14·33)
0·1
(0·1 to 0·2)
0·1
(0·0 to 0·1)
–59·5
(–67·15 to –45·56)
Uterine ﬁ broids 1·2
(0·9 to 1·7)
0·9
(0·7 to 1·2)
–29·7
(–43·96 to –6·20)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–57·8
(–66·54 to –43·72)
Polycystic ovarian syndrome 0·2
(0·1 to 0·3)
0·1
(0·1 to 0·2)
–56·2
(–63·48 to –29·90)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–68·5
(–73·81 to –49·56)
Endometriosis 0·5
(0·4 to 0·6)
0·2
(0·2 to 0·4)
–54·7
(–62·11 to –29·37)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–68·9
(–74·05 to –51·25)
Genital prolapse 0·9
(0·7 to 1·2)
0·6
(0·5 to 0·9)
–29·9
(–44·02 to –8·28)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
–55·7
(–65·45 to –42·31)
Other gynaecological diseases 2·5
(1·8 to 3·2)
1·6
(1·3 to 2·2)
–37·4
(–48·19 to –15·38)
0·1
(0·0 to 0·1)
0·0
(0·0 to 0·0)
–59·7
(–67·23 to –46·18)
Haemoglobinopathies and haemolytic 
anaemias
182·7
(91·5 to 302·5)
240·4
(106·0 to 456·1)
20·6
(–1·35 to 92·91)
3·1
(1·6 to 5·0)
3·4
(1·5 to 6·3)
0·4
(–19·05 to 51·95)
Thalassaemias 36·2
(21·2 to 49·4)
24·8
(16·9 to 32·1)
–36·4
(–46·90 to 14·05)
0·6
(0·3 to 0·8)
0·3
(0·2 to 0·4)
–43·7
(–52·63 to –2·83)
Sickle cell disorders 112·9
(39·4 to 222·6)
176·2
(56·3 to 385·7)
45·3
(14·30 to 131·19)
1·8
(0·6 to 3·4)
2·4
(0·8 to 5·3)
28·8
(1·53 to 94·35)
G6PD deﬁ ciency 3·4
(2·0 to 4·6)
4·1
(2·6 to 5·6)
12·7
(–7·12 to 91·90)
0·1
(0·0 to 0·1)
0·1
(0·0 to 0·1)
–8·2
(–23·19 to 45·12)
Other haemoglobinopathies and 
haemolytic anaemias
30·3
(19·8 to 38·6)
35·4
(24·3 to 44·9)
15·1
(3·42 to 46·66)
0·8
(0·5 to 1·0)
0·6
(0·4 to 0·7)
–25·8
(–31·66 to –9·80)
Endocrine, metabolic, blood, and 
immune disorders
113·5
(90·6 to 134·4)
191·0
(150·5 to 218·5)
69·5
(49·11 to 85·62)
2·7
(2·2 to 3·2)
3·0
(2·4 to 3·4)
11·6
(0·55 to 20·87)
Musculoskeletal disorders 65·9
(55·0 to 73·4)
116·3
(100·4 to 137·7)
77·1
(54·42 to 105·22)
1·7
(1·5 to 1·9)
1·9
(1·6 to 2·2)
8·5
(–4·62 to 23·48)
Rheumatoid arthritis 27·8
(23·8 to 31·7)
38·1
(33·0 to 46·9)
35·6
(16·43 to 64·74)
0·8
(0·7 to 0·9)
0·6
(0·5 to 0·8)
–20·5
(–31·22 to –4·53)
Other musculoskeletal disorders 38·1
(30·3 to 44·1)
78·2
(65·2 to 90·3)
107·2
(76·94 to 145·59)
0·9
(0·8 to 1·1)
1·2
(1·0 to 1·4)
32·7
(14·17 to 51·37)
Other non-communicable diseases 831·7
(690·7 to 1 061·0)
746·6
(674·1 to 846·2)
–7·6
(–25·31 to 4·05)
12·9
(10·9 to 16·1)
10·5
(9·5 to 11·9)
–16·4
(–30·83 to –7·20)
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Congenital anomalies 750·6
(611·8 to 969·7)
632·1
(561·3 to 730·3)
–13·5
(–30·40 to –0·80)
11·0
(9·0 to 14·1)
8·7
(7·7 to 10·0)
–18·9
(–34·07 to –7·54)
Neural tube defects 151·3
(109·1 to 256·3)
68·9
(40·9 to 124·4)
–54·8
(–65·35 to –42·39)
2·1
(1·5 to 3·6)
0·9
(0·6 to 1·7)
–56·6
(–66·71 to –44·61)
Congenital heart anomalies 366·2
(293·0 to 485·2)
323·4
(288·3 to 372·6)
–9·8
(–29·83 to 7·37)
5·4
(4·4 to 7·0)
4·5
(4·0 to 5·1)
–15·8
(–33·64 to –0·61)
Orofacial clefts 7·6
(4·2 to 11·5)
3·3
(1·9 to 5·2)
–57·8
(–68·83 to –33·93)
0·1
(0·1 to 0·2)
0·0
(0·0 to 0·1)
–58·5
(–69·40 to –35·04)
Down’s syndrome 42·5
(16·4 to 73·0)
36·4
(20·4 to 52·4)
–12·9
(–39·13 to 40·14)
0·7
(0·3 to 1·1)
0·5
(0·3 to 0·7)
–22·6
(–45·11 to 19·89)
Chromosomal unbalanced 
rearrangements
19·1
(8·5 to 41·2)
17·3
(10·6 to 26·8)
5·5
(–40·18 to 35·89)
0·3
(0·1 to 0·6)
0·2
(0·1 to 0·4)
–3·0
(–43·13 to 25·13)
Other congenital anomalies 163·9
(119·9 to 301·9)
182·8
(150·2 to 261·9)
18·0
(–16·45 to 40·74)
2·4
(1·8 to 4·4)
2·5
(2·1 to 3·6)
8·5
(–20·90 to 29·30)
Skin and subcutaneous diseases 59·1
(54·1 to 63·1)
99·4
(89·9 to 107·3)
68·3
(51·36 to 86·44)
1·6
(1·5 to 1·7)
1·6
(1·5 to 1·8)
2·5
(–7·66 to 10·83)
Cellulitis 27·0
(19·0 to 34·1)
29·5
(22·5 to 39·3)
8·0
(–5·23 to 30·03)
0·7
(0·5 to 0·8)
0·5
(0·4 to 0·6)
–29·8
(–38·47 to –16·25)
Pyoderma 16·7
(11·6 to 23·1)
37·7
(30·2 to 42·9)
129·9
(71·83 to 186·99)
0·4
(0·3 to 0·6)
0·6
(0·5 to 0·7)
44·0
(14·02 to 75·43)
Decubitus ulcer 13·7
(11·5 to 16·9)
28·5
(24·4 to 33·0)
109·6
(82·53 to 132·42)
0·5
(0·4 to 0·6)
0·5
(0·4 to 0·6)
8·3
(–4·81 to 19·09)
Other skin and subcutaneous 
diseases
1·7
(1·2 to 2·2)
3·8
(3·0 to 4·9)
138·4
(74·18 to 201·77)
0·0
(0·0 to 0·1)
0·1
(0·0 to 0·1)
35·9
(4·37 to 69·36)
Sudden infant death syndrome 22·0
(12·7 to 40·2)
15·1
(9·6 to 21·4)
–29·5
(–54·51 to –4·22)
0·3
(0·2 to 0·6)
0·2
(0·1 to 0·3)
–31·0
(–55·52 to –6·34)
Injuries 4325·8
(4095·7 to 4524·0)
4786·9
(4507·9 to 5072·8)
10·4
(4·23 to 18·04)
88·5
(84·5 to 93·0)
70·0
(65·9 to 74·2)
–21·0
(–25·27 to –15·85)
Transport injuries 1150·0
(1092·9 to 1253·9)
1482·7
(1364·8 to 1588·8)
29·3
(17·11 to 38·66)
23·2
(22·1 to 25·1)
21·2
(19·5 to 22·7)
–8·4
(–16·54 to –2·02)
Road injuries 1058·4
(1005·0 to 1167·2)
1395·8
(1286·1 to 1492·7)
32·4
(19·21 to 41·84)
21·3
(20·3 to 23·4)
20·0
(18·4 to 21·3)
–6·1
(–15·12 to 0·28)
Pedestrian road injuries 389·7
(339·6 to 472·0)
543·8
(452·0 to 629·1)
40·2
(17·55 to 58·63)
8·0
(7·0 to 9·6)
8·0
(6·7 to 9·2)
0·1
(–15·84 to 12·51)
Cyclist road injuries 68·6
(58·5 to 83·3)
90·6
(74·2 to 106·6)
32·0
(13·51 to 51·06)
1·4
(1·2 to 1·7)
1·3
(1·1 to 1·6)
–7·5
(–20·14 to 5·51)
Motorcyclist road injuries 202·0
(169·3 to 236·4)
248·5
(200·9 to 294·4)
22·8
(7·72 to 40·45)
3·9
(3·2 to 4·5)
3·4
(2·8 to 4·0)
–12·2
(–22·77 to 0·56)
Motor vehicle road injuries 364·4
(324·4 to 409·1)
492·7
(431·0 to 555·1)
35·5
(24·24 to 46·49)
7·3
(6·5 to 8·2)
6·9
(6·1 to 7·8)
–4·9
(–12·90 to 2·69)
Other road injuries 33·8
(21·9 to 44·1)
20·2
(14·4 to 25·5)
–40·7
(–54·01 to –7·44)
0·7
(0·4 to 0·9)
0·3
(0·2 to 0·4)
–57·3
(–67·23 to –34·33)
Other transport injuries 91·6
(77·4 to 102·0)
86·9
(72·0 to 97·2)
–5·3
(–18·27 to 10·72)
1·9
(1·6 to 2·1)
1·2
(1·0 to 1·4)
–33·6
(–42·61 to –22·72)
Unintentional injuries other than 
transport injuries
2017·2
(1848·6 to 2 165·7)
2006·7
(1857·1 to 2 183·1)
–1·0
(–8·96 to 10·95)
40·8
(38·2 to 43·8)
30·4
(28·0 to 32·9)
–25·7
(–31·89 to –18·23)
Falls 340·5
(311·7 to 411·5)
556·4
(448·5 to 610·7)
66·7
(21·25 to 82·98)
9·0
(8·2 to 10·8)
9·1
(7·3 to 9·9)
3·4
(–23·97 to 11·61)
Drowning 544·9
(409·2 to 635·8)
368·1
(311·0 to 515·4)
–35·0
(–43·35 to 17·98)
9·4
(7·2 to 10·8)
5·2
(4·4 to 7·3)
–46·3
(–52·33 to –6·00)
Fire, heat, and hot substances 299·6
(262·7 to 352·9)
237·5
(199·3 to 282·9)
–21·2
(–33·96 to –1·98)
5·9
(5·2 to 7·0)
3·5
(2·9 to 4·1)
–41·9
(–50·85 to –29·74)
Poisonings 120·2
(104·1 to 168·5)
98·0
(70·2 to 110·8)
–12·7
(–44·83 to –0·08)
2·4
(2·1 to 3·3)
1·4
(1·0 to 1·6)
–36·0
(–58·97 to –27·57)
Exposure to mechanical forces 232·7
(186·3 to 273·9)
196·8
(177·9 to 244·6)
–15·6
(–31·65 to 18·68)
4·1
(3·4 to 4·8)
2·8
(2·5 to 3·5)
–32·6
(–43·48 to –9·05)
(Table 2 continues on next page)
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while that of other haemoglobinopathies fell (table 2). 
The residual category of endocrine, metabolic, blood, and 
immune disorders increased by 11·6% (table 3).
Age-standardised death rates for injuries and most 
speciﬁ c causes of injury also fell between 1990 and 2013, 
but typically much less than for diseases (table 2). 
Age-standardised death rates for transport injury 
decreased since 1990, with most deaths from road injuries. 
The number of deaths from unintentional injuries as a 
whole remained essentially unchanged since 1990, 
although age-standardised death rates fell by more than a 
quarter (table 2). Especially large falls occurred for 
drowning, ﬁ res, unintentional suﬀ ocation, and venomous 
animal contact (table 2). Age-standardised death rates also 
fell for self-harm and interpersonal violence (table 2). 
Among injuries, only falls, foreign body in other body 
part, adverse eﬀ ects of medical treatment, and pedestrian 
road injuries had increased age-standardised death rates, 
but these were not statistically signiﬁ cant.
For only three level 2 causes did the age-standardised 
death rates increase: neurological disorders; diabetes, 
urogenital, blood, and endocrine diseases; and 
musculoskeletal disorders (ﬁ gure 8). Increases in the 
musculoskeletal disorders were driven by the category 
other musculoskeletal disorders; causes with high 
number of death in this category were systemic lupus 
All ages deaths (thousands) Age-standardised death rate (per 100 000)
1990 2013 Median % change 1990 2013 Median % change
(Continued from previous page)
Unintentional ﬁ rearm injuries 51·4
(44·5 to 60·0)
47·3
(41·0 to 55·7)
–7·6
(–26·30 to 13·15)
1·0
(0·9 to 1·2)
0·7
(0·6 to 0·8)
–32·8
(–46·94 to –18·02)
Unintentional suﬀ ocation 84·0
(26·9 to 124·6)
37·6
(29·1 to 80·7)
–58·3
(–74·65 to 90·29)
1·2
(0·4 to 1·8)
0·5
(0·4 to 1·1)
–59·7
(–75·13 to 71·19)
Other exposure to mechanical forces 97·2
(88·8 to 119·9)
111·9
(95·5 to 122·4)
16·6
(–13·64 to 30·93)
1·9
(1·7 to 2·3)
1·6
(1·4 to 1·7)
–14·7
(–36·50 to –5·26)
Adverse eﬀ ects of medical treatment 93·5
(77·2 to 110·2)
141·7
(107·5 to 165·9)
53·2
(27·88 to 73·38)
2·1
(1·8 to 2·6)
2·2
(1·7 to 2·6)
4·6
(–11·30 to 16·34)
Animal contact 95·5
(59·8 to 126·6)
79·6
(62·3 to 138·7)
–22·0
(–35·47 to 34·57)
1·9
(1·2 to 2·5)
1·2
(0·9 to 2·0)
–43·0
(–52·23 to –2·49)
Venomous animal contact 76·3
(47·5 to 104·7)
57·2
(44·1 to 102·5)
–30·1
(–43·14 to 28·05)
1·5
(0·9 to 2·0)
0·8
(0·6 to 1·5)
–49·3
(–58·49 to –6·80)
Non-venomous animal contact 19·2
(11·5 to 26·3)
22·4
(16·4 to 36·8)
11·2
(–9·33 to 73·85)
0·4
(0·2 to 0·5)
0·3
(0·2 to 0·6)
–16·9
(–31·27 to 25·18)
Foreign body 142·2
(99·5 to 211·6)
165·7
(114·8 to 219·1)
16·2
(–10·22 to 45·91)
2·9
(2·1 to 4·3)
2·6
(1·8 to 3·4)
–10·2
(–29·81 to 5·96)
Pulmonary aspiration and foreign 
body in airway
139·8
(97·2 to 209·7)
162·1
(109·8 to 214·7)
15·5
(–11·10 to 45·78)
2·9
(2·0 to 4·2)
2·5
(1·7 to 3·4)
–10·6
(–30·35 to 5·87)
Foreign body in other body part 2·5
(1·6 to 3·5)
3·6
(2·7 to 5·4)
51·5
(–3·11 to 84·33)
0·1
(0·0 to 0·1)
0·1
(0·0 to 0·1)
6·8
(–25·59 to 31·38)
Other unintentional injuries 148·1
(119·9 to 162·8)
162·8
(143·9 to 180·3)
9·3
(–4·23 to 33·11)
3·1
(2·5 to 3·4)
2·4
(2·1 to 2·7)
–21·1
(–30·53 to –4·99)
Self-harm and interpersonal violence 1052·8
(929·3 to 1152·0)
1247·1
(1067·2 to 1390·9)
18·2
(8·38 to 29·00)
22·4
(19·8 to 24·6)
17·8
(15·3 to 19·8)
–20·8
(–27·32 to –13·83)
Self-harm 712·0
(630·6 to 784·7)
842·4
(718·1 to 939·0)
17·8
(6·04 to 32·20)
15·8
(13·9 to 17·3)
12·2
(10·4 to 13·6)
–23·1
(–30·45 to –13·97)
Interpersonal violence 340·7
(253·9 to 415·1)
404·7
(298·7 to 496·6)
18·4
(10·24 to 29·34)
6·6
(4·9 to 8·1)
5·6
(4·1 to 6·9)
–16·0
(–21·65 to –8·41)
Assault by ﬁ rearm 127·6
(89·9 to 165·1)
180·4
(120·5 to 231·3)
41·3
(26·05 to 55·53)
2·5
(1·7 to 3·2)
2·5
(1·6 to 3·2)
0·0
(–10·58 to 10·11)
Assault by sharp object 94·0
(65·1 to 127·8)
114·3
(77·1 to 163·2)
21·0
(6·27 to 40·68)
1·8
(1·3 to 2·5)
1·6
(1·1 to 2·2)
–15·2
(–25·63 to –1·29)
Assault by other means 119·1
(84·4 to 142·9)
110·0
(78·7 to 142·1)
–8·5
(–16·48 to 7·97)
2·3
(1·6 to 2·8)
1·5
(1·1 to 2·0)
–33·9
(–39·44 to –22·31)
Forces of nature, war, and legal 
intervention
105·8
(77·2 to 170·7)
50·4
(34·4 to 88·8)
–53·1
(–58·41 to –46·15)
2·2
(1·5 to 3·6)
0·7
(0·5 to 1·3)
–66·2
(–70·18 to –61·18)
Exposure to forces of nature 33·4
(19·4 to 63·5)
19·2
(13·5 to 32·0)
–43·9
(–58·70 to –6·92)
0·7
(0·4 to 1·4)
0·3
(0·2 to 0·5)
–60·4
(–71·50 to –33·98)
Collective violence and legal 
intervention
72·4
(54·7 to 106·5)
31·2
(20·3 to 57·0)
–57·9
(–66·76 to –45·85)
1·5
(1·1 to 2·2)
0·5
(0·3 to 0·8)
–69·3
(–75·76 to –61·23)
Data in parentheses are 95% uncertainty intervals. 
 Table 2: Global deaths for 235 causes in 1990 and 2013 for all ages and both sexes combined and age-standardised death rates
Articles
140 www.thelancet.com   Vol 385   January 10, 2015
Neonates age <1 month Children age 1–59 months
1990 (thousands) 2013 (thousands) Median % change 1990 (thousands) 2013 (thousands) Median % change
All causes 4506·8
(4394·5 to 
4612·8)
2614·3
(2506·4 to 
2723·2)
–42·0
(–44·5 to –39·5)
7608·5
(7447·7 to 7757·3)
3665·7
(3449·4 to 
3905·8)
–52·0
(–54·7 to –48·6)
Communicable, maternal, 
neonatal, and nutritional 
diseases
4063·8
(3935·0 to 4181·4)
2275·5
(2163·6 to 
2374·6)
–44·0
(–46·6 to –41·4)
6012·6
(5724·0 to 6256·5)
2766·2
(2528·6 to 3010·5)
–54·0
(–57·5 to –50·4)
HIV/AIDS ·· ·· ·· 35·2
(32·3 to 38·3)
63·8
(58·5 to 71·6)
81·1
(64·5 to 99·9)
Diarrhoeal diseases 124·8
(110·5 to 140·5)
44·8
(36·8 to 53·3)
–64·2
(–70·6 to –56·7)
1482·4
(1339·7 to 1633·3)
474·9
(398·1 to 545·0)
–68·0
(–72·8 to –62·5)
Intestinal infectious diseases ·· ·· ·· 82·0
(46·7 to 135·2)
62·4
(33·0 to 103·6)
–24·2
(–37·2 to –8·1)
Lower respiratory infections 399·3
(362·2 to 436·9)
196·5
(169·3 to 224·5)
–50·9
(–57·3 to –43·7)
1768·8
(1597·7 to 1926·6)
708·6
(628·6 to 791·4)
–59·9
(–64·8 to –54·5)
Meningitis 35·6
(27·7 to 47·0)
20·6
(14·9 to 26·8)
–42·6
(–52·7 to –28·4)
262·5
(212·1 to 346·3)
121·4
(90·2 to 157·0)
–54·0
(–63·4 to –41·5)
Whooping cough ·· ·· ·· 129·8
(49·9 to 280·7)
56·4
(20·7 to 127·0)
–57·1
(–83·9 to 12·7)
Tetanus 216·9
(174·8 to 370·5)
26·0
(12·3 to 38·9)
–87·0
(–95·8 to –80·1)
65·4
(48·2 to 121·6)
5·5
(3·9 to 7·7)
–91·2
(–95·5 to –86·9)
Measles ·· ·· ·· 472·4
(265·3 to 749·9)
82·1
(41·7 to 145·0)
–83·1
(–90·3 to –68·5)
Malaria 18·1
(13·4 to 23·5)
16·8
(11·0 to 26·4)
–9·6
(–42·6 to 52·8)
566·3
(470·8 to 662·0)
570·0
(437·5 to 733·2)
–1·3
(–27·7 to 40·9)
Preterm birth complications 1452·1
(1190·6 to 1677·3)
693·0
(553·6 to 853·9)
–52·5
(–58·6 to –45·0)
118·4
(80·1 to 157·3)
49·4
(34·5 to 69·8)
–58·3
(–69·4 to –41·3)
Neonatal encephalopathy 
(birth asphyxia/trauma)
820·8
(651·3 to 993·1)
611·5
(491·9 to 724·0)
–25·3
(–38·1 to –9·8)
53·3
(35·5 to 72·6)
32·3
(21·4 to 48·7)
–40·6
(–58·2 to –9·0)
Neonatal sepsis and other 
neonatal infections
328·3
(186·3 to 462·1)
342·2
(214·9 to 479·3)
4·6
(–17·3 to 38·5)
18·1
(9·2 to 28·3)
23·8
(13·3 to 38·0)
30·3
(–15·9 to 114·6)
Other neonatal disorders 489·9
(381·6 to 654·9)
238·2
(187·7 to 297·0)
–51·3
(–62·5 to –35·0)
87·7
(58·5 to 123·5)
38·1
(25·0 to 59·8)
–57·4
(–73·9 to –27·8)
Nutritional deﬁ ciencies ·· ·· ·· 451·6
(376·5 to 560·5)
260·7
(197·9 to 316·6)
–42·3
(–52·4 to –30·1)
Syphilis 122·6
(68·9 to 194·3)
63·7
(37·0 to 98·4)
–47·9
(–58·6 to –35·5)
100·9
(56·9 to 157·6)
56·9
(32·5 to 90·9)
–43·3
(–56·8 to –28·5)
Other communicable diseases 55·3
(37·9 to 79·1)
22·4
(16·4 to 30·7)
–59·0
(–70·6 to –44·7)
317·7
(283·8 to 355·0)
159·9
(134·5 to 192·6)
–49·7
(–58·7 to –39·8)
Non-communicable diseases 366·4
(316·1 to 443·9)
292·3
(258·4 to 349·7)
–19·8
(–32·4 to 4·3)
906·4
(766·4 to 1138·2)
578·8
(462·6 to 739·5)
–36·6
(–43·4 to –23·6)
Congenital anomalies 303·6
(256·8 to 375·4)
246·6
(219·0 to 280·0)
–17·6
(–33·1 to –0·1)
343·6
(255·5 to 493·5)
248·7
(198·8 to 322·9)
–25·7
(–40·6 to –13·7)
Sudden infant death 
syndrome
3·0
(1·2 to 6·1)
2·4
(1·1 to 4·5)
–13·8
(–60·1 to 54·0)
19·1
(11·2 to 34·3)
12·7
(8·4 to 18·4)
–32·2
(–55·5 to –4·9)
Other non-communicable 
diseases
59·8
(52·3 to 70·5)
43·3
(32·4 to 76·9)
–31·3
(–43·3 to 18·7)
543·7
(469·1 to 642·8)
317·4
(244·2 to 422·8)
–42·8
(–52·6 to –23·3)
Injuries 76·6
(58·5 to 95·1)
46·4
(37·5 to 63·5)
–41·7
(–53·4 to –2·9)
689·5
(567·1 to 776·3)
320·7
(277·8 to 371·5)
–54·6
(–61·1 to –41·9)
Road injuries 4·1
(3·3 to 5·1)
3·8
(2·6 to 5·3)
–6·6
(–30·8 to 30·5)
105·2
(88·7 to 128·2)
64·5
(51·3 to 79·5)
–38·3
(–52·6 to –23·7)
Drowning 2·7
(1·9 to 3·5)
1·8
(1·1 to 2·8)
–38·2
(–56·7 to 16·9)
212·3
(132·4 to 275·1)
80·1
(61·7 to 111·4)
–63·3
(–74·1 to –20·4)
Other injuries 69·9
(52·2 to 88·2)
40·8
(32·1 to 58·0)
–44·1
(–55·9 to –1·0)
372·0
(280·9 to 424·3)
176·2
(153·1 to 203·7)
–53·7
(–60·8 to –37·6)
Data in parentheses are 95% uncertainty intervals. Shows major causes of death within each level 1 group that accounted for deaths in children. 
Table 3: Selected causes of global child deaths in 1990 and 2013
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erythematosus, systemic sclerosis (scleroderma), 
pyogenic arthritis, and chronic osteomyelitis (data not 
shown). The average relative diﬀ erence between 
countries (the inter-country Gini coeﬃ  cient) ranged from 
0·31 for non-communicable diseases to 0·90 for forces 
of nature, war, and legal intervention. Mean diﬀ erences 
in the age-standardised rates between countries ranged 
from 0·32 for musculoskeletal disorders to 104·87 for 
communicable, maternal, neonatal, and nutritional 
diseases. Generally, inequality was much greater for 
communicable, maternal, neonatal, and nutritional 
causes than for non-communicable causes or injuries. 
An important exception to that general pattern was war 
and disaster, which were extraordinarily unequal across 
countries. For neoplasms, chronic respiratory diseases, 
and forces of nature, war, and legal intervention the 
age-standardised death rate had fallen and the 
two convergence metrics improved signiﬁ cantly from 
1990 to 2013. For many communicable, maternal, 
neonatal, and nutritional causes, age-standardised death 
rates and mean absolute diﬀ erences decreased but 
relative diﬀ erences increased. For digestive diseases, 
unintentional injuries, and other communicable, 
maternal, neonatal, and nutritional diseases, death rates 
and mean absolute diﬀ erences were falling and relative 
diﬀ erence was not signiﬁ cantly diﬀ erent than zero.
Global causes of child death
We divided child causes of death into those occurring in 
children younger than age 1 month and those aged 
1–59 months (table 3). The number of neonatal deaths 
decreased from 4·5 [UI 4·4–4·6] million in 1990, to 
2·6 [2·5–2·7] million in 2013, a 42% (40–45) decrease. The 
most important cause of neonatal death in 2013 was 
neonatal encephalopathy, followed by neonatal sepsis, 
congenital anomalies, and lower respiratory infections 
(table 3). Causes with more than a 50% reduction in the 
number of neonatal deaths include tetanus, diarrhoeal 
diseases, lower respiratory infections, other neonatal 
disorders, and other communicable diseases. 
For children aged 1–59 months, the global number of 
deaths fell by 52·0% from 1990 (7·6 [UI 7·4–7·8] 
million) to 2013 (3·7 [3·4–3·9] million). Communicable, 
neonatal, and nutritional causes accounted for 
three-quarters of deaths in 2013, the remainder from 
non-communicable diseases and injuries (table 3). For 
this age group, two causes each accounted for more 
than half a million deaths and collectively accounted for 
Figure 8: Measures of convergence for causes of death in 188 countries
All causes
Communicable, maternal, neonatal, and nutritional diseases
HIV/AIDS and tuberculosis
Diarrhoea, lower respiratory, and other common infectious diseases
Neglected tropical diseases and malaria
Maternal disorders
Neonatal disorders
Nutritional deﬁciencies
Other communicable, maternal, neonatal, and nutritional diseases
Non-communicable diseases
Neoplasms
Cardiovascular diseases
Chronic respiratory diseases
Cirrhosis
Digestive diseases
Neurological disorders
Mental and substance use disorders
Diabetes, urogenital, blood, and endocrine diseases
Musculoskeletal disorders
Other non-communicable diseases
Injuries
Transport injuries
Unintentional injuries
Self-harm and interpersonal violence
Forces of nature, war, and legal intervention
 –24·2%
 –40·5%
 –23·0%
 –49·6%
 –24·5%
 –43·4%
 –41·1%
 –28·9%
 –37·2%
 –18·5%
 –14·8%
 –21·9%
 –30·1%
 –13·6%
 –33·2%
 2·5%
 –6·4%
 14·5%
 8·3%
 –17·6%
 –20·8%
 –8·5%
 –25·5%
 –20·7%
 –65·9%
Age-standardised 
death rates (% change)
Mean absolute diﬀerence in 
age-standardised death rate
 182·04
 104·87
 35·91
 40·44
 9·28
 2·88
 9·75
 8·00
 2·96
 86·74
 18·65
 59·97
 32·35
 6·45
 7·31
 5·51
 1·77
 16·67
 0·32
 2·49
 17·31
 5·80
 9·21
 6·06
 0·85
2013
 –19·40
 –42·23
 –1·37
 –29·80
 –4·37
 –1·64
 –5·07
 –1·40
 –1·54
 2·02
 –6·44
 7·51
 –18·44
 –0·08
 –3·31
 0·24
 –0·04
 3·99
 0·01
 0·27
 –0·33
 0·84
 –2·67
 0·23
 –1·65
Change 
(1990–2013)
Change 
(1990–2013)
Gini coeﬃcient
0·19
0·54
0·69
0·49
0·78
0·69
0·44
0·59
0·49
0·13
0·15
0·18
0·36
0·30
0·32
0·18
0·44
0·30
0·18
0·24
0·23
0·25
0·28
0·34
0·90
2013
 0·024
 0·068
 0·114
 0·027
 0·023
 0·085
 0·068
 0·044
 0·011
 0·021
 –0·021
 0·044
 –0·030
 0·028
 –0·001
 –0·003
 0·002
 0·026
 –0·012
 0·071
 0·039
 0·048
 0·001
 0·072
 –0·038
Signiﬁcant increase Signiﬁcant decreaseNo signiﬁcant increase
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more than a third of deaths: lower respiratory infections, 
and malaria (table 3). Four causes accounted for 
100 000–500 000 deaths: diarrhoeal disease, meningitis, 
congenital anomalies, and nutritional deﬁ ciencies 
(table 3). Another seven causes each caused 
50 000–100 000 deaths: drowning, syphilis, measles, 
whooping cough, intestinal infectious diseases, HIV/
AIDS, and road injuries (table 3). Deaths fell by more 
than 50% between 1990, and 2013, for diarrhoeal 
diseases, lower respiratory infections, meningitis, 
whooping cough, tetanus, measles, preterm birth 
complications, drowning, other neonatal disorders, and 
other injuries. Of the causes detailed in table 3, only 
HIV/AIDS increased signiﬁ cantly from 1990, to 2013, 
although from 2005, to 2013, deaths fell from 25·95 
(UI 24·54–27·50) per 100 000 to 9·83 (9·01–11·04) per 
100 000. In high-income countries, cancers accounted 
for 5·86% (5·06–6·66) of deaths for children younger 
than 5 years compared with only 1·02% (0·89–1·16%) 
in low-income countries.
Figure 9 shows death rates of children for 19 major 
cause groups for the 21 GBD regions. Because infants 
younger than age 1 month are exposed to, at most, 
1 person-month, rates in that group were high compared 
with children aged 1–59 months. Across regions, death 
rates varied widely for preterm birth complications, 
neonatal encephalopathy (birth asphyxia and birth 
trauma), other neonatal disorders and jaundice, sepsis, 
and lower respiratory infections (ﬁ gure 9). In addition, 
lower respiratory infections, HIV/AIDS, congenital 
syphilis, malaria, diarrhoeal diseases and congenital 
abnormalities had an important contribution. Congenital 
anomalies varied by more than ﬁ ve-times from a high in 
central sub-Saharan Africa to a low in high-income Asia 
Paciﬁ c. Eastern, central, and western sub-Saharan Africa 
had substantially high death rates for children aged 
1–59 months compared with other regions including 
south Asia (ﬁ gure 9B). These higher rates were largely 
related to malaria, diarrhoeal diseases, measles, and 
nutritional disorders.
Global YLLs
Between 1990 and 2013, large falls occurred for measles, 
meningitis, tetanus, syphilis, and whooping cough 
(ﬁ gure 10). Increases of 50% or more are evident for 
diabetes, HIV/AIDS, hypertensive heart disease, chronic 
kidney disease, Alzheimer’s disease and other dementias, 
interstitial lung disease, and pancreatic cancer. Among 
the top ten causes in 1990, nine remain in the top ten in 
2013, with HIV/AIDS moving in and tuberculosis 
moving to 11th. The largest percentage increases in YLLs 
were for HIV/AIDS (343·97%, 95% UI 245·48–444·17), 
atrial ﬁ brillation and ﬂ utter (211·89%, 182·55–242·63), 
peripheral vascular disease (119·79%, 101·04–136·78), 
and drug use disorders (119·22%, 83·77–140·02).
Identiﬁ cation of key transition points in the 
comparative importance of diﬀ erent causes of premature 
mortality will help to better inform programme 
evaluation. From 1990 to 2013, worldwide crude YLLs fell 
by about 16% (from 2005·5 million to 1685·4 million), 
more so for communicable, maternal, neonatal, and 
nutritional diseases (39% decrease, 1098·3 million to 
667·8 million) compared with non-communicable 
diseases (20% increase, 674·6 million to 806·5 million), 
and injuries (9% decrease, 232·6 million to 
210·8 million). Recent progress with disease control 
programmes for HIV/AIDS and malaria is clear, as is the 
substantial and steady progress to prevent child deaths 
from neonatal disorders, diarrhoeal diseases, and lower 
respiratory infections; YLLs from these diseases fell by 
40–65% since 1990. The success of vaccination 
programmes since 1990 is also evident (ﬁ gure 11), with 
YLLs from measles and tetanus, in particular, at very low 
levels in 2013. Speciﬁ c trends for major non-
communicable diseases are much less evident, with 
incremental decreases for several leading causes of 
cancer, as well as from major vascular and chronic 
respiratory diseases, contributing to the 30% reduction 
in YLLs since 1990 (37 021·0 to 24 493·4 per 100 000). 
With the exception of drowning, only modest progress 
was made in reducing premature mortality from other 
leading causes of injury, with the eﬀ ect of the 1994 
genocide in Rwanda clearly visible (ﬁ gure 11).
Causes of diarrhoea and lower respiratory infection
Deaths caused by diarrhoea fell by 51% (46–56) between 
1990 and 2013 (table 2). Rotavirus was the main cause of 
diarrhoea in children younger than 5 years. It was also 
the most common cause of diarrhoea deaths in this age 
group in 2013, with a slight decrease in the population 
attributable fraction since 1990, followed by cholera, 
Cryptosporidium, and shigellosis (table 4). At least 55·6% 
of diarrhoea in 2013 was unexplained by these pathogens 
in all ages, an increase from 48·1% in 1990 (table 4).
The distribution of Shigella and Aeromonas in patients 
had a signiﬁ cant ecological association with sanitation 
(data not shown) and along with non-typhoid Salmonella, 
deaths from these pathogens fell by 5·4% (28 062 deaths) 
since 1990. Rotavirus was the most important pathogen 
for children younger than age 5 years in east and 
southeast Asia and eastern Europe, with a population 
attributable fraction of 35–41% (104–6390); although it 
had the lowest population attributable fraction in 
high-income north America, central sub-Saharan Africa, 
and Caribbean. Shigella was an important pathogen in 
north Africa and Middle East and Oceania (causing 
19·4% [11·8–29·4] of deaths, 3790 [1976–6381] deaths and 
13·9% [9·5–19·3] of deaths, 118·4 [45·4–249·6] deaths, 
respectively). Cryptosporidium in sub-Saharan Africa, 
cholera in central sub-Saharan Africa, Andean Latin 
America, and Oceania, and enterotoxigenic E coli were 
important causes of diarrhoea death. Campylobacter did 
not have a signiﬁ cant epidemiological relationship with 
diarrhoea in most countries and was an important cause 
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only in some age groups in the GEMS data in India, 
Bangladesh, and Mozambique (data not shown). 
Clostridium diﬃ  cile caused more than 45% of diarrhoea 
deaths in western Europe, high-income north America, 
high-income Asia Paciﬁ c, and Australasia in 2013, 
ranging from eight deaths in Australasia to 92 in high-
income North America, and to a lesser extent in central 
Europe (20·1% [14·0–27·1] or 16 [14–19] deaths, and 
eastern Europe (19·0% [12·6–26·6] or 47 [38–57] deaths).
Cholera caused 45 000 (23 000–68 000) deaths of 
children younger than age 5 years, with most deaths 
(34 000 [76%]) in central and eastern sub-Saharan Africa 
and south and southeast Asia. Cholera was the third 
leading cause of diarrhoea deaths for all ages in 2013, 
behind rotavirus and shigellosis (table 4). 
Clostridium diﬃ  cile was particularly important in adults 
in high-income countries, where it caused as many as 
95% of diarrhoea deaths in elderly people.
Globally in 2013, pneumococcus was responsible for 
the largest number of lower respiratory infection deaths 
in children younger than age 5 years—followed by 
H inﬂ uenzae type B, respiratory syncytial virus, and 
inﬂ uenza—and in people of all ages (table 4). The 
fraction of deaths caused by lower respiratory infection 
in children younger than age 5 years attributable to 
H inﬂ uenzae type B has decreased substantially since 
1990, as a result of the global scale-up of H inﬂ uenzae 
type B vaccine, with the largest decreases in high-income 
regions and Latin America (data not shown), where 
vaccine coverage is highest. The fraction of lower 
respiratory infection deaths in children younger than 
5 years attributable to pneumococcus also fell in high-
income regions such as western Europe, north America 
and Australasia, caused by the scale-up of pneumococcal 
conjugate vaccine, but continued to account for a large 
proportion of such deaths in eastern Europe and 
elsewhere. Many lower respiratory infection deaths 
attributable to the four pathogens occurred in older 
populations.
Country-speciﬁ c probabilities of death during childhood 
and young adolescence
We computed conditional probabilities of death for 
three phases of life (children and young adolescents, 
reproductive age, and middle age) by country and 
cause; conditional probabilities are a useful summary 
because the values are readily interpretable. The 
probability of death in children and adolescents (age 
0–14 years) varied greatly between and within regions, 
from a low of three per 1000 girls in Iceland to a high of 
179 per 1000 boys in Guinea-Bissau (ﬁ gure appendix 1). 
In the more demographically advanced regions 
(measured by mean age of death, fertility, and mortality 
change) the probability of death was below ten per 1000 
people for both sexes in all countries except Albania, 
Bulgaria, Belarus, Brunei, Moldova, Macedonia, 
Romania, Russia, and Ukraine. Causes of death were 
Figure 9: Child death rates by region and cause groups in 2013
(A) Of children younger than age 1 month per person-year of exposure. (B) Of children aged 1–59 months per 
person-year of exposure. The set of causes is mutually exclusive and collectively exhaustive. SIDS=sudden infant 
death syndrome.
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dominated by congenital anomalies and neonatal 
causes. In southeast Asia, Malaysia had the lowest 
probability of death and Laos the highest, with 
substantial mortality from lower respiratory infections, 
diarrhoea, and neonatal disorders. Drowning was an 
important cause of death for children in this region. In 
1990 mean rank (95% UI) 2013 mean rank (95% UI) Median % change
44·9 (42 to 48) 44 Alzheimer’s disease
28·6 (22 to 33) 28 Asthma
41·3 (38 to 44) 41 Breast cancer
11·5 (11 to 13) 11 COPD
41·3 (37 to 46) 42 Cardiomyopathy
5·1 (5 to 6) 5 Cerebrovascular disease
35·8 (33 to 40) 36 Chronic kidney disease
18·0 (17 to 19) 18 Cirrhosis
37·2 (35 to 39) 38 Colorectal cancer
8·9 (6 to 11) 9 Congenital anomalies
26·8 (25 to 29) 26 Diabetes
2·0 (2 to 2) 2 Diarrhoeal diseases
13·5 (12 to 18) 13 Drowning
49·2 (44 to 59) 49 Encephalitis
59 Encephalitis
49·3 (44 to 54) 50 Epilepsy
52 Epilepsy
45·8 (42 to 49) 45 Oesophageal cancer
32·6 (28 to 36) 31 Falls
25·2 (22 to 29) 25 Fire and heat
28·4 (23 to 34) 27 HIV/AIDS
34·3 (29 to 39) 34 Hypertensive heart disease
23·5 (21 to 30) 23 Interpersonal violence
35·6 (25 to 46) 35 Iron–deﬁciency anaemia
4·0 (4 to 4) 4 Ischaemic heart disease
38·6 (36 to 41) 39 Leukaemia
28·7 (27 to 32) 29 Liver cancer
1·0 (1 to 1) 1 Lower respiratory infections
19·6 (18 to 21) 20 Lung cancer
8·0 (6 to 10) 8 Malaria
21·4 (20 to 23) 21 Maternal disorders
12·2 (7 to 18) 12 Measles
15·0 (12 to 17) 15 Meningitis
6·4 (5 to 9) 6 Neonatal encephalopathy
3·0 (3 to 4) 3 Preterm birth
17·1 (12 to 25) 17 Neonatal sepsis
31·3 (28 to 35) 30 Other cardiovascular
41·0 (36 to 45) 40 Peptic ulcer disease
48·4 (40 to 54) 47 Poisonings
60 Poisonings
14·5 (12 to 18) 14 Protein–energy malnutrition
43·3 (33 to 53) 43 Pulmonary aspiration
33·2 (29 to 39) 32 Rheumatic heart disease
9·6 (8 to 11) 10 Road injuries
15·9 (14 to 18) 16 Self–harm
46·1 (24 to 71) 46 Sickle cell
24·1 (23 to 26) 24 Stomach cancer
22·7 (16 to 33) 22 Syphilis
18·5 (12 to 21) 19 Tetanus
69 Tetanus
7·5 (6 to 9) 7 Tuberculosis
33·4 (22 to 48) 33 Typhoid fever
49·2 (38 to 79) 48 Unintentional suﬀocation
77 Unintentional suﬀocation
37·2 (19 to 61) 37 Whooping cough
58 Whooping cough
29·3 (27 to 31)29 Alzheimer disease 89% (81 to 103)
33·7 (27 to 37)32 Asthma –22% (–35 to –4)
47·1 (42 to 54)47 Brain cancer 27% (10 to 40)
57 Brain cancer
31·9 (30 to 35)30 Breast cancer 37% (28 to 46)
11·3 (10 to 12)12 COPD –1% (–9 to 9)
33·3 (30 to 38)31 Cardiomyopathy 32% (14 to 47)
2·7 (2 to 3)3 Cerebrovascular disease 24% (18 to 32)
46·2 (42 to 54)46 Cervical cancer 14% (4 to 23)
53 Cervical cancer
20·6 (19 to 25)19 Chronic kidney disease 90% (74 to 103)
13·4 (13 to 15)13 Cirrhosis 36% (28 to 45)
27·9 (26 to 30)27 Colorectal cancer 44% (38 to 49)
10·3 (8 to 12)10 Congenital anomalies –18% (–33 to –4)
17·2 (16 to 19)17 Diabetes 67% (59 to 77)
5·5 (4 to 8)4 Diarrhoeal diseases –62% (–66 to –57)
20·7 (16 to 24)20 Drowning –46% (–54 to 3)
48·4 (43 to 54)49 Endocrine, metabolic, blood, 
and immune disorders
29% (7 to 49)
58 Endocrine, metabolic, blood, 
and immune disorders
37·2 (34 to 40)38 Oesophageal cancer 31% (18 to 48)
28·8 (26 to 33)28 Falls 18% (–14 to 40)
34·5 (30 to 38)34 Fire and heat –35% (–46 to –15)
6·0 (4 to 8)6 HIV/AIDS 344% (245 to 444)
24·5 (20 to 29)24 Hypertensive heart disease 56% (33 to 75)
21·2 (18 to 27)22 Interpersonal violence 10% (2 to 21)
40·8 (36 to 48)40 Interstitial lung disease 86% (26 to 194)
64 Interstitial lung disease
45·2 (36 to 59)45 Iron–deﬁciency anaemia –37% (–52 to –21)
1·0 (1 to 1)1 Ischaemic heart disease 31% (24 to 41)
38·7 (37 to 41)39 Leukaemia –9% (–16 to –3)
21·1 (19 to 24)21 Liver cancer 42% (26 to 58)
2·3 (2 to 3)2 Lower respiratory infections –48% (–54 to –43)
15·0 (14 to 16)15 Lung cancer 39% (31 to 48)
49·6 (45 to 55)50 Lymphoma 43% (23 to 57)
62 Lymphoma
6·9 (4 to 10)8 Malaria –5% (–26 to 24)
26·1 (24 to 29)26 Maternal disorders –23% (–32 to –12)
43·8 (30 to 62)43 Measles –83% (–90 to –68)
22·9 (19 to 26)23 Meningitis –43% (–53 to –33)
8·7 (6 to 11)9 Neonatal encephalopathy –26% (–38 to –11)
6·3 (4 to 9)7 Preterm birth –53% (–59 to –45)
15·7 (12 to 22)16 Neonatal sepsis 6% (–16 to 38)
33·7 (30 to 37)33 Other cardiovascular –12% (–17 to 4)
44·2 (42 to 48)44 Pancreatic cancer 74% (67 to 80)
66 Pancreatic cancer
43·8 (40 to 51)42 Peptic ulcer disease –20% (–36 to –6)
17·9 (16 to 22)18 Protein–energy malnutrition –28% (–40 to –15)
47·4 (39 to 59)48 Pulmonary aspiration –22% (–40 to 18)
41·9 (37 to 48)41 Rheumatic heart disease –37% (–44 to –26)
5·9 (4 to 8)5 Road injuries 15% (2 to 23)
14·4 (13 to 16)14 Self–harm 9% (–3 to 24)
35·0 (17 to 63)36 Sickle cell 42% (8 to 138)
25·0 (23 to 27)25 Stomach cancer –2% (–9 to 5)
34·8 (25 to 46)35 Syphilis –46% (–57 to –33)
11·1 (10 to 12)11 Tuberculosis –31% (–40 to –24)
35·7 (24 to 52)37 Typhoid fever –13% (–27 to 1)
Group 1
Non-communicable
Injuries
Figure 10: Top 50 causes of global years of life lost in 1990 and 2013
An interactive version of this ﬁ gure is available at http://vizhub.healthdata.org/gbd-compare/. COPD=chronic obstructive pulmonary disease.
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central Asia, probabilities of death ranged from 17 per 
1000 people in Armenia to 65 per 1000 people in 
Turkmenistan, with unusually high contributions from 
lower respiratory infections; drowning was also an 
important cause. Bahrain, Oman, and United Arab 
Emirates had death rates below ten per 1000 for girls, 
whereas in Sudan and Yemen, they were more than 40 
per 1000. Mortality in these countries was dominated by 
congenital and neonatal causes. Pulmonary aspiration 
and foreign body in trachea and lung was an unusually 
high cause of child death in Bolivia based on the 
available vital registration data. In south Asia, the 
contribution of drowning in Bangladesh was notable 
but mortality was still dominated by neonatal causes, 
diarrhoea, and pneumonia in all the countries of the 
region. Throughout sub-Saharan Africa, patterns of 
causes of death varied but malaria, HIV/AIDS, 
tuberculosis, nutritional deﬁ ciencies, and haemo-
globinopathies played an important part in many 
countries. Mauritius, Seychelles, and Cape Verde all 
had much lower probabilities of death during childhood 
than did other countries in this region. Countries with 
the highest probabilities of death in central and western 
sub-Saharan Africa had important contributions from 
malaria. Interpersonal violence was an important 
contributor to the probability of death in children and 
adolescents in many countries of Latin America and 
several in southern Africa.
Country-speciﬁ c probabilities of death during 
reproductive age
The probability of death in reproductive-age adults 
(exact age 15 years to exact age 50 [35q15]) ranged from 
1·2% for women in Andorra to 52% for men in Lesotho 
(ﬁ gure appendix 2). In high-income regions, the 
probability of death was generally twice as high for men 
as for women. Across all countries, transport injuries 
made an important contribution, especially in men.
Among men in low-income countries, suicide and 
transport accidents made important contributions. In 
some countries, such as Norway and USA, drug and 
alcohol use disorders account for more than 8% of the 
total probability of dying in this age interval for either 
sex. In central Europe, interpersonal violence was high 
in Albania, drug and alcohol disorders were notable in 
Poland, Croatia, Slovakia, and Montenegro, and 
cirrhosis was a common cause in Bulgaria, Croatia, 
Hungary, Poland, Romania, Slovakia, and Slovenia. In 
east Asia, liver cancer was an important cause of death. 
In southeast Asia, maternal mortality in Laos, 
Cambodia, Myanmar, and Timor-Leste were important 
contributors for women. For men in the same region, 
interpersonal violence in Philippines, Sri Lanka, and 
Thailand were notable; suicide in Sri Lanka also 
accounted for a large probability of death (2·2%). Other 
studies have suggested that interpersonal violence in 
Philippines is concentrated in Mindanao.82
Figure 11: Global years of life lost by large cause groupings for 1990 to 2013
COPD=chronic obstructive pulmonary disease.
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Risk of death from transport injuries was greater than 
2% for men in Afghanistan, Côte d’Ivoire, Cameroon, 
Ecuador, Gabon, Guinea-Bissau, Equatorial Guinea, 
Kazakhstan, Mauritania, Nigeria, Oman, Sierra Leone, 
El Salvador, Thailand, and Uganda. Probability of death 
from cirrhosis in Myanmar was 1·9% for men. 
Tuberculosis stood out in Cambodia, Indonesia, Laos, 
Myanmar, and Philippines for men. The gap between 
the probability of death for men and women was 
particularly large in eastern Europe and central Asia. 
Mongolia had the highest probability of death in 
reproductive age for men in these two regions, as a 
result of unusually high probabilities of interpersonal 
violence, self-harm, alcohol and drug use, cirrhosis, liver 
cancer, and tuberculosis. More generally for men, in 
eastern Europe and central Asia, there were major 
Children younger than age 5 years All ages
1990 2013 1990 2013 Rate of change 
for deaths 
1990–2013 (%)
Deaths 
(thousands)
Population 
attributable 
fractions (%)
Deaths 
(thousands)
Population 
attributable 
fractions (%)
Deaths 
(thousands)
Population 
attributable 
fractions (%)
Deaths 
(thousands)
Population 
attributable 
fractions (%)
Diarrhoea
Adenovirus 63·0
(44·4 to 89·9)
3·9
(2·7 to 5·5)
18·3
(11·8 to 25·5)
3·5
(2·4 to 4·9)
81·3
(55·9 to 115·9)
3·2
(2·1 to 4·4)
31·8
(21·5 to 44·7)
2·5
(1·7 to 3·6)
–61·2%
(–67·8 to –52·5)
Aeromonas 12·3
(6·4 to 21·4)
0·8
(0·4 to 1·3)
5·5
(2·6 to 10·1)
1·1
(0·5 to 1·9)
28·0
(16·7 to 44·9)
1·1
(0·7 to 1·7)
13·0
(7·3 to 22·0)
1·0
(0·6 to 1·7)
–53·6%
(–66·1 to –37·8)
Amoebiasis 5·8
(2·6 to 10·0)
0·4
(0·2 to 0·6)
1·3
(0·6 to 2·3)
0·2
(0·1 to 0·5)
18·3
(8·9 to 30·6)
0·7
(0·3 to 1·2)
11·3
(5·0 to 19·7)
0·9
(0·4 to 1·6)
–39·1%
(–57 to –17·5)
Campylobacter enteritis 20·8
(11·0 to 31·9)
1·3
(0·7 to 2·0)
9·5
(3·7 to 15·7)
1·8
(0·7 to 3·0)
28·4
(16·4 to 42·8)
1·1
(0·6 to 1·6)
14·1
(6·9 to 22·4)
1·1
(0·5 to 1·8)
–50·7%
(–63·7 to –37·5)
Cholera 81·7
(39·1 to 117·0)
5·1
(2·5 to 7·2)
45·2
(23·4 to 67·6)
8·7
(4·5 to 12·7)
125·3
(61·1 to 173·4)
4·9
(2·4 to 6·7)
69·9
(37·7 to 97·0)
5·5
(3·0 to 7·7)
–44·3%
(–56·8 to –26·6)
Clostridium diﬃ  cile 2·1
(2·0 to 2·3)
0·1
(0·1 to 0·1)
2·5
(2·4 to 2·7)
0·5
(0·4 to 0·6)
20·8
(19·9 to 21·9)
0·8
(0·7 to 0·9)
41·5
(39·1 to 43·9)
3·3
(3·0 to 3·6)
99·4%
(84·3 to 114·3)
Cryptosporidiosis 92·4
(68·7 to 125·1)
5·8
(4·3 to 7·8)
35·2
(25·9 to 48·2)
6·8
(5·1 to 9·3)
98·8
(72·8 to 132·7)
3·8
(2·8 to 5·2)
41·9
(30·0 to 58·4)
3·3
(2·4 to 4·7)
–57·8%
(–64·8 to –49·6)
Enteropathogenic 
Escherichia coli infection
4·3
(1·3 to 7·8)
0·3
(0·1 to 0·5)
1·8
(0·7 to 3·4)
0·3
(0·1 to 0·7)
4·3
(1·3 to 7·8)
0·2
(0·1 to 0·3)
1·8
(0·7 to 3·4)
0·1
(0·1 to 0·3)
–57·5%
(–76·5 to –32)
Enterotoxigenic 
Escherichia coli infection
86·0
(61·3 to 114·1)
5·4
(3·8 to 7·2)
23·1
(17·0 to 30·4)
4·4
(3·4 to 5·9)
134·7
(97·5 to 178·2)
5·2
(3·8 to 6·8)
59·2
(44·2 to 77·7)
4·7
(3·5 to 6·1)
–56·0%
(–63·0 to –46·9)
Norovirus 7·3
(2·7 to 11·8)
0·5
(0·2 to 0·7)
1·8
(0·7 to 3·1)
0·3
(0·1 to 0·6)
7·3
(2·7 to 11·8)
0·3
(0·1 to 0·5)
1·8
(0·7 to 3·2)
0·1
(0·1 to 0·2)
–75·8%
(–85·1 to –61·6)
Other Salmonella 
infections
19·2
(11·1 to 29·1)
1·2
(0·7 to 1·8)
3·8
(1·6 to 6·7)
0·7
(0·3 to 1·2)
58·9
(42·4 to 77·8)
2·3
(1·6 to 3·0)
24·3
(16·0 to 33·3)
1·9
(1·3 to 2·6)
–58·9%
(–65·4 to –51·1)
Rotaviral enteritis 398·9
(334·5 to 464·2)
24·8
(21·4 to 28·2)
122·4
(96·6 to 152·1)
23·5
(20·1 to 27·2)
477·5
(397·9 to 555·1)
18·5
(15·8 to 21·2)
176·6
(140·4 to 218·4)
14·0
(11·4 to 16·6)
–63·2%
(–68·5 to –57·1)
Shigellosis 161·0
(130·0 to 200·3)
10·0
(8·2 to 12·2)
33·4
(24·9 to 43·5)
6·4
(5·1 to 7·9)
254·2
(207·9 to 311·7)
9·9
(8·2 to 11·9)
73·9
(58·9 to 93·8)
5·8
(4·7 to 7·3)
–70·9%
(–74·4 to –67·3)
No identiﬁ ed aetiology* 652·4
(542·4 to 783·1)
40·6
(35·3 to 46·8)
215·9
(169·6 to 265·2)
41·5
(35·7 to 48·1)
1240·9
(1096·8 to 1421·5)
48·1
(43·5 to 53·5)
702·9
(619·2 to 796)
55·6
(51·4 to 60·3)
–43·2%
(–49·3 to –36·1)
Lower respiratory infections
Haemophilus inﬂ uenzae 
type B pneumonia
427·1
(–39·8 to 853·4)
19·7
(–1·8 to 39·1)
108·7
(–9·9 to 226·9)
12·0
(–1·1 to 25·5)
427·1
(–39·8 to 853·4)
12·5
(–1·2 to 24·8)
108·7
(–9·9 to 226·9)
4·1
(–0·4 to 8·8)
–75·1%
(–79·1 to –71·2)
Inﬂ uenza 36·3
(14·2 to 73·5)
1·7
(0·7 to 3·3)
15·1
(5·7 to 30·4)
1·7
(0·6 to 3·3)
85·1
(36·1 to 156·2)
2·5
(1·1 to 4·5)
105·4
(45·3 to 188·1)
4·0
(1·7 to 7·3)
24·0%
(3·4 to 47·7)
Pneumococcal 
pneumonia
652·4
(402·6 to 879·4)
30·1
(19·0 to 40·2)
264·0
(155·7 to 365·8)
29·2
(18·0 to 39·2)
919·5
(553·1 to 1320·5)
26·9
(16·3 to 38·4)
594·4
(295·6 to 970·2)
22·4
(11·4 to 35·9)
–36·1%
(–52·7 to –19·8)
Respiratory syncytial 
virus pneumonia
145·1
(82·7 to 228·0)
6·7
(3·8 to 10·5)
41·1
(23·0 to 65·5)
4·5
(2·6 to 7·1)
185·5
(114·4 to 268·6)
5·4
(3·5 to 7·9)
81·5
(53·6 to 109·9)
3·1
(2·0 to 4·2)
–55·7%
(–63 to –47·2)
No identiﬁ ed aetiology* 907·2
(407·3 to 1451·3)
41·9
(19·0 to 66·7)
476·2
(313·3 to 651·6)
52·6
(35·2 to 70·2)
1803·4
(1211·8 to 2452·5)
52·7
(35·4 to 71·1)
1762·6
(1385·3 to 2134·1)
66·5
(52·8 to 79·9)
–0·8%
(–19·8 to 22·9)
Data in parentheses are 95% uncertainty intervals. *Number or proportion of diarrhea or lower respiratory infection deaths attributable to any diarrhea or lower respiratory infection pathogens. Because of 
interaction between pathogens (especially for lower respiratory infection), the value is the minimum amount of unexplained deaths.
 Table 4: Counterfactual deaths and population attributable fractions for diarrhoea and lower respiratory infection pathogens for 1990 and 2013
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contributions from ischaemic heart disease, self-harm, 
alcohol and drug use, cirrhosis, and tuberculosis; HIV 
played an important part in Ukraine and Russia. In 
north Africa and Middle East, transport injuries and 
ischaemic heart disease were predominant. For women 
in the region, breast cancer in all countries and maternal 
mortality in Sudan and Yemen were also major factors.
In Latin America and Caribbean, there was a large 
contribution of interpersonal violence in men, with the 
probability of death exceeding 2% in Brazil, Colombia, 
El Salvador, Guatemala, Honduras, and Venezuela. 
Despite generally high violence in the region, Cuba, Costa 
Rica, Bolivia, and Peru had low probabilities of death 
from violence. In men, the probability of death because of 
HIV/AIDS exceeded 1% in Belize, Haiti, Saint Vincent 
and the Grenadines, The Bahamas, Grenada, Guyana, 
Suriname, and Trinidad and Tobago. Cirrhosis 
contributed more than 1% to the probability of death of 
men in Guatemala, Mexico, and Guyana. Cervical cancer 
was a larger contributor to the probability of death than 
was breast cancer in eight countries of Latin America and 
Caribbean (Bolivia, Ecuador, Guatemala, Nicaragua, Peru, 
Paraguay, El Salvador, and Venezuela). Probabilities of 
death for men and women in Afghanistan were more 
than twice that of other countries in the region; for 
women, maternal mortality was the largest cause. In 
Oceania, Samoa and Tonga had much lower probabilities 
of death than did other countries in the region. 
Throughout sub-Saharan Africa, there were major 
contributions for women from maternal mortality, 
HIV/AIDS, and tuberculosis. For men in the region, HIV/
AIDS, tuberculosis, and transport injuries dominated in 
most countries. Liver cancer was also a major factor, 
particularly for men in western sub-Saharan Africa.
Country-speciﬁ c probabilities of death during middle age
The probability of death in middle age (exact age 50 years 
to exact age 75 years [25q50]) ranged from 10·3% for women 
in Andorra to 76·3% for men in Lesotho (ﬁ gure appendix 3). 
In all countries, ischaemic heart disease and stroke were 
important contributors to the risk of death in middle age, 
and were greater for men than for women. Probabilities of 
death from ischaemic heart disease ranged from 0·8% in 
Japan for women to more than 24% in Belarus for men. In 
high-income regions, lung cancer was as a major 
contributor to the risk of death for men. Breast cancer for 
women and prostate cancer for men also made substantial 
contributions. Probability of death from liver cancer was 
greater than 2% in China, Mongolia, Myanmar, North 
Korea, South Korea, Taiwan (province of China), Thailand, 
and Vietnam.
In central Europe, chronic respiratory diseases and 
cirrhosis made clear contributions in Bulgaria, Croatia, 
Hungary, Poland, Romania, and Slovenia. In some high-
income countries, including Singapore, Argentina, and 
Uruguay, lower respiratory infections were important 
causes of death for this age group, more so for men than 
for women. In southeast Asia, liver cancer, diabetes, and 
tuberculosis made larger contributions than in many other 
regions, particularly in Myanmar, Philippines, Laos, 
Indonesia, and Cambodia. Elsewhere in the region, stroke, 
ischaemic heart disease, other cardiovascular and 
circulatory diseases, and chronic respiratory diseases were 
predominant. In all countries of eastern Europe and 
central Asia, stroke and ischaemic heart disease were 
particularly prominent for both sexes. Liver cancer in 
Mongolia had the highest probability of causing death in 
the world for this age group.
Egypt had extraordinarily high cirrhosis mortality, 
particularly from hepatitis C, in middle aged men and 
women. Deaths caused by diabetes were particularly 
high in Morocco, Bahrain, Oman, and Qatar. In central 
Latin America and Caribbean, diabetes made large 
contributions to causes of death in men and women; the 
highest probability of death in these regions from 
diabetes for males was 9·2% in Trinidad and Tobago and 
8·4% for women in Guyana. Chronic kidney disease was 
particularly high in El Salvador, Mexico, and Nicaragua; 
more so for men than for women.75,76 In the Caribbean, 
diabetes, stroke, and ischaemic heart disease accounted 
for 33·4% of the probability of death in this age group in 
Haitian men, and 54·8% in Guyanese women.
In all the countries of Oceania, diabetes accounted for 
an extremely large fraction of mortality in middle-aged 
women. For nearly all countries in sub-Saharan Africa, 
stroke and other cardiovascular diseases (including 
cardiomyopathies) were important. HIV/AIDS and 
tuberculosis, diarrhoea, and lower respiratory infections 
were also estimated to be important causes in almost 
every country in the region. The probability of death 
from liver cancer was high in most countries of western 
sub-Saharan Africa.
Country-speciﬁ c leading causes of YLLs
Worldwide, the top ten causes of YLLs were ischaemic 
heart disease, lower respiratory infections, stroke, 
diarrhoea, road injury, HIV/AIDS, preterm birth, 
malaria, neonatal encephalopathy, and congenital 
causes (ﬁ gure 12). The diﬀ erences between high-
income and low-income countries was substantial. Self-
harm was the fourth highest cause of YLLs in 
high-income countries and the 14th in low-income 
countries. Lung cancer, self harm, Alzheimer’s disease 
and other dementias, cirrhosis, chronic obstructive 
pulmonary disease, and colorectal cancer were in the 
top ten causes in high-income countries but not in low-
income countries. Conversely, diarrhoea, malaria, HIV/
AIDS, preterm birth complications, neonatal 
encephalopathy, and congenital disorders were in the 
top ten in low-income, but not high-income, regions.
Ischaemic heart disease, stroke, and lung cancer were 
the top three causes in 32 GBD developed countries. 
More notable diﬀ erences in the rankings across high-
income countries were self-harm as the second highest 
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cause of YLLs in South Korea, Alzheimer’s disease and 
other dementias as the third highest cause in Canada, 
Finland, and Israel, and lower respiratory infections as 
the second cause in Singapore and the third highest 
cause in Argentina and Japan. Cirrhosis was the third 
highest cause in Chile. Colorectal cancer was a top ﬁ ve 
cause in 13 high-income countries and diabetes was in 
three high-income countries.
In central Europe, eastern Europe, and central Asia, 
ischaemic heart disease and stroke dominated but in 
Bosnia and Herzegovina, Serbia, Latvia, and Russia 
cardiomyopathies were also in the top ﬁ ve. As a result of 
higher child mortality in these regions, Azerbaijan, 
Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, and 
Uzbekistan had preterm, or neonatal encephalopathy, in 
the top ﬁ ve causes. In eastern Europe, ﬁ ve causes 
(ischaemic heart disease, stroke, self-harm, cirrhosis, 
and road injury) made up 49·7% of YLLs (95% UI 
48·5–51·3; or 29·3 million [28·5–30·2]). In Latin 
America and Caribbean, more variation exists in the 
leading cause of YLLs. Lower respiratory infections were 
the leading cause in Bolivia, Peru, Guatemala, and 
Ecuador; HIV/AIDS was in Haiti; interpersonal violence 
was in Colombia, El Salvador, and Venezuela; stroke was 
in Jamaica; congenital anomalies were in Nicaragua, and 
ischaemic heart disease was in the rest. Road injury was 
in the top ﬁ ve for 17 of 29 countries. Diabetes was also in 
the top ﬁ ve for 13 countries. Chronic kidney disease was 
in the top ﬁ ve for Barbados, Costa Rica, El Salvador, 
Mexico, and Nicaragua. Perhaps most unusually, 
interpersonal violence was in the top ﬁ ve causes in 15 
countries in the region, but only one country outside 
Latin America and Caribbean, namely South Africa.
In east Asia, the top ﬁ ve causes of YLLs, in order, were 
stroke, ischaemic heart disease, road injury, chronic 
obstructive pulmonary disorder, and lung cancer. These are 
Figure 12: Top ten causes in 2013 of years of life lost by location
The top 15 global causes of years of life lost are coloured. VCT=Saint Vincent and the Grenadines. TTO=Trinidad and Tobago. FSM=Federated States of Micronesia. PNG=Papua New Guinea. UAE=United 
Arab Emirates. CAR=Central African Republic. STP=São Tomé and Princípe. IHD=ischaemic heart disease. LRI=lower respiratory infections. Road inj=road injuries. NN Preterm=preterm birth 
complications. NN enceph=neonatal encephalitis. Congenital=congenital disorders. C=cancer. COPD=chronic obstructive pulmonary disease. CKD=chronic kidney disease. CMP=cardiomyopathies. 
Other cardio=other cardiovascular disease. Drugs=drug use disorders. Alcohol=alcohol use disorders. Violence=interpersonal violence. HTN HD=hypertensive heart disease. F body asp=pulmonary 
aspiration and foreign body in airway. NN sepsis=neonatal sepsis. PEM=protein–energy malnutrition. TB=tuberculosis. Vis leish=visceral leishmaniasis. Other mech=other mechanical forces. 
Endocrine=endocrine, metabolic, blood, and immune disorders. Maternal=maternal disorders. Sickle=sickle cell disorders. 
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almost the same top ﬁ ve causes as in USA: the only 
diﬀ erence is Alzheimer’s disease and other dementias, 
which was fourth and road injury was sixth, providing 
evidence of epidemiological convergence between east 
Asian countries and some high-income countries. In 
Oceania, ischaemic heart disease, lower respiratory 
infections, diabetes, and diarrhoea were important. In 
Papua New Guinea, malaria was also a top ﬁ ve cause. 
Southeast Asia as a whole, Indonesia, Myanmar, and 
Philippines have tuberculosis as a top ﬁ ve cause of YLLs. 
Road injury was a top ﬁ ve cause in Indonesia, Malaysia, 
Thailand, and Vietnam. Cirrhosis was in the top ﬁ ve in 
Myanmar and liver cancer in Thailand and Vietnam. 
Among the countries of south Asia, the leading causes are 
a mix of neonatal causes and ischaemic heart disease, lower 
respiratory infections, and stroke in most countries. 
Tuberculosis was the third highest cause in India.
In north Africa and Middle East, ischaemic heart 
disease and stroke, preterm birth complications, 
congenital anomalies, and road injury were prominent 
leading causes of YLLs. In four countries—Oman, Qatar, 
Saudi Arabia, and United Arab Emirates—road injury 
was the leading cause of YLLs. Cirrhosis was the third 
highest cause of YLLs in Egypt. Self-harm was in the top 
ﬁ ve in Bahrain, Qatar, and United Arab Emirates. The 
proﬁ le of leading causes of YLLs in sub-Saharan Africa 
was greatly diﬀ erent from the rest of the world with the 
exception of Cape Verde, Mauritius, and Seychelles. HIV/
AIDS was the leading cause in 18 countries. Malaria was 
the leading cause in 14 countries. Lower respiratory 
infection was the leading cause in Angola, Comoros, 
Ethiopia, Madagascar, Rwanda, South Sudan, Côte 
d’Ivoire, Mauritania, and São Tomé and Princípe. 
Diarrhoea was the leading cause in D R Congo, Eritrea, 
Somalia, and Chad. Tuberculosis was in the top 
ﬁ ve causes in 18 countries. Violence was the ﬁ fth highest 
cause in South Africa. Road injury was the ﬁ fth highest 
cause in Equatorial Guinea, Gabon, Botswana, Swaziland, 
Cameroon, and Nigeria.
Discussion
Main ﬁ ndings
The GBD 2013 incorporates many new datasets for cause 
of death, particularly from China, and new data for 
155 other countries. Compared with the GBD 2010, it 
provides the most comprehensive and up-to-date 
assessment of causes of death. The results for the GBD 
2013 are based on re-estimation of all causes from 1990 to 
2013, and thus supersede all previously published GBD 
time series (panel). Publication of country-level results 
provides many opportunities for comparing a country’s 
performance with that of its peers.
On the broadest level, our analysis of 240 causes of 
death for 188 countries conﬁ rms that global life 
expectancy at birth has continued to improve over the 
past 23 years and these improvements are driven largely 
by falls in diarrhoea, lower respiratory infections, and 
neonatal causes in low-income countries, and decreases 
in cardiovascular diseases and some cancers in middle-
income and high-income countries. HIV/AIDS has had a 
large enough eﬀ ect to negate progress made in other 
causes contributing to decreases in life expectancy, 
particularly in southern sub-Saharan Africa.
This general progress masks enormous heterogeneity 
across countries and age groups. Even within regions, 
substantially diﬀ erent mortality, leading causes of death, 
and trends exist. Outside sub-Saharan Africa, premature 
mortality is dominated by relatively few causes including 
ischaemic heart disease, stroke, lower respiratory 
infections, road injury, diarrhoea, preterm birth 
complications, neonatal encephalopathy, congenital 
anomalies, tuberculosis, chronic obstructive pulmonary 
disease, cirrhosis, self-harm, and lung cancer. In 
addition to these common causes, great regional and 
country variation exists, such as the dominant role of 
interpersonal violence in most countries of central Latin 
America and Brazil.
Our study points to extraordinary epidemiological 
progress: global age-standardised death rates fell 
signiﬁ cantly for 157 of 240 causes from 1990 to 2013. 
The largest decreases were for some of the major 
communicable diseases including diarrhoeal diseases, 
lower respiratory infections, tuberculosis, and measles. 
Age-standardised rates for many non-communicable 
causes are also falling. At the same time, numbers of 
deaths from 115 of these 240 causes, have increased, 
driven by both growth in population and shifts in the 
population age-structure towards older ages. For a 
further 58 causes, changes in the age-standardised 
death rate over the 23 year period were not statistically 
diﬀ erent from no change. For some of these causes, 
sparse data might have contributed to wide UIs and in 
other cases uncertainty might have arisen from 
inconsistent coding across countries. However, eight 
speciﬁ c causes account for more than 100 000 deaths 
and their age-standardised death rates have increased 
signiﬁ cantly since 1990: HIV/AIDS, liver cancer caused 
by hepatitis C, pancreatic cancer, atrial ﬁ brillation and 
ﬂ utter, drug use disorders, diabetes, chronic kidney 
disease, and sickle cell disorders. Of these causes, 
three (HIV/AIDS, diabetes, and chronic kidney disease) 
account for more than a half a million deaths each. 
HIV/AIDS, however, has been decreasing as a cause of 
death since 2005. These causes, which run counter to 
an extraordinary global trend towards lower age-
standardised death rates, deserve special attention.
The rise and subsequent fall of HIV/AIDS is well 
known as is the rise in diabetes. Increases for atrial 
ﬁ brillation and ﬂ utter, pancreatic cancer, drug use 
disorders, and chronic kidney disease have received 
far less global attention. Drug use disorders and 
chronic kidney diseases cause many more deaths in 
some regions and countries than in others. 
Nevertheless, they are important emerging global 
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challenges that show the potential adverse eﬀ ects of 
some behaviours and socioeconomic developments. In 
view of the important behavioural component for 
some of these causes, there is potentially an important 
role for public health policy and resources to modify 
these causes of death. These diseases, particularly 
HIV/AIDS and drug use disorders are also subject to 
social stigmatisation, which adds an important 
challenge for eﬀ ective policy interventions. Although 
global age-standardised death rates have increased for 
very few causes, there is remarkable and important 
variation in trends across countries such that causes 
with falling global age-standardised rates are 
increasing in some countries—for example, ischaemic 
heart disease in China.
Convergence or divergence?
Ambitious goals have been set for maternal and child 
mortality,84–86 such as the end of preventable maternal and 
child death in a generation. The Lancet Commission 
Global health 2035: a world converging within a generation 
has argued that a grand convergence in health is possible 
between high-income, middle-income, and low-income 
countries.24 Trends in the past 23 years provide an 
important starting point for framing how great a challenge 
achieving these aspirations will be and the political will 
and ﬁ nancial resources required. Part of the answer 
depends on how the goals are framed—for example, what 
does convergence mean? In the development literature on 
economic convergence,87–89 convergence has been framed 
in terms of poverty rates or in terms of income inequality 
measured by the Gini coeﬃ  cient or other measures of 
inequality. Work on convergence in life expectancy has 
tended to focus on measures of absolute diﬀ erence90–92 
rather than relative diﬀ erence.93 We found unequivocal 
divergence in mortality rates for women aged 25–39 years 
and older than 80 years and for men aged 20–44 years and 
65 years and older, similar to previous estimates of 
divergence of life expectancy at birth since the 1980s.94 In 
these age groups, both the Gini coeﬃ  cient and the mean 
absolute diﬀ erence in death rates are rising. In all other 
age groups, except girls aged 10–14 years, relative 
inequality is increasing but the absolute gap is narrowing. 
Framing a grand convergence as simply achieving a 
reduction in the diﬀ erences in mortality rates across 
countries might not be suﬃ  ciently ambitious to meet the 
goals of many national policy makers. If mortality 
decreases in all countries by the same percent per year, 
absolute diﬀ erence will decrease and relative diﬀ erences 
will stay constant. For age groups in which global relative 
and absolute diﬀ erences in death rates are diverging, 
extraordinary eﬀ orts will be needed to achieve laudable 
goals such as a grand convergence. If convergence 
includes reducing the ratio of the highest to lowest death 
rates, even for under-5 mortality, major new eﬀ orts will be 
needed to have faster percent decreases in countries with 
higher mortality.
Arguments that convergence is technically and 
ﬁ nancially feasible are grounded on the rapid 
improvements of some countries.24 For example, from 
1990 to 2013, 13 countries (all low-income), achieved 
increases in life expectancy greater than 10 years 
(appendix pp 141–151). The real challenge is whether the 
strategies to decrease mortality used by these countries 
are generalisable or transferable to those countries who 
are making the least progress. The Lancet Commission 
on global health 2035 drew attention to the four Cs 
(Cuba, Costa Rica, Chile, and China). Life expectancy has 
improved faster than the global aggregate trend in China 
and Chile in the past 23 years.
The good news is that some countries that were 
low-income in 1990 have achieved remarkable progress in 
the past 23 years—for example, in Nepal, life expectancy 
has increased by 12·16 years since 1990, reaching 
70·64 years in 2013 for both sexes combined (appendix 
pp 141–151). Other examples of improvements greater 
than 12 years for both sexes combined include Rwanda, 
Ethiopia, Niger, Maldives, Timor-Leste, and Iran. Because 
Panel: Research in context
Systematic review
The GBD 2013 assessment of causes of death is a major 
improvement in the evidence base compared with GBD 2010 
through the inclusion of new data from vital registration 
systems, verbal autopsy studies, maternal mortality 
surveillance, injury surveillance and other sources. Through 
the inclusion of sub-national data on China, Mexico, and UK 
the evidence base for causes of death has been greatly 
expanded. Redistribution algorithms for ill-deﬁ ned causes of 
death used to enhance the comparability of data were based 
on new statistical models. GBD 2013 also beneﬁ ts from 
several improvements in the methods used to estimate all-
cause mortality and speciﬁ c causes of death such as HIV/AIDS. 
GBD 2013 provides a more up-to-date and comprehensive 
assessment of causes of death than do other studies of cause 
of death in particular age groups (CHERG), for particular 
causes (GLOBOCAN),83 and previous GBD analyses 
(GBD 2010).2–8
Interpretation
This study provides a comprehensive description of mortality 
levels and patterns worldwide, and provides the evidence to 
assess progress of global development goals, including 
control of non-communicable diseases, and priorities for 
further global health and development debates. Because the 
study provides a complete re-analysis of trends for each cause 
from 1990 to 2013, it supersedes the results of the GBD 2010 
study. This is the ﬁ rst time that country-speciﬁ c results for all 
188 countries with populations of more than 50 000 people 
have been comprehensively published. Country-speciﬁ c data 
provide the opportunity to examine the extent to which 
epidemiological convergence is occurring across countries.
For CHERG estimates see 
http://cherg.org/main.html
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the Rwandan genocide occurred after 1990, the progress 
from the peak of mortality during the genocide until 2013 
is even larger, 49·63 years. Studies have already assessed 
progress in Bangladesh, Ethiopia, and Niger, particularly 
in reducing child mortality.95 Further study of these 
countries might provide insights about how to achieve 
low mortality, including the role of development 
assistance for health, rapid economic growth, and 
addressing chronic challenges such as famines. Simple 
assessments built up from individual technology 
analyses, such as the Disease Control Priorities-2,96 
assume a high-level of health system eﬃ  ciency and 
contextual factors that enable technology to be delivered 
such as levels of maternal education. Plans to achieve a 
grand convergence in the face of diverging mortality will 
need to take into account low levels of health system 
eﬃ  ciency and low levels of health system resourcing in 
some countries and the greater eﬀ orts needed to achieve 
high intervention coverage in low-income countries with 
inadequate primary health-care systems and low levels of 
educational attainment. The challenge of improving 
health system management, particularly locally, is a 
crucial component of the future plans.
The analysis of average relative diﬀ erence between 
countries and average absolute diﬀ erence between 
countries by cause (data not shown) shows the general 
pattern that many communicable, maternal, and neonatal 
causes, along with war and natural disasters, are highly 
unequal across countries; almost all have average relative 
diﬀ erences of more than 50%. Among the 
non-communicable disease categories, mental and 
substance use disorders is the only cause with a mean 
relative diﬀ erence greater than 40%. Following the more 
stringent criteria for convergence—in which global rates 
and the Gini coeﬃ  cient are both falling—only neoplasms 
and chronic respiratory diseases are converging. As more 
countries go through the epidemiological transition, it 
seems likely that cross-country inequalities or relative 
diﬀ erences for communicable causes will rise and 
inequalities for non-communicable causes will narrow. 
Narrowing inequalities across countries will not necessarily 
narrow inequalities for non-communicable disease within 
countries. Because mortality exponentially rises with age, 
at least after age 50 years, relative diﬀ erences at older ages, 
when mortality becomes concentrated, tend to be small. 
Causes such as diabetes, chronic kidney disease, and 
alcohol and drug use disorders—for which global death 
rates are rising and inequality is increasing—are 
exceptions to this general pattern.
Non-communicable diseases
Age-standardised death rates for cardiovascular and 
circulatory diseases have fallen in high-income and many 
middle-income countries since 1990. Rapid falls have 
occurred in some countries. For example, ﬁ ve countries 
(Israel, Denmark, Norway, South Korea, and UK), had at 
least a 65% decrease in age-standardised death rates for 
ischaemic heart disease. Many other countries have had 
decreases of 40–65%. Age-adjusted death rates caused by 
haemorrhagic stroke fell by three-quarters in South Korea.
The ageing and growth of populations has led to an 
increase in the total number of cardiovascular deaths, 
accounting for almost a third of all deaths globally in 
2013. Ischaemic heart disease, ischaemic stroke, and 
haemorrhagic stroke continue to cause most 
cardiovascular and circulatory deaths in almost all 
countries. Some Balkan countries are an exception; 
cardiomyopathy was a leading cause of death, possibly as 
a result of alcohol exposure or local patterns of garbage 
codes.97 Additional studies are needed to establish 
whether this ﬁ nding is driven by medical certiﬁ cation 
practices or is related to alcohol or some other factor.97 
Age-standardised death rates for atrial ﬁ brillation and 
ﬂ utter and peripheral vascular disease have increased, 
possibly because of increased awareness of these 
conditions or better survival from cardiovascular diseases 
that share the same risk factors. Much uncertainty 
remains for trends in mortality caused by rheumatic 
heart disease, partly because endemic populations are 
concentrated within poorer subnational regions where 
data collection is limited and rheumatic heart disease 
might not always be coded as the underlying cause of 
death.98 Eﬀ orts to benchmark changes in cardiovascular 
and circulatory diseases will beneﬁ t from increasing 
access to verbal autopsy in India and sub-Saharan Africa, 
household surveys focused on chronic diseases, and 
improvements in electronic health records.
Generally, cancer deaths are increasing but 
age-standardised cancer death rates are falling. Some 
cancer-related risk factors, such as tobacco consumption, 
have decreased, but others, such as obesity, have 
increased. The substantial general fall in cancers require 
further explanation. Death rates for ﬁ ve cancers increased 
(non-Hodgkin lymphoma, mesothelioma, kidney cancer, 
pancreatic cancer, and multiple myeloma); some 
explanations, such as the potential link between the rise 
of diabetes and pancreatic cancer might account for some 
of these reversals. Because of diﬀ erent rates of decrease 
for other sites, the mix of cancers is steadily changing, 
particularly in low-income regions, such as the relative 
importance of breast cancer compared with cervical 
cancer. These local changes have important implications 
for the development of cancer care programmes and 
training. Because of the strong relation between cancer 
mortality and age, ageing of the world’s population is the 
most important driver of the rising number of cancer 
deaths in most countries. Most countries can expect to 
have to deal with more patients who need diagnosis, 
treatment, and palliation in coming years.
Alzheimer’s disease and other dementias
We used a substantially diﬀ erent approach to estimate 
Alzheimer’s disease and other dementia mortality in the 
GBD 2013 by focusing on studies of prevalence and 
For the age-standardised death 
rates by cause for each country 
see http://vizhub.healthdata.
org/cod
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using data from countries with the highest death to 
prevalence ratios in 2013 to estimate mortality in other 
regions and back in time. This change greatly lowers the 
increase compared with GBD 2010 in the age-
standardised death rate for dementia although the 
numbers of dementia deaths nevertheless increased. 
Lower increases in the age-standardised rate were 
because the meta-regression of prevalence studies did 
not show a rapidly rising trend; one study, reported 
decreases in age-speciﬁ c rates, although our overall 
assessment suggests a slight increase in age-speciﬁ c 
rates.99 Even in high-income countries with complete 
medical certiﬁ cation of causes of death, we argue that 
dementia was systematically underestimated as a cause 
of death in earlier periods. Other studies, such as the 
National Mortality Followback Study in USA, support 
this idea.100 Dementia deaths might have been 
misclassiﬁ ed into categories such as senility. Our 
garbage code redistribution algorithms for this broad 
category might have under-allocated dementia deaths in 
earlier periods. For future research, we may want to 
more carefully trace to which garbage codes dementia 
deaths might have been assigned using hospital linkage 
or other approaches.
The other eﬀ ect of using this approach is that we 
estimated considerably more dementia deaths in 
middle-income countries than in the GBD 2010. 
Prevalence studies suggest dementia occurs in these 
countries although it is rarely recorded on a death 
certiﬁ cate as a cause of death. Our overall conclusion is 
that dementia is more common worldwide and that 
numbers are increasing because of population ageing 
with only a small component of the increase caused by 
rising age-speciﬁ c rates. The analysis of dementia will 
beneﬁ t from further population-based prevalence 
surveys, especially with repeated measurement over time 
using standardised deﬁ nitions and methods. As further 
studies of this type become available and incorporated 
into the GBD, our estimates of dementia burden might 
be substantially revised. Trends in the category 
Alzheimer’s disease and other dementias might mask 
upward trends in Alzheimer’s and downward trends in 
vascular dementia; however, these disorders are diﬃ  cult 
to tell apart in population-based prevalence studies and 
cause of death data. Nevertheless, our ﬁ nding that the 
number of dementia deaths is increasing implies that 
governments should remain concerned about the rising 
demands for care that will come with population ageing 
even if future rates do not increase substantially.
Diarrhoea and lower respiratory infections
We report that the distribution of the causes of diarrhoea 
is diﬀ erent around the world. The distribution of 
pathogens has also changed signiﬁ cantly since 1990—for 
example, almost 50% (20 343 [9054–41 216] deaths) of all 
cholera deaths in children occur in sub-Saharan Africa. 
Because we used GEMS data to estimate relative risks, it 
is perhaps not surprising that our results are comparable 
to their ﬁ ndings.57 The population attributable fraction for 
pathogens such as Campylobacter, Shigella, and Salmonella 
were not signiﬁ cant in some countries and some ages. 
Because of the nature of case notiﬁ cation data, we had to 
estimate all types of cholera and were unable to 
breakdown cholera into O1, non-O1, and O-139.
In high-income countries, C diﬃ  cile is an important 
threat that has increased during the past two decades. 
65% (744 413 deaths) of unexplained diarrhoea in people 
older than 5 years is an important knowledge gap. 
Although the new counterfactual approach is successful 
for estimating attributable death empirically and 
adjusts for the overall pathogen load in the country, it 
still suﬀ ers from limitations such as the potential low 
sensitivity of diagnostic tests. Some pathogens are 
more prevalent in controls than in cases, which might 
present a distorted causal picture because of continuous 
shedding of pathogen long after the acute phase.101–105 
These ﬁ ndings could also suggest a protective eﬀ ect of 
infection from one or more pathogens against other 
pathogens or could be simply caused by a diﬀ erential 
decrease in the sensitivity of diagnostic tests (for other 
pathogens) where diarrhoea presents assuming a single 
pathogen caused the diarrhoea. More sensitive 
diagnostic tests help to improve sensitivity but at the 
price of decreased speciﬁ city because of contamination 
and post-diarrhoea pathogen excretion. Follow-up 
studies with multiple measurements of pathogens in 
children during healthy and diarrhoea periods could 
help to elucidate the true causal associations. Better 
case deﬁ nition and more strict criteria for pathogens 
such as excluding recent cases of diarrhoea could 
decrease exposure misclassiﬁ cations.
Our estimates of the fraction of under-5 lower 
respiratory infection deaths attributable to the four 
causes of pneumonia (pneumococcus, H inﬂ uenzae B, 
respiratory syncytial virus, and inﬂ uenza) are much the 
same as previous estimates, with pneumococcus and 
H inﬂ uenzae B the predominant causes.63,64,106–108 The 
large fraction of lower respiratory infection attributable 
to pneumococcus and H inﬂ uenzae B, particularly in 
low-income regions where the absolute burden is 
highest, shows the potential beneﬁ t of continuing to 
scale up pneumococcal conjugate and H inﬂ uenzae B 
vaccination. We calculated the contribution of each 
cause with a counterfactual approach. This approach 
means that they do not add up to 100% but also that 
there might be overlap; for example, death from lower 
respiratory infection might involve viral and bacterial 
co-infection. These results should also be interpreted 
with caution because of the data used to generate these 
estimates. Data for cause are sparse and prone to several 
biases, which is shown in the large UIs.
Estimates of the mortality burden of pneumococcal 
pneumonia in children rely on data from vaccine probe 
studies, which showed that disease in infants fell after 
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pneumococcal conjugate vaccination; there are no 
sensitive diagnostic tests to detect non-bacteraemic 
pneumococcal pneumonia in children. To calculate 
burden in the absence of a diagnostic assay, the 
pneumococcal conjugate vaccination probe studies 
assumed a vaccine eﬃ  cacy against non-bacteraemic 
pneumonia caused by vaccine types equal to that of 
protection from vaccine type bacteraemia (75%). Data 
from a large randomised trial of pneumococcal conjugate 
vaccination in adults conﬁ rmed eﬃ  cacy against 
bacteraemic pneumonia of 75%, but eﬃ  cacy against 
non-bacteraemic pneumonia was only 45%.109 If similar 
eﬃ  cacy estimates are applied to infants, then the 
contribution of the pneumococcus to pneumonia 
mortality in infants could be as high as 63% 
(166 324 deaths). Because data were sparse, we did not 
estimate the fraction of deaths caused by H inﬂ uenzae B 
among people aged 5 years and older. The before-and-after 
vaccine eﬃ  cacy studies used to estimate the burden of 
pneumococcus were limited to high-income settings. 
These types of studies might also be biased because of 
underlying temporal trends in hospital admissions for 
lower respiratory infection. Furthermore, the only 
variation included for pneumococcus and H inﬂ uenzae B 
is a result of diﬀ erences in vaccination coverage.
The observational studies used for respiratory syncytial 
virus and inﬂ uenza were based on case series data from 
predominantly tertiary-level hospitals, which might not be 
representative of the underlying population and are prone 
to varying case-deﬁ nitions and diagnostic methods. Finally, 
hospital discharge data for the relative diﬀ erences in case-
fatality for respiratory syncytial virus and inﬂ uenza 
compared with pneumococcus and H inﬂ uenzae B were 
limited to high-income and middle-income countries. 
Several of these shortcomings are being addressed by the 
Pneumonia Etiological Research for Child Health project.110
Injuries
Most global road traﬃ  c deaths occur in low-income and 
middle-income countries and are rapidly increasing 
because of the growth in motorisation. Mortality rates 
caused by traﬃ  c-related injuries are increasing in 
low-income and middle-income countries. Pedestrians 
are most often aﬀ ected, followed by car occupants and 
motorcyclists. Conversely, traﬃ  c deaths are decreasing in 
high-income countries. We noted a similar divergence 
between low-income and high-income countries for 
occupational injuries: they generally fell in high-income 
countries (with the exception of deaths resulting from 
asbestos-related mesotheliomas), whereas occupational 
injury deaths have increased in low-income countries 
(data not shown).
Suicide continues to be a major public health problem 
in many regions. Half of all suicide deaths occur in 
China and India alone. However, the trends are in 
opposite directions, decreasing rapidly in China but 
rising in India between 1990 and 2013. Both countries 
have undergone economic growth and urbanisation, a 
key factor in limiting access to lethal pesticides, a 
common method of suicide by poisoning in both 
countries.111 Therefore, as yet unexplained reasons must 
exist for the divergence between the two countries.
We recorded several sharp increases in mortality 
caused by war and disaster. Particularly, the 2010 Haiti 
earthquake, conﬂ ict in Syria over the past several years, 
the 2011 Tōhoku earthquake and tsunami in Japan, and 
conﬂ ict in Libya in 2011 have caused considerable loss 
of life. The war in Syria led to an estimated 29 947 deaths 
(19 392–54 903) in 2013, and about 10 504 deaths and 
21 422 deaths in each of the preceding 2 years. 
Uncertainty around these estimates is large because 
several diﬀ erent estimates exist. These estimates are of 
the direct deaths attributable to armed conﬂ icts and 
natural disasters and do not account for the full eﬀ ects 
of mechanisms such as the breakdown of health 
systems or critical infrastructure. For example, the 
conﬂ ict in Syria has had a substantial eﬀ ect on routine 
immunisation for polio, with coverage now as low as 
50% in some areas.112 The estimation of direct deaths 
caused by war and natural disasters is one of the most 
challenging components of the GBD measurement. We 
depend on the work of various groups to collate 
combatant reports, newspaper reports, humanitarian 
agency assessments, and other direct accounts to 
approximate the number of deaths. Vital registration 
systems often do not function in war or conﬂ ict but 
might be more useful in countries with natural 
disasters as a way of measuring the number of deaths. 
More work is needed to better measure shock mortality.
India
India accounts for 19% of the world’s deaths in 2013. 
Estimations of cause of death for India are important both 
for health policy in India and for global understanding of 
causes of death. India has had remarkable progress in 
reducing both child and adult mortality over the past 
23 years. Average yearly rates of decline were 1·3% per 
year for adults and 3·7% for children.
Unfortunately, less cause of death data were available for 
2013 than for 1990 or 2000. The Medical Certiﬁ cation of 
Causes of Death system provided ongoing information 
about patterns of urban mortality with better completeness 
in some states than in others. In rural areas, the Survey of 
Causes of Death (Rural) routinely reported causes of death 
from verbal autopsy from 1980 to 1998. This survey was 
replaced with a verbal autopsy sample collected by the 
Registrar-General of India based on the ongoing Sample 
Registration Scheme. Data for 2002–04 have been reported 
but not in full detail—results were released in a series of 
articles spanning 2008–14 but even these have not 
provided the standard tabulation of deaths by International 
Classiﬁ cation of Diseases cause, age, and sex used by 
most countries. Verbal autopsies were collected after 2004 
but no data have been analysed or released. Attempts to 
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add verbal autopsy to other major data collection eﬀ orts of 
the Government of India, such as the Annual Health 
Survey and the latest round of the District Level Household 
Survey, have so far been unsuccessful. Small community 
studies continue to be published but there is a major gap 
in knowledge of rural cause of death.
In view of the rapid change in India, including decreases 
in child mortality and adult mortality, simple predictions 
based on the 2002–04 data are inadequate. Our modelling 
strategy takes into account trends for key covariates that 
explain some changes in age-speciﬁ c rates for many 
causes; nevertheless, more recent national data would be 
helpful to develop more precise estimates of causes of 
death for India. Epidemics such as Chikungunya, dengue, 
and H1N1 inﬂ uenza also point to the need for better 
ongoing surveillance of causes of death in India that does 
not suﬀ er from long time lags.113–116
Comparing diﬀ erent global health estimates
Comparison of the GBD 2013 results with GBD 2010 for 
1990 or 2010 shows some important diﬀ erences. The 
overall correlation coeﬃ  cient of age-sex-country-cause 
rates was 0·998 in both 1990 and 2010 but some causes 
have changed substantially at the global level. The 
ten causes in terms of the largest change in the number 
of global deaths were Alzheimer’s disease and other 
dementias, ischaemic heart disease, interstitial lung 
disease and pulmonary sarcoidosis, cerebrovascular 
disease, neonatal encephalopathy caused by birth 
asphyxia and trauma, lower respiratory infections, other 
cardiovascular and circulatory diseases, cirrhosis, 
malaria, and chronic kidney disease. These changes 
might be because of new data, modiﬁ cations of garbage 
coding algorithms, and revised modelling strategies 
(appendix). Generally, the data used has substantially 
increased: from 8967 site-years to 14 244 site-years.
Some speciﬁ c changes are worth noting. First, data for 
China has greatly increased. Given China’s population, the 
incorporation of large amounts of new data for cause of 
death led to large changes in China and these aﬀ ected even 
global estimates. The ﬁ ve largest changes for China in 
2013 compared with the GBD 2010 were ischaemic heart 
disease, Alzheimer’s disease and other dementias, 
cerebrovascular disease, interstitial lung disease and 
pulmonary sarcoidosis, and chronic obstructive pulmonary 
disease. Second, more detailed cause of death data covering 
189 causes instead of 98 causes were available for Russia 
for the GBD 2013. This aﬀ ected several smaller causes, 
such as those related to alcohol. Third, we included new 
vital registration data for Turkey for 2010–12. Fourth, we 
modelled India in two components, urban and rural, 
which enabled us to make much more use of some data 
sources such as the Survey of Causes of Death (Rural) for 
rural India. Because India is large, these changes have a 
global eﬀ ect. Fifth, for cancers, we incorporated 
1145 registry-years of new data, including 128 from the 
Cancer Incidence in Five Continents Volume X.48 Sixth, the 
change to use of a Bayesian noise reduction algorithm for 
smoothing has reduced the number of outliers, particularly 
in small verbal autopsy studies, some of which were 
included in the GBD 2010. Seventh, changes to garbage 
code redistribution algorithms, particularly the use of 
statistically derived algorithms that vary by region and 
country, has had eﬀ ects on injuries, cancers, and 
cardiovascular diseases.  Other changes included treating 
unspeciﬁ ed anaemia as a garbage code whereas in the 
GBD 2010 it was mapped to iron-deﬁ ciency anaemia, 
moving abdominal hernia from other digestive diseases to 
hernia, as well as moving deaths related to speciﬁ c 
procedures to the category of adverse eﬀ ects of medical 
treatment. In the GBD 2010, we included abdominal 
hernia, including umbilical hernia, ventral hernia, and 
diaphragmatic hernia in the category “other digestive 
diseases”. In the GBD 2013, we combined these with 
inguinal hernia and femoral hernia into one cause named 
“hernia”. Additionally, we moved some ill-deﬁ ned causes 
from the other digestive diseases category to more speciﬁ c 
causes, thereby reducing the number of deaths in other 
digestive and changing the distribution of all digestive 
deaths among its more disaggregated causes. Seventh, the 
assessment of all-cause mortality in the GBD 2013 
beneﬁ ted from both new data and improved approaches 
for assessment of the age pattern of mortality in the model 
life-table system. Finally, the more detailed analysis of 
HIV/AIDS led to major changes both for HIV/AIDS 
(particularly in countries with concentrated epidemics) 
and for other causes, particularly in the people of 
reproductive age and in countries with moderate-to-large 
epidemics.
The International Agency for Research on Cancer 
produces cancer estimates by country, age, sex, and cancer 
site for 2008 and 2012 (GLOBOCAN). Our deﬁ nitions and 
the GLOBOCAN deﬁ nitions are compatible for 25 sites. 
For these cancer sites, the total estimated prevalence from 
GLOBOCAN was 6 848 204 cases in 2008 and 
7 483 018 cases in 2012. By comparison, the GBD estimates 
were 6 930 377 for 2008, and 7 437 018 for 2012. Worldwide, 
the largest variation in estimates occurs for thyroid cancer, 
testicular cancer, and other pharynx cancers, with 
diﬀ erences of 20–30%. The rough similarity of results at 
worldwide masks substantial national variation. 
Comparing age-standardised death rates for 2012, the 
correlation ranges from 0·94 for tracheal, bronchus, and 
lung cancer, to 0·20 for thyroid cancer. Five cancers have 
correlations below 0·5 (ovarian, non-Hodgkin lymphoma, 
testicular, Hodgkin lymphoma, and thyroid). A further six 
cancers have correlations of 0·5–0·7 (uterine, 
nasopharynx, lip and oral cavity, breast, leukaemia, and 
multiple myeloma).
Because both GLOBOCAN and our estimates used 
population-based cancer registry data and vital registration 
data as inputs, the wide variation in results requires 
explanation. As with all comparisons of global health 
estimates, the diﬀ erences stem from data, data processing, 
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and model development. We included a wider range of 
registries than did GLOBOCAN, particularly in China, 
and we used of a broader database of vital registration 
data. Our redistribution of cancer of unknown primary 
was based on a statistical model. The most important 
diﬀ erences, however, probably stem from the modelling 
strategy. For all cancer sites in all countries, we used 
CODEm. GLOBOCAN used nine diﬀ erent methods to 
estimate cancer mortality depending on the country.83,117 
The choice of method can lead to surprising diﬀ erences in 
estimated rates for neighbouring countries without data. 
For example, the age-standardised death rate for male 
thyroid cancer in Timor Leste is 250% higher than that for 
Indonesia; age-standardised death rates for testicular 
cancer diﬀ er by 1300% between Mali and Mauritania. The 
GLOBOCAN estimates have a substantial subjective 
component in the choice of which modelling strategy to 
use and do not provide any estimate of uncertainty. 
Empirical assessment of the validity of the GLOBOCAN 
methods—for example, through cross-validation—would 
help to understand the strength of the approach.
Understanding causes of death begins with 
assessment of all-cause mortality. There are some 
notable diﬀ erences between our assessment of global 
age-speciﬁ c deaths and those produced by the United 
Nations Population Division in their World Population 
Prospects 2012 revision (WPP2012). For the three 
periods (1995–2000, 2000–05, and 2005–10) as deﬁ ned 
in WPP2012, the total numbers of deaths were 2·4–3·6% 
higher (6·1 million–9·1 million deaths) than estimated 
by us. These diﬀ erentials translate into a diﬀ erence of 
7·8 million deaths for the 5-year period between 2005 
and 2010. The diﬀ erence is greatest for younger age 
groups. For 2005–10, estimated under-5 deaths from 
WPP2012 are 10·7% higher (3·9 million more deaths) 
than for the GBD 2013.
The WPP2012 global under-5 death estimates were also 
higher than those of UNICEF; part of this diﬀ erence 
might be a result of the agencies releasing their estimates 
at diﬀ erent times. The biggest relative diﬀ erence was for 
the adolescent age group (age 5–14 years). For 2005–10, 
the estimated deaths in adolescents from WPP2012 were 
45·1% higher than in the GBD 2013, even though the 
absolute diﬀ erence was about 2·2 million for a 5-year 
period, less than 1% (2·17 million of 264·7 million) of the 
total deaths for the same period. The diﬀ erences are even 
greater at the GBD regional level. For 2005–10, the 
relative diﬀ erence between WPP2012 and GBD 2013 
ranged from 26·7% (122 800) lower in WPP2012 in 
Oceania, to 36·0% (1·9 million) higher in WPP2012 
in central sub-Saharan Africa. WPP2012 tends to have 
high estimates of adolescent mortality compared with 
the GBD 2013 for all regions in sub-Saharan Africa, 
Andean Latin America, north Africa and Middle East, 
and southeast Asia. Overall, we ﬁ nd more diﬀ erences in 
estimates for sub-Saharan Africa across all age group in 
both relative and absolute terms.
Such discrepancy originates from diﬀ erent assessments 
of child mortality rates and the diﬀ erence in model 
life-table systems, both of which used child mortality rate 
to generate age-speciﬁ c mortality rates. Estimating 
mortality for the adolescent age group is important.118–120 
As part of the background research for the GBD 2013, we 
assessed the Demographic Health Surveys complete 
birth history data for age groups 5–9 years and 10–14 years 
and compared this data in countries with almost 
complete vital registration or sample registration 
systems, such as India. We also systematically assessed 
estimates of adolescent mortality from sites of the health 
and demographic surveillance systems, a network known 
as INDEPTH. When we assessed the ratio of 5q5 
(probability of death from age 5 years to age 10 years) and 
5q10 (probability of death from age 10 years to age 15 years) 
to under-5 mortality, conﬂ icting pictures arise: our GBD 
2013 estimates are sometimes higher than one source 
and lower than the other. Further analysis is warranted to 
validate our approaches for estimating adolescent 
mortality in low-income and middle-income countries 
without working vital registration systems. In addition, 
eﬀ orts are needed to improve both data collection and 
method development to better estimate mortality for 
adolescents.
As in the GBD 2010, we noted diﬀ erences for causes of 
child death compared with those produced by the Child 
Health Epidemiology Reference Group (CHERG; 
table 5). Given the complexity of both approaches, it is 
CHERG GBD 2013
Neonates aged 0–27 days
Congenital abnormalities 270 (207–366) 251 (221–291)
Diarrhoea 50 (17–151) 52 (44–61)
Pneumonia 325 (209–470) 213 (186–242)
Intrapartum-related complications* 717 (610–876) 657 (532–770)
Sepsis or meningitis 393 (252–552) 369 (237–504)
Tetanus 58 (20–276) 34 (16–48)
Other neonatal disorders 181 (115–284) 470 (411–557)
All causes 3072† 2807 (2719–2898)
Children aged 1–59 months
Injury 354 (274–429) 350 (310–394)
Diarrhoea 751 (538–1031) 536 (461–607)
AIDS 159 (131–185) 102 (95–111)
Pneumonia 1071 (977–1176) 772 (693–850)
Malaria 564 (432–709) 699 (576–855)
Measles 114 (92–176) 95 (52–166)
Meningitis 180 (136–237) 129 (98–163)
Other disorders 1356 (1112–1581) 1355 (1211–1524)
All causes 4550† 4039 (3883–4207)
Data are thousands of deaths (95% uncertainty interval). GBD=Global Burden of Disease Study. CHERG=Child Health 
Epidemiology Reference Group. *Compares GBD cause “Neonatal encephalopathy (birth asphyxia/trauma)” with 
CHERG cause “intrapartum-related complications”. †CHERG did not report uncertainty estimates for all-cause 
mortality in children. 
 Table 5: Comparison of GBD and CHERG estimated child deaths for select causes in 2010
For the INDEPTH Network see 
http:// www.indepth-network.
org/
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diﬃ  cult to isolate the reason for the diﬀ erences. 
One reason might be the diﬀ erent studies used: we 
included 5039 site-years of vital registration and 358 of 
verbal autopsy data compared with 578 and 192 for 
CHERG. Our modelling strategy was founded on 
modelling each individual cause separately, using the 
most appropriate method for each cause, and then 
combining the diﬀ erent cause estimates into an overall 
assessment consistent with all-cause mortality using 
CoDCorrect. CHERG used separate modelling strategies 
for HIV/AIDS, measles, pertussis, and malaria outside 
of Africa, and four diﬀ erent models for the remainder of 
the child causes. Separate logistic models, each with 
subtly incomparable cause lists, were used for neonates 
and children older than 1 month, for low mortality 
countries excluding China, for high mortality countries 
excluding India, for India alone, and for China alone. 
This partition of the world into separate models was not 
justiﬁ ed statistically—for example, they have not shown 
statistically diﬀ erent relationships with covariates for 
their four sets of models. Additionally, post-estimation 
adjustments were applied to pneumonia, meningitis, 
and malaria to account for intervention eﬀ ectiveness; 
pneumonia, sepsis, meningitis, and tetanus to account 
for the reliance on a combined severe infection cause in 
the primary model; and diarrhoea, neonatal sepsis, and 
sudden infant death syndrome in China to account for 
studies that report few causes.
We used a more empirical approach. We quantiﬁ ed 
both the root-mean squared error and validity of the UIs 
through cross-validation; CHERG has not to date reported 
any cross-validation results. Given the possibility that 
diﬀ erent relationships might exist between covariates 
such as access to clean water or sanitation and diarrhoeal 
mortality in diﬀ erent parts of the world, we undertook a 
sensitivity analysis in which we excluded vital registration 
data from high-income regions from the models for lower 
respiratory infections and diarrhoea. We detected no 
substantial diﬀ erences for estimated global cause of death 
patterns in these cases. Furthermore, in CHERG, 
neonatal causes were assumed to not cause deaths after 
1 month although high quality vital registration systems 
routinely report deaths from these causes that extend into 
the second month of life.
Challenges and limitations
In the GBD 2013, we did not include several clinical 
pathways to death on the cause list, such as heart failure, 
sepsis, fungal infection, and acute kidney injury. These 
clinical entities following the underlying cause construct 
of the International Classiﬁ cation of Disease are treated as 
garbage codes and redistributed to the likely underlying 
cause. Although this approach is consistent with the idea 
of assigning each death uniquely to the underlying cause, 
it masks endpoints for clinical service delivery. For 
example, most fungal infections are relatively minor, but 
potentially millions of people contract invasive fungal 
diseases121 that can be important pathways to death. 
Similar assessments can be made for sepsis, acute kidney 
injury, and heart failure. In future iterations of the GBD, 
we will aim to quantify mortality that occurs through 
these intermediate causes. Such intermediate cause 
estimation cannot be presented in the same causes lists as 
underlying causes of death but can provide supplemental 
and important information that would otherwise go 
unrecognised in global epidemiology.
Even in high-income countries with complete vital 
registration systems, our results diﬀ er from oﬃ  cial 
statistics.122 This diﬀ erence is largely caused by the 
emphasis in the GBD on enhancing comparability through 
redistribution of deaths assigned to garbage codes. 
Country-speciﬁ c data for cause of death show substantial 
national variation in coding practices. Generally, we used 
global or regional algorithms to redistribute deaths 
assigned to garbage codes. This approach is fairly coarse 
and does not capture local variation in certiﬁ cation practice 
or timing of implementation of coding rules. The GBD 
2013 is the most detailed eﬀ ort to date to try and 
systematically deal with garbage code redistribution. Some 
changes, such as the treatment of ill-deﬁ ned cancers or 
heart failure using statistical approaches, altered the GBD 
2013 results compared with the GBD 2010. We believe that 
the GBD results including the fraction of deaths assigned 
to diﬀ erent types of garbage codes can be useful for 
national statistical authorities’ eﬀ orts to improve medical 
certiﬁ cation of causes of death. We also believe that 
through the extensive network of GBD collaborators, we 
can move in future research to more country-speciﬁ c 
redistribution algorithms. To ensure comparability, 
however, these national variations will have to be grounded 
in a sound statistical approach and theory of measurement.
A study of this scope has many limitations. First is 
the quality of the underlying medical certiﬁ cation of 
causes of death and verbal autopsy data. Even medical 
certiﬁ cation of causes of death has limitations, which is 
shown by the need for garbage code redistribution.106,123,124 
Moreover, verbal autopsy data vary substantially in 
terms of the instrument used and the training given to 
physicians assigning causes of death. These 
shortcomings might reduce the comparability of cause 
of death data between countries and of our estimates 
based on these data.
Second, we did not incorporate uncertainty from garbage 
code redistribution into our estimation of UIs. Propagating 
such uncertainty into the CODEm models will require 
revision of the modelling strategy or an enormous increase 
in computational time. As evidenced by the change for 
some causes compared with the GBD 2010 as a result of 
changes in redistribution derived from statistical methods, 
this is an important area for future research.
Third, the major expansion of data for China and the 
associated changes in the estimates for some but not all 
causes, shows that UIs cannot take into account data that 
have not been included in the analysis.
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Fourth, for some causes, CODEm produces larger UIs 
in high-income countries than might be expected. This 
diﬀ erence is largely the result of heterogeneity across 
high-income countries for a cause that cannot be explained 
by the models. This eﬀ ect is more notable for causes such 
as diabetes, for which there are reasons to believe that 
large variation in certiﬁ cation practice remains in high-
income countries.125 Because diabetes or increased fasting 
plasma glucose is a risk factor for macrovascular 
outcomes, diﬀ erences in how physicians interpret the 
meaning of underlying cause could explain such national 
variation in practice. In the GBD, the full consequences of 
high fasting plasma glucose are captured in the risk factor 
assessment;8 deaths caused by diabetes in our analysis 
were only those that were recorded on the death certiﬁ cate 
to be the underlying cause.
Fifth, although we tried to improve the comparability of 
cause of death data over time through mapping variants of 
the International Classiﬁ cation of Diseases and 
garbage-code redistribution, some time trends might be 
aﬀ ected by changes in diagnostic technology. Some causes, 
such as cancers, might have been less likely to have been 
diagnosed in the 1980s and 1990s, when imaging and other 
diagnostic techniques were not widespread.
Sixth, for chronic kidney disease, the breakdown 
into deaths from diabetes, hypertension, acute 
glomerulonephritis, and other depends on both detailed 
cause of death data and renal registry data. In clinical 
practice, assigning chronic kidney disease to a particular 
cause might be diﬃ  cult for patients with both hypertension 
and diabetes.
Seventh, in some unusual cases such as chronic 
respiratory diseases in India, the sum of modelled 
estimates for CoDCorrect level 2 causes are much smaller 
than the level 1 modelled estimate leading to very large 
corrections for the CoDCorrect step. Very large 
corrections for CoDCorrect suggests that the component 
models for these causes can be improved in the future 
with better data or methods.
Eighth, for natural history models, most notably for 
HIV/AIDS, changes in parameter assumptions such as 
the death rate on or oﬀ  antiretroviral therapy, can have a 
large eﬀ ect on estimated mortality. We believe that 
progressive revision of these models improves the 
estimates but nevertheless, validation of natural history 
models is diﬃ  cult. For CODEm, we were able to quantify 
with the cross-validation strategy model performance but 
this is not possible with the natural history models.
Ninth, a strength of the GBD approach is that all 
estimates of cause-speciﬁ c mortality must sum to 
all-cause mortality in a country-age-sex-year group. 
However, this means that estimates for a speciﬁ c cause 
are aﬀ ected by the estimates for all other causes. Causes 
of death such as malaria, that have very wide UIs are 
particularly aﬀ ected by the estimates of other causes.
Tenth, models used to generate estimates of all-cause 
mortality and cause-speciﬁ c mortality make use of a long 
list of covariates. Uncertainty in these covariates, such as 
GDP per head, was not routinely quantiﬁ ed but 
nevertheless might be substantial. We were not able to 
propagate uncertainty in the independent variables used 
in the modelling stages into the ﬁ nal results. 95% UIs 
might therefore be under-estimated. However, when we 
have tested in a few cases the eﬀ ect of propagating 
uncertainty in the independent variables in the case of 
the HIV crude death rate, the changes to UIs, were 
minor (data not shown).
Eleventh, we made extraordinary eﬀ orts to propagate 
uncertainty throughout our all-cause mortality estimation 
process, which is not yet common practice in modern 
demographic research. However, uncertainty in covariates 
used in the ﬁ rst stage model of child and adult mortality 
rate was not included because of the complexity of added 
computation and the fact that these covariates have little 
eﬀ ect on our ﬁ nal estimates, as indicated by our 
preliminary testing.
Lastly, empirical age patterns of mortality, which are 
vital for the estimation of mortality for many low-income 
and middle-income countries, mostly come from 
high-income countries with great vital registration 
systems and some low-income and middle-income 
countries in the most recent period. Countries in the 
sub-Saharan African region are least represented in our 
empirical database of age pattern of mortality (appendix 
pp 81–89). Propagating uncertainty from both under-5 
and adult mortality rates (two key entry parameters for 
our new model life-table system), and from the standard 
life-table generation process has given our death 
estimates in sub-Saharan African countries substantial 
uncertainty; accurate documentation of age pattern of 
mortality in these countries are key for producing best 
all-cause mortality estimates in the future.
Conclusion
Global public policy to reduce premature death needs a 
detailed, up-to-date, and accurate understanding of 
progress (or lack thereof) of disease and injury control 
strategies. This understanding applies not just to 
diseases that have been the focus of global public health 
eﬀ orts for the past few decades, but increasingly, as we 
have shown, for newly recognised contributors to global 
health trends. Through the process of providing yearly 
updates, the GBD is transforming into a collective 
approach to global health surveillance. Ideally, it will 
aggregate data from all available sources and provide a 
coherent view of health levels and trends that is timely, 
valid, and local. To fully achieve a collective process of 
global health surveillance, the time lag will need to be 
shortened between data collection, reporting, and 
inclusion in the GBD. Public policy in countries will be 
much better informed if more frequent assessments 
are accompanied by less uncertainty around the 
estimates. Uncertainty will decrease not so much as a 
result of further methodological advances in disease 
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modelling and data synthesis, but much more as a 
result of greater investment and awareness among 
countries and donors alike of the need to strengthen 
vital registration systems.
Global collective action to reduce mortality from major 
communicable diseases such as diarrhoea, measles, 
tetanus, tuberculosis, and, more recently, HIV/AIDS and 
malaria, is working, but will require continued 
intervention eﬀ orts and resources and will probably be 
even more responsive if periodic assessments such as 
that reported here are available and used. While progress 
is being made to control several major non-communicable 
diseases of global concern, others have been largely 
neglected but are rising in importance, particularly drug 
use disorders, cirrhosis, diabetes, and chronic kidney 
disease. Greater prominence to reducing disease burden 
from these diseases, as well as continuing priority for 
injury control, is strongly suggested by our analysis. The 
ﬁ ndings on global, regional, and national trends in 
mortality from diseases should provide an important 
baseline for discussions about the next generation of 
health goals and targets after the Millennium 
Development Goals.
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